

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A digital Cognitive Behavioural Therapy and Emotion Regulation intervention in the workplace: Study protocol for a feasibility randomised waitlist-controlled trial to improve employee mental wellbeing and help them stay engaged and productive in work

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060545
Article Type:	Protocol
Date Submitted by the Author:	07-Jan-2022
Complete List of Authors:	Patel, Krishane; University of Warwick Moukhtarian, Talar Rita; University of Warwick, WMG Toro, Carla; University of Warwick, WMG Russell, Sean; Coventry University Daly, Guy; Coventry University Walasek, Lukasz; University of Warwick Tang, Nicole; University of Warwick, Psychology Meyer, Caroline; University of Warwick
Keywords:	MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Adult psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3 **A digital Cognitive Behavioural Therapy and Emotion Regulation intervention in the**
4 **workplace: Study protocol for a feasibility randomised waitlist-controlled trial to**
5 **improve employee mental wellbeing and help them stay engaged and productive in**
6 **work**
7
8
9

10 Krishane Patel^{1*}, Talar Moukhtarian¹, Carla Toro¹, Sean Russell², Guy Daly², Lukasz
11 Walasek³, Nicole Tang³ and Caroline Meyer¹
12
13
14
15

16 **Author affiliation**

17 1 - WMG, University of Warwick, University Road, Coventry, CV4 7AL, UK

18 2- Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1
19 5FB, UK

20 3 - Department of Psychology, University of Warwick, University Road, Coventry, CV4
21 7AL, UK
22
23

24 *Correspondence to Dr Krishane Patel, Behaviour and Wellbeing Science,
25 International Digital Laboratory, Warwick Manufacturing Group, University of Warwick,
26 Lord Bhattacharyya Way, Coventry CV4 7AL

27 Email: krishane.r.patel@warwick.ac.uk
28
29

30 Abstract (283 words)
31

32 Introduction: This trial tests the feasibility of implementing a digital cognitive behavioural
33 therapy for Common Mental Disorders in the workplace. The study protocol follows on the
34 CONSORT (Consolidated Standards of Reporting Trials) recommendations.
35
36

37 Methods and analysis: Feasibility of the implementation for a mixed methods evaluation with
38 a two-arm randomised waitlist control design of an eight-week digital cognitive behavioural
39 therapy (dCBT) intervention through self-guided online platform versus waitlist control (i.e.
40 life as usual). This study examines the ease of third-party buy in from organisations from
41 approach to agreement, the engagement of employees through the trial indicated by the
42 completion of outcome measures. In addition, we also explore how participants use the
43 platform, the appropriateness of the analysis both with reference to the outcome measures and
44 linear modelling. Finally, we examine the acceptability of the intervention based on
45 participants experiences using qualitative interviews through a framework analysis.
46 Assessments take place at baseline (T0), at 8 weeks post-treatment (T1), and at follow-up 16-
47 weeks post-randomisation (T2). We will recruit from the 1st July to 31st December 2021 for
48 employees and self-employed workers with depression and anxiety symptoms (sub-clinical and
49 clinical levels) who are not seeking or engaged in treatment at the time of the trial.
50
51
52

53 Ethics and dissemination: Full approval was given by the University of Warwick Biomedical
54 and Research Ethics Committee (BSREC 45/20-21). The current protocol version is 2.8 (Aug-
55 2021). Publication of results in peer-reviewed journals will inform the scientific, clinical and
56 business communities. We will disseminate results to through webinars, conferences,
57 newsletter as well as a lay summary of results on the study website (mhpp.me).
58
59

60 Trial registration: ISRCTN, ID: ISRCTN31161020. Registered on 08/06/2021.

1
2
3
4 Keywords: Common Mental Disorders, Feasibility, Workplace, iCBT, Online, Emotion
5 Regulation, Mental Health, Productivity
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

- Novel hybrid digital cognitive behavioural therapy for anxiety and depression to test feasibility in workers recruited from small, medium and large businesses in the Midlands region of the UK
- Evaluation of this feasibility trial will be used to inform future large-scale research for early intervention of worker with mild to severe symptoms of insomnia and emotion regulation difficulties will contribute to the understanding of benefits of early interventions in the workplace, its impact on mental health and productivity.
- Mixed-methods research to identify insights of the intervention and study design to improve for future use.
- This study will provide unique insights to generate designs for potential larger nationwide service delivery programme of mental health interventions in the workplace.

Introduction

In the United Kingdom (UK), poor mental health costs the economy an estimated £70 billion/year, equivalent to 4.5% of the UK's GDP [1]. Common Mental Disorders (CMD) comprising of depressive and anxiety related disorders are a major contributor to these costs. Within the workplace, one in six workers experience some form of mental health problems [2]. Furthermore, workers who experience CMDs are significantly less likely to remain in employment than their healthy counterparts [3,4]. The prevalence of mental illness in the workplace is problematic because of a) absenteeism where the loss in workforce as a result of sickness, with an estimated 11.6% of sickness absence caused by CMD [5], totalling almost 16 million days across the UK labour market; b) mental health can diminish productivity in the workplace, a concept called presenteeism [6] which can have significant impact on employee productivity across the labour market.

Psychological therapy (e.g. cognitive behavioural therapy) has been shown to be effective in treating depression and anxiety [7]. One common form of psychological treatment is cognitive behavioural therapy (CBT) which uses cognitive and behavioural principles to treat underlying cognitions and behaviour of psychiatric conditions. CBT has been shown to significantly reduce symptoms of anxiety [8], and depression [9]. Unfortunately, empirical research has shown that many individuals do not make use of services for access to psychological or psychopharmacological treatment, for example only 42.6% of individuals diagnosed with a mental health disorder in the last 12-months make use of services provided [10].

Digital interventions provide low cost, easily scalable delivery methods to provide access at the population-level, and to individuals that usual care services may not reach. This form of digital-based dCBT (dCBT) provides access to resources for self-learning or supervised treatment [11]. dCBT is effective in the prevention [11,12] and treatment of the most common CMD – depression and anxiety [8,13–15] which indicates potential opportunities to tackle large-scale mental health issues through innovative and cost-effective means.

Implementation of CBT and dCBT intervention in workplace settings have been shown to improve mental health and reduce incidence of the clinical levels of CMDs [16,17]. Meta-analyses of workplace interventions for CMDs show a significant standardized mean difference of 0.12, demonstrating small significant effects [18]. A large randomised controlled trial demonstrated that dCBT showed strong effects in treating employees with major depressive episodes [19], furthermore iCBT interventions have also been shown to promote work engagement amongst sub-clinical and healthy workers [20].

The majority of studies to date have focused on clinical levels of depression and less so on individuals with sub-clinical symptoms. It has been suggested that sub-threshold populations of CMDs are greater than their clinical counterparts [21]; furthermore, interventions for subclinical populations are deemed highly cost-effective [22]. Cases of CMDs have been further intensified over the COVID-19 pandemic with rates of generalised-anxiety disorder increasing from one in ten to one in four adults in the US populations [23,24]. Interventions to reduce mental health severity in the workplace can therefore have subsequent effects in workplace absenteeism and productivity, as well as increased job satisfaction [20]. Given the relatively few studies that examine intervention on subclinical and clinical levels of CMDs in the workplace, this trial is the first to explore a fully online intervention for a UK sample in the workplace.

1
2
3 This study - Reducing stress in the workplace using a digital intervention designed to
4 improve employee wellbeing and help them stay engaged and productive in work (REST),
5 will examine the feasibility of an dCBT for mild to severe depression and anxiety for
6 employees in the workplace. The REST study is one of three trials under the Mental Health
7 Productivity Pilots (MHPP), funded by the Midlands Engine [25] with a focus to improve
8 workforce mental health and productivity.
9

10 11 12 **Research aims**

13 The primary aim of this trial is to investigate the feasibility of a multi-centre waitlist RCT in
14 the Midlands region of England that examines whether an dCBT treatment for employees
15 reporting mild to clinical levels of depression or anxiety reduces symptom severity for
16 employees in the workplace. The trial will partner with participating employers to recruit
17 participants from workplace settings through employers and through social media
18 advertisement.
19

20
21 Nested within this primary aim is an exploration of the feasibility of the methodological
22 approach, focusing particularly upon:

- 23 • Willingness of organisations to participate in a trial (Objective 1);
- 24 • Willingness of employees to participate in a trial (Objective 2);
- 25 • Adherence of participants to the treatment as measured through platform user data
26 (Objective 3);
- 27 • Appropriateness of the analytical approach (Objective 4).
- 28 • Acceptability of the intervention based on participants subjective experiences
29 (Objective 5)
30
31

32
33 The results of this feasibility trial will be used to inform a future RCT to understand whether
34 an dCBT can help to reduce symptom severity and improve mental health and productivity
35 for employees in the workplace. In addition, secondary aims are to assess the barriers and
36 enablers of the intervention programme to identify key mechanisms of actions through a
37 process evaluation. Tertiary aims explore the impact of the intervention by examining the
38 reduction in symptom severity for depressive and general anxiety related symptoms as
39 measured through the Patient Health Questionnaire-9 (PHQ-9) and the General Anxiety
40 Disorder-7 (GAD-7) psychometrics as well as work productivity.
41
42

43 **Methods**

44 **Trial Design**

45 We implement a multi-centre, waitlist randomised controlled trial (wRCT) in which we
46 explore the feasibility of delivering an CBT intervention against a waitlist-control group
47 (WLC) with no active treatment. We target recruitment for participants with mild to severe
48 depression or general anxiety symptoms who have not received a formal diagnosis or in
49 receipt of professional care for a mental health condition. The iCBT will be delivered via a
50 self-guided digital online platform over an eight-week period.
51
52

53
54 Participants will be screened for the presence of depressive and anxious symptoms. Upon
55 verification that inclusion criteria are met, participants will provide informed consent,
56 complete outcome measure assessments, and complete the intervention through web-based
57 platforms. Online assessment of the primary and secondary dependent variables will take
58 place at week 0 baseline (pre-intervention), week 8 (post-treatment) and week 16 (follow-up).
59
60

All participants in the WLC group will be offered the dCBT intervention at week 8 (see Fig. 1 for trial flowchart).

Ethical approval has been granted from the University of Warwick Biomedical and Research Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN (ISRCTN13596153).

Participants

The REST trial shares a common screening process with two additional trials and therefore a shared Participant Information Leaflet (PIL) is used, under the umbrella of the INWORK program. However, no access is provided between trials and all studies use mutually exclusive inclusion/exclusion criteria to ensure no overlapping participant sample populations or competition in recruitment.

We will recruit full-time and part-time employees and workers self-employed and from organisations across the Midlands region of England who fulfil the inclusion/exclusion criteria (Table 1). This is defined by the Midlands Engine as a population of approximately 11 million, with 4.5 million jobs (Midlands Engine, 2021).

Table 1. Inclusion/Exclusion criteria for REST study

Inclusion criteria	Exclusion criteria
Able to give informed consent	Currently receiving treatment (psychological or pharmacological) from mental health services (e.g. GP, private clinic, Improving Access to Psychological Therapies (IAPT) services, specialist and community mental health services)
English-speaking	Retiring in the next 10 months
In employment (including being on furlough)	Currently taking part in other psychological intervention trials
Insomnia Severity Index score: $x < 8$	
General Anxiety Disorder-7 score: $x > 5$ or Patient Health Questionnaire-9 score: $x > 5$	In shift work*
≥ 18 years of age	

*We do not specify on working hours, or place of work

Components of the REST intervention

The REST intervention is an online self-guided programme structured into eight-weekly sessions with varying number of topics each week, lasting approximately 60 minutes each. The content incorporates techniques from Cognitive Behavioural Therapy (CBT) and Emotion Regulation [26] using workplace relevant examples. The goals of the intervention are to reduce symptoms of stress, depression and anxiety and provide participants with practical skills and techniques to help cope with stressful situations. The core components of the REST intervention can be shown below on Table 2.

Table 2. REST content across the intervention

Week 1	<ul style="list-style-type: none"> • What is stress? • Stress cycle • REST diary • Setting SMART goals
Week 2	<ul style="list-style-type: none"> • Non-judgmental awareness • Behavioural activation • Emotion focused skills
Week 3	<ul style="list-style-type: none"> • Work-related stress • Rumination and worrying • Problem solving skills
Week 4	<ul style="list-style-type: none"> • Cognitions • Managing unhelpful thinking styles • Cognitive restructuring
Week 5	<ul style="list-style-type: none"> • Work-life balance • Time management Skills
Week 6	<ul style="list-style-type: none"> • Physiology of stress • Relaxation techniques
Week 7	<ul style="list-style-type: none"> • Behavioural change • Healthy lifestyle choices (e.g. sleep, physical activity)
Week 8	<ul style="list-style-type: none"> • Programme summary • Relapse management • Self-compassion • Resilience

Waitlist control

Participants initially allocated to the waitlist control group, will be asked to provide a baseline response to primary and secondary measures but will not receive any active treatment for the first eight weeks. After the eight-week period, waitlist control participants will be asked to provide a post-control group measure for primary and secondary outcomes at which point they will be automatically enrolled into the intervention group for a further eight weeks.

Measures

Participants will be prompted by email to complete all outcome measures on a secure online survey platform (Qualtrics). The order of the assessments will be consistent across all participants and all time-points. If participants do not complete measures within 5 days they will receive three further email reminders every five days of non-response. Every effort will be made to obtain outcome data from participants, even those who discontinue the intervention.

Primary outcomes

To examine the feasibility of our intervention under a multi-centre waitlist randomised controlled trial design, we explore five primary objectives. We examine Objective 1 by

1
2
3 monitoring organisational traffic (defined as conversion rates and absolute counts) into the
4 trial across four identified stages:

5 Stage 1: Contacted

6 Stage 2: Teleconference

7 Stage 3: Further engagement

8 Stage 4: Verbal agreement and branch selection
9

10
11 For each partnership with an organisation we document the number of centres
12 as well as the number of employees.
13

14
15 We examine Objective 2 by exploring participant traffic across the trial flow (through social
16 media and employer pathways). We define the trial flow for participants traffic as follows:

- 17 1. Expression of interest
- 18 2. Screener completion
- 19 3. Invitation to trial
- 20 4. Consent to study and randomisation
- 21 5. Post-study (which is defined as end of control and beginning of intervention for those
22 initially placed in the waitlist control group)
- 23 6. Follow-up measures or outcome measures from Qualtrics
24
25

26 We will explore the conversion rates and absolute counts of employees from each stage of the
27 trial flow, evaluating over both recruitment pathways.
28

29
30 We explore Objective 3 through the user data of platform access for the dCBT intervention.
31 We will explore how much content was consumed by individuals on average, and the time to
32 complete each block on average.
33

34 We explore Objective 4 through analysis of secondary measures listed below. We firstly
35 explore the appropriateness of the assessment measures themselves; this is conducted by
36 exploring the completion rate of questionnaires, we will further explore the descriptive
37 statistics (e.g. distribution of the outcome measures, skew, kurtosis, ICC, means and
38 variances).
39
40

41 We will evaluate the fit of our statistical model comparing a fixed-effects regression model
42 against a mixed-effects linear model (accounting for clusters in organisation level).
43 Furthermore, we also evaluate the statistical cleaning procedures using a sensitivity analysis
44 in which we compare multiple imputation methods against complete case analysis.
45
46

47 We also examine the feasibility of the trial implementation through semi-structured
48 qualitative interviews as part of Objective 5, which will explore the feasibility and barriers of
49 the intervention. We will use thematic analysis to identify the common themes mapped to a
50 framework to provide a theoretical perspective on how to improve the intervention.
51
52

53 **Secondary outcomes**

54 Our secondary outcomes explore the impact of the intervention on prevalent mental health
55 questionnaires to assess symptom severity in anxiety and depression. In addition, we also
56 explore the impact of the intervention on job satisfaction, well-being, quality of life, work
57 productivity and insomnia severity. The different measures are listed in the Supplementary
58 section and will be collected at baseline (T0) post-study (T1), and follow up (T2). In addition,
59 the GAD-7, PHQ-9 and the Insomnia Severity Index will be used as part of the screening
60

questionnaire set to identify eligible participants for the study. See the supplementary file for a detailed list of the outcome measures being used, along with a summary of their psychometric properties.

Sample size

Given little a-priori information, we will explore the feasibility of recruiting participants into the trial. We will recruit for eight months from June to December 2021. We will explore the recruitment rate over time across the employer and direct social media advertisement.

Recruitment procedures

The REST study will recruit through multiple channels. The first pathway denotes employers registering interest as partners via the MHPP website (mhpp.me), who will act as gatekeepers to their employees. They will not recruit participants themselves but only signpost the information. Employers will advertise the intervention within their organisations through newsletters and emails.

The second pathway is through direct recruitment by the research team via online social media (e.g., Twitter, LinkedIn and Facebook) and print (e.g., leaflets and flyers in public and retail settings) advertisements. Individuals who express interest through this pathway will be from the wider working community in the Midlands but not employed by one of the partner organisations.

Initial interest will be taken through a survey form hosted by the Qualtrics servers. This will only take brief employment information (organisation name, location and email address) in order to determine whether this individual is listed under a partner or through direct recruitment strategies.

The research team will then contact interested employees by sending them the INWORK PIL. This trial uses a two-stage consent process, where after initial interest, participants will be asked to take part in an eligibility screening questionnaire set, after which those eligible will be invited to take part in the trial. The screening questionnaire set consists of the GAD-7, PHQ-9 and the ISI. We will also ask participants to confirm they are older than 18, whether they have a diagnosis of a mental health condition, are under the management of a mental health service.

If the scores on any of the three scales yield above the clinical threshold, we will recommend these individuals to contact their GP and signpost to contact Improving Access to Psychological Therapies services. Symptom severity will not exclude them from taking part in the study. Participants will need to acknowledge reading the advice to continue with the screening questionnaire set. Individuals who pass the eligibility criteria as listed in Table 1 above will be invited into the REST trial.

Patient and Public Involvement

Patient and Public Involvement We have formed a group of four individuals with lived experience of mental health problems who are currently in employment, and they will contribute during the trial by reviewing participant information sheets, consent form, intervention materials and questionnaire measures. They will advise on recruitment procedures and methods to engage prospective participants/retain enrolled participants.

Randomisation

Participants are assigned to the dCBT or WLC arms through a simple randomisation with blocking using a 1:1 allocation ratio. We use random length block between two and eight, to minimise the risk of uneven groups. The randomisation is conducted using ‘*blockrand*’ package [27]. We stratify the randomisation process across centres based on employee size within the partnered employer pathway.

Due to unknown organisation size considerations, individuals through direct recruitment will not be stratified over centres. Randomisation will be conducted by a researcher independent of allocating participants and will be blinded to the subsequent allocations. Members of the research team will be unable to influence randomisation and will be concealed from future assignments.

Allocation concealment mechanism

The trial statistician (KP) will provide a prescriptive randomisation allocation sequence file stored in a *.csv file. The file is provided to the trial coordination team, who enrolls participants into the trial, doing so automatically allocates a condition to each participant. The allocation list is locked to prevent any tampering.

Implementation

The trial statistician (KP) generates the random allocation sequence, and the code to match each participant to their respective allocation sequence (through row wise matching of row numbers). The allocation is conducted as part of the trial coordination team enrolling participants into the trial Masterfile as part of parsing in logistical data. Participants are assigned to their respective allocation through an email sent by the trial coordination team.

Blinding

As this is a single-blind waitlist RCT, participants after consent will be informed of the two allocation groups, will not be blinded to their randomisation outcome and will be explicitly informed of their allocation once randomised. The trial coordination team who handle the administrative and logistical requirements of the trial will be unblinded to the allocation of participants, however the researchers will be blinded to the trial allocation. Statistical analyses will be conducted by members of the research team who will only have access to all non-identifiable data.

Analyses

We will record and report all participant flow through the trial in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. We will report descriptive statistics for recruitment, dropout, and completeness of interventions, in addition we will report a sample breakdown across sociodemographic.

We assess the feasibility of the REST trial in accordance with the five research objectives:

- Willingness of organisations to participate in a trial (Objective 1);
- Willingness of employees to participate in a trial (Objective 2);
- Adherence of participants to the treatment as measured through platform user data (Objective 3);
- Appropriateness of the analytical approach (Objective 4).
- Acceptability of the intervention based on participants subjective experiences (Objective 5)

Objective 1 explores organisational traffic in partnering with third-party organisations to recruit employees in workplace settings. To analyse organisational traffic into the study we use descriptive statistics calculating frequency counts and percentage. Table 3 below demonstrates the template in which we will document and present the information across (Stage 1- Engagement; Stage 2-Teleconference; Stage 3-Further engagement; Stage 4-Verbal agreement and centre selection).

Table 3. Organisational traffic into the REST study

Employer ID	Number of Employees	Number of potential centres	Stage 1	Stage 2	Stage 3	Stage 4
1	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
2	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
...	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
n	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
Total	N	N	N	N	N	N
Attrition	%	%	%	%	%	%

Objective 2 investigates the feasibility of recruiting and maintaining participants in the REST trial. We explore Objective 2 by examining participant traffic across the trial flow (see Figure 1), through social media and employer recruitment pathways. To analyse organisational traffic into the study, we use descriptive statistics calculating frequency counts and percentage across the trial stages (see Table 4).

Table 4. Organisational traffic into the REST study

Recruitment Pathway	Employer ID	Express interest	Screeener	Invite to Trial	Consent, randomise and baseline measure completion (T0)	Post-study outcome measure completion at 8 weeks (T1)	Follow-up measure completion at 16 weeks post randomisation (T2)
Employer pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%
Direct Social media advertisement pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%

1
2
3
4 We will also conduct a chi-squared test to compare overall attrition rates across the two
5 recruitment pathways to determine if there is any practical utility in one form of recruitment
6 over another.
7

8
9 Objective 3 investigates the adherence of participants to the treatment as measured through
10 platform user data. Here we explore the user data from the platform through exploring the
11 average amount of content consumed by individuals on average for the dCBT intervention.
12 We will also explore the time taken to consume each block on average.
13

14
15 Objective 4 explores the appropriateness of the analysis, which consists of exploratory
16 analyses of the secondary measures (which will be used to measure the trial in future case), as
17 well as understanding the most appropriate model to fit to the data. To examine the
18 appropriateness of the assessment measures themselves. We will explore the distribution of
19 the different outcome measures by assessing the skew, kurtosis, means and variances, we will
20 also report the intra-cluster correlation coefficient.
21

22
23 To explore the most appropriate model, we will compare three linear regression models; a
24 simplified fixed effect model, a full fixed-effects model (which includes covariates beyond
25 the control vectors (please see Supplementary for list of such measures) and a mixed-effects
26 regression (includes a random effect to account for clusters in organisation level) and finally
27 a complete case analysis using mixed-effects model (to conduct a sensitivity analysis of
28 multiple imputation). We will use an intention-to-treat analysis to ensure robustness of the
29 results. We will compare the simplified, full and mixed model fits to identify the most
30 appropriate analysis for a randomised-controlled trial.
31

32
33 Missing data will be reported (alongside reasons for missingness where available), and the
34 missing data pattern will be explored. To explore the impact of missing data, we will run a
35 sensitivity analysis comparing the complete case analysis against multiple imputation to see
36 any observed differences in effects.
37

38
39 Objective 5 will be examined through semi-structured qualitative interviews to explore the
40 feasibility of the intervention, facilitators and barriers that impact engagement with the
41 intervention and subsequent behavioural changes. In these interviews, we aim to understand
42 the mechanisms of behaviour change, as facilitated by the intervention, and explore
43 implementation processes to identify the contextual factors that act as barriers and facilitators
44 to engagement. To do this, we ask about user perceptions and experiences of the intervention.
45 We will explore the perceived benefits from the participants perspective, as well as any
46 negative effects and fidelity constraints. We will randomly select 25 participants who have
47 completed the intervention (from both treatment and control arms) and have consented to be
48 contacted about follow-up interviews. These individuals will be invited to take part in an
49 online videoconferencing interview over Microsoft Teams with researchers from the
50 University of Warwick who are independent from the treatment delivery team of the
51 individual. Interviews will be audio-recorded using OBS studio and then subsequently
52 transcribed by a third-party University approved vendor. Qualitative interviews will be
53 conducted using a semi-structured interview schedule, consisting of open-ended questions
54 and suggested prompts. Interview recordings will be analysed using thematic and framework
55 analysis to identify the barriers and facilitators to change (i.e., what helped or prevented
56 participants from implementing aspects of the programme). We map the qualitative codes to
57 the COM-B model [28], using a framework consisting of the three core behavioural
58
59
60

1
2
3 determinants within this model : capability, opportunity and motivation. Capability refers to
4 physical and psychological capability (such as disability and memory or knowledge
5 respectfully). Opportunity refers to the physical and social connections and affords the
6 behaviours (such as geography and word of mouth referrals). Motivation denotes the
7 activation of approach and avoidance drives [29]. Themes will be generated using the to the
8 COM-B framework as a guide, where barriers and facilitators relating to each behavioural
9 determinant will be identified, and a thematic map will present a conceptualisation of which
10 barriers and facilitators were particularly important in impacting change. Any other insights
11 relevant to intervention feasibility, that cannot be mapped to the COM-B framework, will
12 also be considered when generating themes.
13
14
15
16

17 **[Figure 1 here]**
18
19

20 **Assessment of safety**

21 We anticipate a low risk of serious adverse events (such as death or hospitalisation.)
22 occurring during this trial, given the low base rate of negative events in the literature for
23 dCBT interventions [30]. We will record occurrences of serious adverse events (SAEs) in this
24 trial as resulting; in death, hospitalisation, life threatening, in persistent or significant
25 disability or incapacity, of a congenital abnormality or birth defect or is otherwise considered
26 medically significant by investigator. Adverse events are also a low risk during this trial,
27 however expected adverse events: concentration difficulties and low mood.
28
29
30

31 To report an AE or SAE, forms will be sent to the trial management team (CB, CK), who will
32 log them in a central database for trial monitoring. All forms will be logged in a central
33 database and reviewed by the trial management team on a monthly basis, with a cumulative
34 review of all safety information by an independent Trial Monitoring Committee (TMC). In
35 addition, the trial management team will monitor and send the total numbers of SAEs per
36 month to the TMC Chair – in order to expedite a safety review if more SAEs are being seen
37 than would be expected.
38
39

40 Given the online nature of the intervention and little contact with participants, it is unlikely
41 that the research team will be aware of SAE or AE unless reported by participants through
42 contact channels such as emails.
43
44

45 **Dissemination**

46 We will publish the results of this study in peer-reviewed journals. Findings will also be
47 presented at both national and international scientific meetings. The anonymised data will be
48 made accessible online wherever possible, if permitted by journal policies.
49
50

51 **Discussion**

52 In this intervention we test the feasibility of implementing a waitlist randomised-controlled
53 trial of dCBT intervention in sub-threshold non-clinical and clinical populations in the
54 workforce. The results from this feasibility trial will be used to inform a fully-powered
55 waitlist randomised controlled trial, which will test the efficacy of an dCBT intervention on
56 depression and anxiety in a workplace setting, the unique contribution will also be to show
57 that such effects are associated with improvement in work related outcomes such as
58 productivity.
59
60

Trial status

Recruitment commenced on 18 June 2021 and will be stopped on 31st December 2021.

Authors' contributions

CM is principal investigator. CM, NT, LW, CT, KP, and TM were involved in the design of the study. CT and KP led the treatment development. KP drafted the manuscript and all authors revised and approved the final manuscript.

Competing interests

Ethics approval and consent to participate

In accordance with Good Clinical Practice, all participants are provided with an information sheet and are required to provide informed consent for the screener and the trial, in order to participate. This included consent for their anonymised data to be published. Ethical approval for the study was granted by the University of Warwick's Biomedical Science and Research Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN (ISRCTN31161020). Protocol modifications will be submitted for approval to the BSREC committees prior to implementation, with the protocol amendments being disseminated across the research team and updated to the trial registry.

Funding

This research is supported by Midlands Engine (R.ESWM.3932). The study funders had no role in the study design, collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication


Acknowledgments

We thank all our participants without whom this research will not be possible. We thank the patient and public advisory committee of the study for their invaluable feedback in the different stages of the study. We also thank the research assistants, therapists and project administrator team facilitating the smooth delivery of the trial.

References

- 1 OECD. Mental Health and Work – United Kingdom. 2014. www.oecd.org/els/%0Amental-health-and-work-united-kingdom-9789264204997-en.htm
- 2 Deloitte. Mental health and employers; Refreshing the case for investment. 2020. <https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-monitor-deloitte-oct-2017.pdf%0Ahttps://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-mon>
- 3 Butterworth P, Leach LS, Pirkis J, *et al*. Poor mental health influences risk and duration of unemployment: a prospective study. *Soc Psychiatry Psychiatr Epidemiol* 2012;**47**:1013–21.
- 4 Social Exclusion Unit. Mental Health and Social Exclusion. London: 2004.
- 5 ONS. Sickness absence in the UK labour market. 2020.
- 6 Bubonya M, Cobb-Clark DA, Wooden M. Mental Health and Productivity at Work: Does What You Do Matter? *IZA Discuss Pap No 9879, Inst Study Labor* Published Online First: 2016. <http://hdl.handle.net/10419/141638> www.econstor.eu (accessed 6 Dec 2021).
- 7 Cuijpers P, Karyotaki E, de Wit L, *et al*. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. *Psychother Res* 2020;**30**:279–93.
- 8 Romijn G, Batelaan N, Kok R, *et al*. Internet-delivered cognitive behavioral therapy for anxiety disorders in open community versus clinical service recruitment: meta-analysis. *J Med Internet Res* 2019;**21**:e11706.
- 9 Gartlehner G, Gaynes BN, Amick HR, *et al*. Nonpharmacological versus pharmacological treatments for adult patients with major depressive disorder. 2015.
- 10 Mack S, Jacobi F, Gerschler A, *et al*. Self-reported utilization of mental health services in the adult German population—evidence for unmet needs? Results of the DEGS1-Mental Health Module (DEGS1-MH). *Int J Methods Psychiatr Res* 2014;**23**:289–303.
- 11 Ebert DD, Cuijpers P, Muñoz RF, *et al*. Prevention of mental health disorders using internet-and mobile-based interventions: a narrative review and recommendations for future research. *Front psychiatry* 2017;**8**:116.
- 12 Sander L, Rausch L, Baumeister H. Effectiveness of internet-based interventions for the prevention of mental disorders: a systematic review and meta-analysis. *JMIR Ment Heal* 2016;**3**:e6061.
- 13 Josephine K, Josefine L, Philipp D, *et al*. Internet-and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. *J Affect Disord* 2017;**223**:28–40.
- 14 Andersson G, Carlbring P, Titov N, *et al*. Internet interventions for adults with anxiety and mood disorders: a narrative umbrella review of recent meta-analyses. *Can J Psychiatry* 2019;**64**:465–70.
- 15 Andrews G, Basu A, Cuijpers P, *et al*. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. *J Anxiety Disord* 2018;**55**:70–8.
- 16 Kojima R, Fujisawa D, Tajima M, *et al*. Efficacy of cognitive behavioral therapy training using brief e-mail sessions in the workplace: a controlled clinical trial. *Ind Health* 2010;**48**:495–502.
- 17 Phillips R, Schneider J, Molosankwe I, *et al*. Randomized controlled trial of computerized cognitive behavioural therapy for depressive symptoms: effectiveness

- 1
2
3 and costs of a workplace intervention. *Psychol Med* 2014;**44**:741–52.
- 4 18 Tan L, Wang M-J, Modini M, *et al*. Preventing the development of depression at work:
5 a systematic review and meta-analysis of universal interventions in the workplace.
6 *BMC Med* 2014;**12**:74. doi:10.1186/1741-7015-12-74
- 7 19 Imamura K, Kawakami N, Furukawa TA, *et al*. Does Internet-based cognitive
8 behavioral therapy (iCBT) prevent major depressive episode for workers? A 12-month
9 follow-up of a randomized controlled trial. *Psychol Med* 2015;**45**:1907–17.
- 10 20 Imamura K, Kawakami N, Furukawa TA, *et al*. Effects of an internet-based cognitive
11 behavioral therapy intervention on improving work engagement and other work-
12 related outcomes: an analysis of secondary outcomes of a randomized controlled trial.
13 *J Occup Environ Med* 2015;**57**:578–84.
- 14 21 Haller H, Cramer H, Lauche R, *et al*. The prevalence and burden of subthreshold
15 generalized anxiety disorder: a systematic review. *BMC Psychiatry* 2014;**14**:1–13.
- 16 22 Lokkerbol J, Wijnen B, Ruhe HG, *et al*. Design of a health-economic Markov model
17 to assess cost-effectiveness and budget impact of the prevention and treatment of
18 depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;**21**:1031–42.
- 19 23 Panchal N, Kamal R, Orgera K, *et al*. The implications of COVID-19 for mental health
20 and substance use. *Kaiser Fam Found* 2020;**21**.
- 21 24 Santomauro DF, Herrera AMM, Shadid J, *et al*. Global prevalence and burden of
22 depressive and anxiety disorders in 204 countries and territories in 2020 due to the
23 COVID-19 pandemic. *Lancet* 2021;**398**:1700–12.
- 24 25 Mental Health Productivity Pilots. The Mental Health and Productivity Pilot (MHPP).
25 2021. <https://mhpp.me/> (accessed 9 Aug 2021).
- 26 26 Berking M, Whitley B. *Affect Regulation Training: A Practitioners' Manual*. Irvine,
27 California: : Springer 2010.
- 28 27 Snow G. blockrand: Randomization for block random clinical trials. *R Packag version*
29 2013;**1**.
- 30 28 Michie S, Atkins L, West R. The behaviour change wheel. *A Guid to Des Interv 1st ed*
31 *Gt Britain Silverback Publ* 2014.
- 32 29 Vlaev I, Dolan P. Action Change Theory : A Reinforcement Learning Perspective on
33 Behavior Change. *Rev Gen Psychol* 2015;**19**:69–95. doi:10.1037/gpr0000029
- 34 30 Oehler C, Görge F, Hegerl U, *et al*. A closer look at negative effects in a guided web-
35 based intervention for mild to moderate depression. *Clin Psychol Sci Pract*
36 2021;**28**:131.
- 37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



BMJ Open: first published as 10.1136/bmjopen-2021-060545 on 9 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Supplementary Material

Secondary Measures

The following psychometric will be used to explore their utility as outcome measures for a future fully powered randomised-controlled trial.

The General Anxiety Disorder-7 (GAD-7) is commonly used in primary and secondary mental health settings to measure symptom severity for General Anxiety Disorder (Spitzer, Kroenke, Williams, & Löwe, 2006). The GAD-7 is comprised on seven items each scored on a four-point Likert scale, a score of 10 has been shown to correctly diagnose cases of generalised anxiety disorder with 89% sensitivity and 82% specificity, with high test-retest reliability (ICC = 0.83). The GAD-7 also shows high concurrent validity with high scores being associated with disability and functional impairment (Ruiz et al., 2011; Spitzer et al., 2006).

The Patient Health Questionnaire-9 (PHQ-9) is commonly used, in primary care settings to assess the severity of depression across the nine DSM-IV criteria for major depressive disorder on a four-point Likert scale (Cameron, Crawford, Lawton, & Reid, 2008). The PHQ-9 has been shown to demonstrate high diagnostic accuracy in at risk populations (Haddad et al., 2013; Janneke et al., 2012), and in clinical populations. A criterion score of ≥ 10 has a 88% sensitivity and specificity for major depressive disorder (Kroenke, Spitzer, & Williams, 2001). Empirical research demonstrates high internal consistency ($\alpha = 0.91$; Hansson, Chotai, Nordstöm, & Bodlund, 2009) and a valid latent structure even when administered in nonclinical samples (CFI = 0.914- 0.983; Ito, Takebayashi, Muramatsu, & Horikoshi, 2018).

The Insomnia Severity Index (ISI) is a seven-item psychometric which has been validated with reference to the diagnostic criteria for primary insomnia in the DSM-IV. The ISI uses a five point Likert scale response to each item (score range 0–28). A score of ≥ 15 identifies cases of clinical insomnia with 94% sensitivity and specificity (Bastien, Vallières, & Morin, 2001). A reduction of 8.4 has been shown to be associated with moderate improvement in clinical populations (Morin, Belleville, Bélanger, & Ivers, 2011), with responses being validated in non-clinical samples as demonstrating a high internal reliability ($\alpha = 0.81 - 0.91$ (Morin et al., 2011; Yu, 2010).

Job productivity - measured through the Work Productivity and Activity Impairment: General Health v2.0 (WPAI:GH; (Reilly, Zbrozek, & Dukes, 1993). The WPAI:GH is a six item psychometric which focuses on: 'Absenteeism', 'Presenteeism', 'Work productivity loss' and 'Activity Impairment'. The WPAI:GH has shown strong psychometric properties with good internal consistency ($\alpha = 0.74$), with a high intraclass correlation coefficient ($r = 0.79 - 0.90$) in clinical populations (Zhang et al., 2010). The WPAI has been used in non-clinical samples and has shown good face validity (Duke & Montag, 2017).

Job satisfaction - measured using the Indiana Job Satisfaction Scale (IJSS; Resnick & Bond, 2001). The IJSS is a 32-item psychometric coded on a four-point Likert response of "Strongly disagree" to "Strongly agree", and is comprised of six subscales: 'General Satisfaction', 'Pay', 'Advancement and Security', 'Supervision', 'Coworkers' and 'How I feel about this job'. The IJSS yields strong psychometric properties with high internal consistence ($\alpha = 0.90$) and test-retest reliability ($r = .75$) (Resnick & Bond, 2001).

1
2
3 Well-being – we measure subjective well-being using the Warwick-Edinburgh Mental Health
4 Well-being Scale (WEMWBS, Tennant et al., 2007). The WEMWBS consists of 14-items on
5 a five-point likert scale ranging from “None of the time” to “All of the time”. The scale has
6 been shown to hold good psychometric properties, with strong internal consistency ($\alpha = 0.91$)
7 and was shown to hold high concurrent validity (Tennant et al., 2007). When applied to
8 nonclinical samples the WEMWBS still shows similar psychometric properties with high
9 internal consistency ($\alpha = 0.94$; test-retest = 0.83; Dong et al., 2016).
10
11

12 Quality of life- measured using the EuroQOL EQ-5D-5L questionnaire (Herdman et al.,
13 2011). The EQ-5D-5L consists of six items, five items measured through five-point likert-
14 scale responses to mobility, self-care, usual activities, pain/discomfort and
15 anxiety/depression, with a sixth item of a rating of health on a visual analogue scale ranging
16 from 0-100. The EQ-5D-5L has shown high internal consistency in clinical samples ($\alpha =$
17 0.86; (Bilbao et al., 2018) and in nonclinical populations ($\alpha = 0.84$; Kim & Ko, 2018).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a pilot or feasibility randomised trial in the title	2
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	2
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	3
	2b	Specific objectives or research questions for pilot trial	3
Methods			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	4
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
	4c	How participants were identified and consented	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	6,7
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	N/A
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	N/A

Sample size	7a	Rationale for numbers in the pilot trial	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8,9
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	9
	11b	If relevant, description of the similarity of interventions	9
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	9, 10
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	N/A
	13b	For each group, losses and exclusions after randomisation, together with reasons	N/A
Recruitment	14a	Dates defining the periods of recruitment and follow-up	N/A
	14b	Why the pilot trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	N/A
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	N/A
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	N/A
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A

	19 a	If relevant, other important unintended consequences	N/A
Discussion			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	13
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	13
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	13
	22 a	Implications for progression from pilot to future definitive trial, including any proposed amendments	13
Other information			
Registration	23	Registration number for pilot trial and name of trial registry	14
Protocol	24	Where the pilot trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	14
	26	Ethical approval or approval by research review committee, confirmed with reference number	14

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355.

*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

BMJ Open

A digital Cognitive Behavioural Therapy and Emotion Regulation intervention in the workplace: Study protocol for a feasibility randomised waitlist-controlled trial to improve employee mental wellbeing and help them stay engaged and productive in work

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060545.R1
Article Type:	Protocol
Date Submitted by the Author:	23-May-2022
Complete List of Authors:	Patel, Krishane; University of Warwick Moukhtarian, Talar Rita; University of Warwick, WMG Toro, Carla; University of Warwick, WMG Russell, Sean; Coventry University Daly, Guy; Coventry University Walasek, Lukasz; University of Warwick Tang, Nicole; University of Warwick, Psychology Meyer, Caroline; University of Warwick
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Occupational and environmental medicine
Keywords:	MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Adult psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3 **A digital Cognitive Behavioural Therapy and Emotion Regulation intervention in the**
4 **workplace: Study protocol for a feasibility randomised waitlist-controlled trial to**
5 **improve employee mental wellbeing and help them stay engaged and productive in**
6 **work**
7
8
9

10 Krishane Patel^{1*}, Talar Moukhtarian¹, Carla Toro¹, Sean Russell², Guy Daly², Lukasz
11 Walasek³, Nicole Tang³ and Caroline Meyer¹
12
13
14
15

16 **Author affiliation**

17 1 - WMG, University of Warwick, University Road, Coventry, CV4 7AL, UK

18 2- Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1
19 5FB, UK

20 3 - Department of Psychology, University of Warwick, University Road, Coventry, CV4
21 7AL, UK
22
23

24 *Correspondence to Dr Krishane Patel, Behaviour and Wellbeing Science, International
25 Digital Laboratory, Warwick Manufacturing Group, University of Warwick, Lord
26 Bhattacharyya Way, Coventry CV4 7AL
27 Email: krishane.r.patel@warwick.ac.uk
28
29

30 Abstract (283 words)
31

32 Introduction: This trial tests the feasibility of implementing a digital cognitive behavioural
33 therapy for Common Mental Disorders in the workplace. The study protocol follows on the
34 CONSORT (Consolidated Standards of Reporting Trials) recommendations.
35
36

37 Methods and analysis: Feasibility of the implementation for a mixed methods evaluation with
38 a two-arm randomised waitlist control design of an eight-week digital cognitive behavioural
39 therapy (dCBT) intervention through self-guided online platform versus waitlist control (i.e.
40 life as usual). This study examines the ease of third-party buy in from organisations from
41 approach to agreement, and the engagement of employees through the trial indicated by the
42 completion of outcome measures. In addition, we also explore how participants use the
43 platform, the appropriateness of the analysis both with reference to the outcome measures and
44 linear modelling. Finally, we examine the acceptability of the intervention based on
45 participants experiences using qualitative interviews through a framework analysis.
46 Assessments take place at baseline (T0), at 8 weeks post-treatment (T1), and at follow-up 16-
47 weeks post-randomisation (T2). We will recruit from the 1st July to 31st December 2021 for
48 employees and self-employed workers with depression and anxiety symptoms (sub-clinical and
49 clinical levels) who are not seeking or engaged in treatment at the time of the trial.
50
51
52

53 Ethics and dissemination: Full approval was given by the University of Warwick Biomedical
54 and Research Ethics Committee (BSREC 45/20-21). The current protocol version is 2.8 (Aug-
55 2021). Publication of results in peer-reviewed journals will inform the scientific, clinical and
56 business communities. We will disseminate results through webinars, conferences, newsletter
57 as well as a lay summary of results on the study website (mhpp.me).
58
59

60 Trial registration: ISRCTN, ID: ISRCTN31161020. Registered on 08/06/2021.

1
2
3
4 Keywords: Common Mental Disorders, Feasibility, Workplace, iCBT, Online, Emotion
5 Regulation, Mental Health, Productivity
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

- We test the feasibility of running a novel hybrid digital cognitive behavioural therapy for anxiety and depression to workers recruited from small, medium and large businesses in the Midlands region of the UK
- This feasibility trial will be used to inform future large-scale research for early intervention of worker with mild to severe symptoms of insomnia and emotion regulation difficulties will contribute to the understanding of benefits of early interventions in the workplace, its impact on mental health and productivity.
- This trial incorporates mixed-methods research to identify barriers and facilitators to engagement of the platform and to inform study design in future use.
- This study will provide unique insights to generate designs for potential larger nationwide service delivery programme of mental health interventions in the workplace.

Introduction

In the United Kingdom (UK), poor mental health costs the economy an estimated £70 billion/year, equivalent to 4.5% of the UK's GDP [1]. Common Mental Disorders (CMD) comprising of depressive and anxiety related disorders are a major contributor to these costs. Within the workplace, one in six workers experience some form of mental health problems [2] which may or may not be as a result of their workplace environment. Furthermore, workers who experience CMDs are significantly less likely to remain in employment than their healthy counterparts [3,4]. The prevalence of mental illness in the workplace is problematic because of a) absenteeism where the loss in workforce as a result of sickness, with an estimated 11.6% of sickness absence caused by CMD [5], totalling almost 16 million days across the UK labour market; b) mental health can diminish productivity in the workplace, a concept called presenteeism [6] which can have significant impact on employee productivity across the labour market.

Psychological therapy (e.g. cognitive behavioural therapy) has been shown to be effective in treating depression and anxiety [7]. One common form of psychological treatment is cognitive behavioural therapy (CBT) which uses cognitive and behavioural principles to treat underlying cognitions and behaviour of psychiatric conditions. CBT has been shown to significantly reduce symptoms of anxiety [8], and depression [9]. Despite evidence showing that psychological therapies such as CBT are effective for depression and anxiety disorders [10], provision in primary care is low and in secondary care has been characterised by long waiting lists. To tackle this issue, Improving Access to Psychological Therapies (IAPT) was introduced to make psychological therapies for depression and anxiety available in a stepped approach within a collaborative model [11,12].

The World Health Organisation predicted around 10 years ago that by 2030 depression will be second to HIV/AIDS in international burden of disease with calls to focus on early intervention and prevention of the condition [13]. Effective early interventions can prevent, delay or reduce the onset or progress of a mental health condition [14], and are more cost-effective than treatments through specialist services or primary care providers [15]. However, to be eligible for therapies through IAPT, individuals must have symptoms above the clinical cut-off (10 and above on the PHQ-9 for depression, or 8 and above on the GAD-7 for anxiety) [16]. Currently, there are no evidence-based early intervention provisions for individuals with subthreshold symptoms.

Digital interventions provide low cost, easily scalable delivery methods to provide access at the population-level, and to individuals that usual care services may not reach. This form of digital-based CBT (dCBT) provides access to resources for self-learning or supervised treatment [16]. dCBT is effective in the prevention [17,18] and treatment of the most common CMD – depression and anxiety [8,19–21] which indicates potential opportunities to tackle large-scale mental health issues through innovative and cost-effective means.

Implementation of CBT and dCBT intervention in workplace settings have been shown to improve mental health and reduce incidence of the clinical levels of CMDs [22,23]. Meta-analyses of workplace interventions for CMDs show a significant standardized mean difference of 0.12, demonstrating small significant effects [24]. A large randomised controlled trial demonstrated that dCBT showed strong effects in treating employees with major depressive episodes [25], furthermore dCBT interventions have also been shown to promote work engagement amongst sub-clinical and healthy workers [26].

1
2
3 The majority of studies to date have focused on clinical levels of depression and less so on
4 individuals with sub-clinical symptoms. It has been suggested that sub-threshold populations
5 of CMDs are greater than their clinical counterparts [27]. In addition, interventions for
6 subclinical populations are deemed highly cost-effective [28]. Cases of CMDs have been
7 further intensified over the COVID-19 pandemic with rates of generalised-anxiety disorder
8 increasing from one in ten to one in four adults in the US populations [29, 30, 31].
9 Interventions to reduce mental health severity in the workplace can therefore have subsequent
10 effects in workplace absenteeism and productivity, as well as increased job satisfaction [26].
11 Given the relatively few studies that examine intervention on subclinical and clinical levels of
12 CMDs in the workplace, this trial is the first to explore a fully online intervention for a UK
13 sample in the workplace.
14
15

16
17 This study - will examine the feasibility of a dCBT for mild to severe depression and anxiety
18 for employees in the workplace. The study is one of three trials under the Mental Health
19 Productivity Pilots (MHPP), funded by the Midlands Engine [25] with a focus to improve
20 workforce mental health and productivity.
21
22

23 **Research aims**

24 The primary aim of this trial is to investigate the feasibility of a multi-centre waitlist RCT in
25 the Midlands region of England that examines whether a dCBT treatment for employees
26 reporting mild to clinical levels of depression or anxiety reduces symptom severity for
27 employees in the workplace. The trial will partner with participating employers to recruit
28 participants from workplace settings through employers and through social media
29 advertisement.
30
31

32 Nested within this primary aim is an exploration of the feasibility of the methodological
33 approach, focusing particularly upon:
34

- 35 • Willingness of organisations to participate in a trial (Objective 1);
- 36 • Willingness of employees to participate in a trial (Objective 2);
- 37 • Adherence of participants to the treatment as measured through platform user data
38 (Objective 3);
- 39 • Appropriateness of the analytical approach (Objective 4).
- 40 • Acceptability of the intervention based on participants subjective experiences
41 (Objective 5)
42
43

44 The results of this feasibility trial will be used to inform a future RCT to understand whether
45 a dCBT can help to reduce symptom severity and improve mental health and productivity for
46 employees in the workplace. In addition, secondary aims are to assess the barriers and
47 enablers of the intervention programme to identify key mechanisms of actions through a
48 process evaluation. Tertiary aims explore the impact of the intervention by examining the
49 reduction in symptom severity for depressive and general anxiety related symptoms as
50 measured through the Patient Health Questionnaire-9 (PHQ-9) and the General Anxiety
51 Disorder-7 (GAD-7) psychometrics as well as work productivity.
52
53

54 **Methods**

55 **Trial Design**

56 We implement a multi-centre, waitlist randomised controlled trial (wRCT) in which we
57 explore the feasibility of delivering a CBT intervention against a waitlist-control group
58 (WLC) with no active treatment. We target recruitment for participants with mild to severe
59
60

depression or general anxiety symptoms who have not received a formal diagnosis or are currently receiving professional care for a mental health condition. The dCBT will be delivered via a self-guided digital online platform over an eight-week period.

Participants will be screened for the presence of depressive and anxious symptoms. Upon verification that inclusion criteria are met, participants will provide informed consent, complete outcome measure assessments, and complete the intervention through web-based platforms. Online assessment of the primary and secondary dependent variables will take place at week 0 baseline (pre-intervention), week 8 (post-treatment) and week 16 (follow-up). All participants in the WLC group will be offered the dCBT intervention at week 8 (see Fig. 1 for trial flowchart).

Ethical approval has been granted from the University of Warwick Biomedical and Research Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN (ISRCTN13596153).

Participants

The REST (Reducing Stress in the workplace) trial shares a common screening process with two additional trials and therefore a shared Participant Information Leaflet (PIL) is used, under the umbrella of the INWORK program. However, no access is provided between trials and all studies use mutually exclusive inclusion/exclusion criteria to ensure no overlapping participant sample populations or competition in recruitment.

We will recruit full-time and part-time employees and workers self-employed and from organisations across the Midlands region of England who fulfil the inclusion/exclusion criteria (Table 1). This is defined by the Midlands Engine as a population of approximately 11 million, with 4.5 million jobs (Midlands Engine, 2021).

Table 1. Inclusion/Exclusion criteria for REST study

Inclusion criteria	Exclusion criteria
Able to give informed consent	Currently receiving treatment (psychological or pharmacological) from mental health services (e.g. GP, private clinic, Improving Access to Psychological Therapies (IAPT) services, specialist and community mental health services)
English-speaking	Retiring in the next 10 months
In employment (including being on furlough)	Currently taking part in other psychological intervention trials
Insomnia Severity Index score: $x < 8^{**}$	
General Anxiety Disorder-7 score: $x > 5$ or Patient Health Questionnaire-9 score: $x > 5$	In shift work*
≥ 18 years of age	

*We do not specify on working hours, or place of work

** We use the Insomnia Severity Index to differentiate REST from other trials being conducted at the same time with the INWORK programme. This criterion is used to ensure that REST can be differentiated and that there is no population overlap between the INWORK trials.

Components of the REST intervention

The REST intervention is an online self-guided programme structured into eight-weekly sessions with varying number of topics each week, lasting approximately 60 minutes each. The content incorporates techniques from Cognitive Behavioural Therapy (CBT) and Emotion Regulation [32] using workplace relevant examples. The goals of the intervention are to reduce symptoms of stress, depression and anxiety and provide participants with practical skills and techniques to help cope with stressful situations. The core components of the REST intervention can be shown below on Table 2.

Table 2. REST content across the intervention

Week 1	<ul style="list-style-type: none"> • What is stress? • Stress cycle • REST diary • Setting SMART goals
Week 2	<ul style="list-style-type: none"> • Non-judgmental awareness • Behavioural activation • Emotion focused skills
Week 3	<ul style="list-style-type: none"> • Work-related stress • Rumination and worrying • Problem solving skills
Week 4	<ul style="list-style-type: none"> • Cognitions • Managing unhelpful thinking styles • Cognitive restructuring
Week 5	<ul style="list-style-type: none"> • Work-life balance • Time management Skills
Week 6	<ul style="list-style-type: none"> • Physiology of stress • Relaxation techniques
Week 7	<ul style="list-style-type: none"> • Behavioural change • Healthy lifestyle choices (e.g. sleep, physical activity)
Week 8	<ul style="list-style-type: none"> • Programme summary • Relapse management • Self-compassion • Resilience

Waitlist control

Participants initially allocated to the waitlist control group, will be asked to provide a baseline response to primary and secondary measures but will not receive any active treatment for the first eight weeks. After the eight-week period, waitlist control participants will be asked to provide a post-control group measure for primary and secondary outcomes at which point they will be automatically enrolled into the intervention group for a further eight weeks.

Measures

Participants will be prompted by email to complete all outcome measures on a secure online survey platform (Qualtrics). The order of the assessments will be consistent across all participants and all time-points. If participants do not complete measures within 5 days they will receive three further email reminders every five days of non-response.

Primary outcomes

To examine the feasibility of our intervention under a multi-centre waitlist randomised controlled trial design, we explore five primary objectives. We examine Objective 1 by monitoring organisational traffic (defined as conversion rates and absolute counts) into the trial across four identified stages:

Stage 1: Contacted

Stage 2: Teleconference

Stage 3: Further engagement

Stage 4: Verbal agreement and branch selection

For each partnership with an organisation we document the number of centres as well as the number of employees.

We examine Objective 2 by exploring participant traffic across the trial flow (through social media and employer pathways). We define the trial flow for participants traffic as follows:

1. Expression of interest
2. Screener completion
3. Invitation to trial
4. Consent to study and randomisation
5. Post-study (which is defined as end of control and beginning of intervention for those initially placed in the waitlist control group)
6. Follow-up measures or outcome measures from Qualtrics

We will explore the conversion rates and absolute counts of employees from each stage of the trial flow, evaluating over recruitment pathways (please see section Recruitment procedures for more information on page 10).

We explore Objective 3 through the user data of platform access for the dCBT intervention. We will explore how much content was consumed by individuals on average, and the time to complete each block on average.

We explore Objective 4 through analysis of secondary measures listed below. We firstly explore the acceptability of the assessment measures themselves; this is conducted by exploring the completion rate of questionnaires, we will further explore the descriptive statistics (e.g. distribution of the outcome measures, skew, kurtosis, ICC, means and variances).

We will evaluate the fit of our statistical model comparing a fixed-effects regression model against a mixed-effects linear model (accounting for clusters in organisation level). Furthermore, we also evaluate the statistical cleaning procedures using a sensitivity analysis in which we compare multiple imputation methods against complete case analysis.

We also examine the feasibility of the trial implementation through semi-structured qualitative interviews as part of Objective 5, which will explore the feasibility and barriers of

1
2
3 the intervention. We will use thematic analysis to identify the common themes mapped to a
4 framework to provide a theoretical perspective on how to improve the intervention.
5

6 7 **Secondary outcomes**

8 Our secondary outcomes explore the impact of the intervention on prevalent mental health
9 questionnaires to assess symptom severity in anxiety and depression. In addition, we also
10 explore the impact of the intervention on job satisfaction, well-being, quality of life, work
11 productivity and insomnia severity. The different measures are listed in the Supplementary
12 section and will be collected at baseline (T0) post-study (T1), and follow up (T2). In addition,
13 the GAD-7, PHQ-9 and the Insomnia Severity Index will be used as part of the screening
14 questionnaire set to identify eligible participants for the study. We also ask participants to
15 self-report use of self-help resources or if they are taking part in any other behavioural
16 treatment of interventions. See the supplementary file for a detailed list of the outcome
17 measures being used, along with a summary of their psychometric properties.
18
19

20 21 **Sample size**

22 Given little a-priori information, we will explore the feasibility of recruiting participants into
23 the trial. We will recruit for eight months from June to December 2021. We will explore the
24 recruitment rate over time across the employer and direct social media advertisement. We will
25 estimate the effect size obtained from the analysis of the trial detailed under Objective 4 in the
26 Analyses section on page 11, for sample size estimation for a future full scale randomised
27 controlled trial.
28

29 We anticipate a nominal sample size of 60 participants based on Lewis et al
30 recommendations for feasibility trials [33].
31

32 33 **Recruitment procedures**

34 The REST study will recruit through multiple channels. The first pathway denotes employers
35 registering interest as partners via the MHPP website (mhpp.me), who will act as gatekeepers
36 to their employees. They will not recruit participants themselves but only signpost the
37 information, Employers will advertise the intervention within their organisations through
38 newsletters and emails.
39

40 The second pathway is through direct recruitment by the research team via online social
41 media (e.g., Twitter, LinkedIn and Facebook) and print (e.g., leaflets and flyers in public and
42 retail settings) advertisements. Individuals who express interest through this pathway will be
43 from the wider working community in the Midlands.
44
45

46 Initial interest will be taken through a survey form hosted by the Qualtrics servers. This will
47 only take brief employment information (organisation name, location and email address) in
48 order to determine whether this individual is listed under a partner or through direct
49 recruitment strategies.
50

51 The research team will then contact interested employees by sending them the INWORK
52 PIL. This trial uses a two-stage consent process, where after initial interest, participants will
53 be asked to take part in an eligibility screening questionnaire set, after which those eligible
54 will be invited to take part in the trial. The screening questionnaire set consists of the GAD-7,
55 PHQ-9 and the ISI. We will also ask participants to confirm they are older than 18, whether
56 they have a diagnosis of a mental health condition, are under the management of a mental
57 health service.
58
59
60

1
2
3 If the scores on any of the three scales yield above the clinical threshold (this is denoted with
4 a score of at-15 on the GAD-7 [34] or the PHQ-9 [35] or 15 of above on the ISI [36], we will
5 recommend these individuals to contact their GP and signpost to contact Improving Access to
6 Psychological Therapies services. Symptom severity will not exclude them from taking part
7 in the study. Participants will need to acknowledge reading the advice to continue with the
8 screening questionnaire set. Individuals who pass the eligibility criteria as listed in Table 1
9 above will be invited into the REST trial.
10
11

12 **Patient and Public Involvement**

13 Patient and Public Involvement We have formed a group of four individuals with lived
14 experience of mental health problems who are currently in employment, and they will
15 contribute during the trial by reviewing participant information sheets, consent form,
16 intervention materials and questionnaire measures. They will advise on recruitment
17 procedures and methods to engage prospective participants/retain enrolled participants.
18
19

20 **Randomisation**

21 Participants are assigned to the dCBT or WLC arms through a simple randomisation with
22 blocking using a 1:1 allocation ratio. We use random length block between two and eight, to
23 minimise the risk of uneven groups. The randomisation is conducted using '*blockrand*'
24 package [37]. We stratify the randomisation process across centres based on employee size
25 within the partnered employer pathway.
26
27

28 Due to unknown organisation size considerations, individuals through direct recruitment will
29 not be stratified over centres. Randomisation will be conducted by a researcher independent
30 of allocating participants and will be blinded to the subsequent allocations. Members of the
31 research team will be unable to influence randomisation and will be concealed from future
32 assignments.
33
34

35 **Allocation concealment mechanism**

36 The trial statistician (KP) will provide a prescriptive randomisation allocation sequence file
37 stored in a *.csv file. The file is provided to the trial coordination team, who enrolls
38 participants into the trial, doing so automatically allocates a condition to each participant. The
39 allocation list is locked to prevent any tampering.
40
41

42 **Implementation**

43 The trial statistician (KP) generates the random allocation sequence, and the code to match
44 each participant to their respective allocation sequence (through row wise matching of row
45 numbers). The allocation is conducted as part of the trial coordination team enrolling
46 participants into the trial Masterfile as part of parsing in logistical data. Participants are
47 assigned to their respective allocation through an email sent by the trial coordination team.
48
49

50 **Blinding**

51 As this is a single-blind waitlist RCT, participants after consent will be informed of the two
52 allocation groups, will not be blinded to their randomisation outcome and will be explicitly
53 informed of their allocation once randomised. The trial coordination team who handle the
54 administrative and logistical requirements of the trial will be unblinded to the allocation of
55 participants, however the researchers will be blinded to the trial allocation. Statistical
56 analyses will be conducted by members of the research team who will only have access to all
57 non-identifiable data.
58

59 Any instances of unblinding would be documented and retained in trial
60 documentation. It is likely that the majority of instances of unblinding would usually be

involve a participant withdrawing for treatment or undergoing treatment cessation due to unforeseen circumstances and would therefore require no further action from the researcher. However, in cases of mistakes where participants have contacted the researcher, then any further contact with that participant will be handled by a separate researcher.

Analyses

We will record and report all participant flow through the trial in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. We will report descriptive statistics for recruitment, dropout, and completeness of interventions, in addition we will report a sample breakdown.

We assess the feasibility of the REST trial in accordance with the five research objectives:

- Willingness of organisations to participate in a trial (Objective 1);
- Willingness of employees to participate in a trial (Objective 2);
- Adherence of participants to the treatment as measured through platform user data (Objective 3);
- Appropriateness of the analytical approach (Objective 4).
- Acceptability of the intervention based on participants subjective experiences (Objective 5)

Objective 1 explores organisational traffic in partnering with third-party organisations to recruit employees in workplace settings. To analyse organisational traffic into the study we use descriptive statistics calculating frequency counts and percentage. Table 3 below demonstrates the template in which we will document and present the information across (Stage 1- Engagement; Stage 2-Teleconference; Stage 3-Further engagement; Stage 4-Verbal agreement and centre selection).

Table 3. Organisational traffic into the REST study

Employer ID	Number of Employees	Number of potential centres	Stage 1	Stage 2	Stage 3	Stage 4
1	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
2	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
...	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
n	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
Total	N	N	N	N	N	N
Attrition	%	%	%	%	%	%

Objective 2 investigates the feasibility of recruiting and maintaining participants in the REST trial. We explore Objective 2 by examining participant traffic across the trial flow (see Figure 1), through social media and employer recruitment pathways. To analyse organisational traffic into the study, we use descriptive statistics calculating frequency counts and percentage across the trial stages (see Table 4).

Table 4. Organisational traffic into the REST study

Recruitment Pathway	Employer ID	Express interest	Screeners	Invite to Trial	Consent, randomise and baseline measure completion (T0)	Post-study outcome measure completion at 8 weeks (T1)	Follow-up measure completion at 16 weeks post randomisation (T2)
Employer pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%
Direct Social media advertisement pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%

We will also conduct a chi-squared test to compare overall attrition rates across the two recruitment pathways to determine if there is any practical utility in one form of recruitment over another.

Objective 3 investigates the adherence of participants to the treatment as measured through platform user data. Here we explore the user data from the platform through exploring the average amount of content consumed by individuals on average for the dCBT intervention. We will also explore the time taken to consume each block on average. The user data provided will include at the aggregate level information on which links were accessed and frequency count data of link usage. We will obtain aggregate data at the individual level such as the amount of content (at the weekly level) consumed by each participant, but not how long was spent on each page.

Objective 4 explores the appropriateness of the analysis, which consists of exploratory analyses of the secondary measures (which will be used to measure the trial in future case), as well as understanding the most appropriate model to fit to the data. To examine the appropriateness of the assessment measures themselves. We will explore the distribution of the different outcome measures by assessing the skew, kurtosis, means and variances, we will also report the intra-cluster correlation coefficient.

To explore the most appropriate model, we will compare three linear regression models; a simplified fixed effect model, a full fixed-effects model (which includes covariates beyond the control vectors (please see Supplementary for list of such measures) and a mixed-effects regression (includes a random effect to account for clusters in organisation level) and finally a complete case analysis using mixed-effects model (to conduct a sensitivity analysis of multiple imputation).

1
2
3 We will try to fit a model as complex as the fits the following decision rule: 20 participants
4 per variable. We adopt a decision rule to ensure that the models can converge and that the
5 results are interpretable. We will only fit models that conform to the above decision rule
6 using the GAD-7 and PHQ-9 as dependent variables. We account for family-wise error using
7 a Bonferroni correction and divide our alpha-level across our two dependent variables.
8
9

10 We aim to fit three models, each growing in further complexity. The first model uses a
11 simple mixed-effects specification which includes dummy variable for treatment effects with
12 an additional factor for cohort, and an interaction term for both treatment and cohort, we also
13 include a random effect for each participant.
14

15 The second model includes the terms specified in the above nested model, in addition, we
16 also include a vector of control variables to account for demographic factors, as well as
17 employer, in addition to potential covariates from the secondary measures (IJSS, WPAI:GH
18 and the WEMWBS) and potential additional treatment. In this model, we also include as a
19 covariate, the baseline values of the ISI, GAD7 and PHQ-9 in this full fixed-effects model.
20
21

22 If the sample size is appropriate we also implement a third more complex model which is the
23 same as the previous model, but we include an additional random-effects term of employer in
24 the mixed-effects model to account for clustering effects.
25
26

27 We will use an intention-to-treat analysis to ensure robustness of the results. We will
28 compare the simplified, full and mixed model fits to identify the most appropriate analysis for
29 a randomised-controlled trial.
30
31

32 Missing data will be reported (alongside reasons for missingness where available), and the
33 missing data pattern will be explored. To explore the impact of missing data, we will run a
34 sensitivity analysis comparing the complete case analysis against multiple imputation to see
35 any observed differences in effects.
36
37

38 Objective 5 will be examined through semi-structured qualitative interviews to explore the
39 feasibility of the intervention, facilitators and barriers that impact engagement with the
40 intervention and subsequent behavioural changes. In these interviews, we aim to understand
41 the mechanisms of behaviour change, as facilitated by the intervention, and explore
42 implementation processes to identify the contextual factors that act as barriers and facilitators
43 to engagement. To do this, we ask about user perceptions and experiences of the intervention.
44 We will explore the perceived benefits from the participants perspective, as well as any
45 negative effects and fidelity constraints. We will randomly select 25 participants who have
46 completed the intervention (from both treatment and control arms) and have consented to be
47 contacted about follow-up interviews. These individuals will be invited to take part in an
48 online videoconferencing interview over Microsoft Teams with researchers from the
49 University of Warwick who are independent from the treatment delivery team of the
50 individual. Interviews will be audio-recorded using OBS studio and then subsequently
51 transcribed by a third-party University approved vendor. Qualitative interviews will be
52 conducted using a semi-structured interview schedule, consisting of open-ended questions
53 and suggested prompts. Interview recordings will be analysed using thematic and framework
54 analysis to identify the barriers and facilitators to change (i.e., what helped or prevented
55 participants from implementing aspects of the programme). We map the qualitative codes to
56 the COM-B model [38], using a framework consisting of the three core behavioural
57 determinants within this model : capability, opportunity and motivation. Capability refers to
58
59
60

1
2
3 physical and psychological capability (such as disability and memory or knowledge
4 respectfully). Opportunity refers to the physical and social connections and affords the
5 behaviours (such as geography and word of mouth referrals). Motivation denotes the
6 activation of approach and avoidance drives [39]. Themes will be generated using the to the
7 COM-B framework as a guide, where barriers and facilitators relating to each behavioural
8 determinant will be identified, and a thematic map will present a conceptualisation of which
9 barriers and facilitators were particularly important in impacting change. Any other insights
10 relevant to intervention feasibility, that cannot be mapped to the COM-B framework, will
11 also be considered when generating themes.
12
13
14

15
16 **[Figure 1 here]**
17

18 19 **Assessment of safety**

20 We anticipate a low risk of serious adverse events (such as death or hospitalisation.)
21 occurring during this trial, given the low base rate of negative events in the literature for
22 dCBT interventions [40]. We will record occurrences of serious adverse events (SAEs) in this
23 trial as resulting; in death, hospitalisation, life threatening, in persistent or significant
24 disability or incapacity, of a congenital abnormality or birth defect or is otherwise considered
25 medically significant by investigator. Adverse events are also a low risk during this trial,
26 however expected adverse events: concentration difficulties and low mood.
27
28

29
30 To report a AE or SAE, forms will be sent to the trial management team (CB, CK), who will
31 log them in a central database for trial monitoring. All forms will be logged in a central
32 database and reviewed by the trial management team on a monthly basis, with a cumulative
33 review of all safety information by an independent Trial Monitoring Committee (TMC). In
34 addition, the trial management team will monitor and send the total numbers of SAEs per
35 month to the TMC Chair – in order to expedite a safety review if more SAEs are being seen
36 than would be expected.
37
38

39 Given the online nature of the intervention and little contact with participants, it is unlikely
40 that the research team will be aware of SAE or AE unless reported by participants through
41 contact channels such as emails.
42
43

44 **Dissemination**

45 We will publish the results of this study in peer-reviewed journals. Findings will also be
46 presented at both national and international scientific meetings. The anonymised data will be
47 made accessible online wherever possible, if permitted by journal policies.
48
49

50 **Discussion**

51 In this intervention we test the feasibility of implementing a waitlist randomised-controlled
52 trial of dCBT intervention in sub-threshold non-clinical and clinical populations in the
53 workforce. The results from this feasibility trial will be used to inform a fully-powered
54 waitlist randomised controlled trial, which will test the efficacy of a dCBT intervention on
55 depression and anxiety in a workplace setting, the unique contribution will also be to show
56 that such effects are associated with improvement in work related outcomes such as
57 productivity.
58
59
60

Trial status

Recruitment commenced on 18 June 2021 and will be stopped on 31st December 2021.

Authors' contributions

CM is principal investigator. CM, NT, LW, CT, KP, and TM were involved in the design of the study. CT and KP led the treatment development. KP drafted the manuscript and all authors revised and approved the final manuscript.

Competing interests**Ethics approval and consent to participate**

In accordance with Good Clinical Practice, all participants are provided with an information sheet and are required to provide informed consent for the screener and the trial, in order to participate. This included consent for their anonymised data to be published. Ethical approval for the study was granted by the University of Warwick's Biomedical Science and Research Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN (ISRCTN31161020). Protocol modifications will be submitted for approval to the BSREC committees prior to implementation, with the protocol amendments being disseminated across the research team and updated to the trial registry.

Funding

This research is supported by Midlands Engine (R.ESWM.3932). The study funders had no role in the study design, collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication

Acknowledgments

We thank all our participants without whom this research will not be possible. We thank the patient and public advisory committee of the study for their invaluable feedback in the different stages of the study. We also thank the research assistants, therapists and project administrator team facilitating the smooth delivery of the trial.

References


- 1 OECD. Mental Health and Work – United Kingdom. 2014. www.oecd.org/els/%0Amental-health-and-work-united-kingdom-9789264204997-en.htm
- 2 Deloitte. Mental health and employers; Refreshing the case for investment. 2020. <https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-monitor-deloitte-oct-2017.pdf%0Ahttps://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-mon>
- 3 Butterworth P, Leach LS, Pirkis J, et al. Poor mental health influences risk and duration of unemployment: a prospective study. *Soc Psychiatry Psychiatr Epidemiol* 2012;47:1013–21.
- 4 Social Exclusion Unit. Mental Health and Social Exclusion. London: 2004.
- 5 ONS. Sickiness absence in the UK labour market. 2020.
- 6 Bubonya M, Cobb-Clark DA, Wooden M. Mental Health and Productivity at Work: Does What You Do Matter? IZA Discuss Pap No 9879, Inst Study Labor Published Online First: 2016.<http://hdl.handle.net/10419/141638>www.econstor.eu (accessed 6 Dec 2021).
- 7 Cuijpers P, Karyotaki E, de Wit L, et al. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. *Psychother Res* 2020;30:279–93.
- 8 Romijn G, Batelaan N, Kok R, et al. Internet-delivered cognitive behavioral therapy for anxiety disorders in open community versus clinical service recruitment: meta-analysis. *J Med Internet Res* 2019;21:e11706.
- 9 Gartlehner G, Gaynes BN, Amick HR, et al. Nonpharmacological versus pharmacological treatments for adult patients with major depressive disorder. 2015.
- 10 Department of Health. Treatment Choice in Psychological Therapies and Counselling: Evidence Based Clinical Practice Guideline. Department of Health, 2001.
- 11 National Collaborating Centre for Mental Health. Depression: Management of Depression in Primary and Secondary Care. National Institute of Health and Clinical Excellence, 2004.
- 12 National Collaborating Centre for Mental Health. Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. National Institute of Health and Clinical Excellence, 2004.
- 13 Mathers, C.D., & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030, *PLoS Med* 2006; 3(11): e44.
- 14 Muñoz RF, Cuijpers P, Smit F, Barrera AZ, Leykin Y. Prevention of major depression. *Annual Review of Clinical Psychology*. 2010;6:181-212.
- 15 Lokkerbol J, Wijnen B, Ruhe HG, et al. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;21:1031–42.
- 16 IAPT. The IAPT Data Handbook. NHS. 2021. Accessed <https://webarchive.nationalarchives.gov.uk/ukgwa/20160302154833/http://www.iapt.nhs.uk/silo/files/iapt-data-handbook-v2.pdf>
- 17 Mack S, Jacobi F, Gerschler A, et al. Self-reported utilization of mental health services in the adult German population—evidence for unmet needs? Results of the DEGS1-Mental Health Module (DEGS1-MH). *Int J Methods Psychiatr Res* 2014;23:289–303.

- 18 Ebert DD, Cuijpers P, Muñoz RF, et al. Prevention of mental health disorders using internet-and mobile-based interventions: a narrative review and recommendations for future research. *Front psychiatry* 2017;8:116.
- 19 Sander L, Rausch L, Baumeister H. Effectiveness of internet-based interventions for the prevention of mental disorders: a systematic review and meta-analysis. *JMIR Ment Heal* 2016;3:e6061.
- 20 Josephine K, Josefine L, Philipp D, et al. Internet-and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. *J Affect Disord* 2017;223:28–40.
- 21 Andersson G, Carlbring P, Titov N, et al. Internet interventions for adults with anxiety and mood disorders: a narrative umbrella review of recent meta-analyses. *Can J Psychiatry* 2019;64:465–70.
- 22 Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. *J Anxiety Disord* 2018;55:70–8.
- 23 Kojima R, Fujisawa D, Tajima M, et al. Efficacy of cognitive behavioral therapy training using brief e-mail sessions in the workplace: a controlled clinical trial. *Ind Health* 2010;48:495–502.
- 24 Phillips R, Schneider J, Molosankwe I, et al. Randomized controlled trial of computerized cognitive behavioural therapy for depressive symptoms: effectiveness and costs of a workplace intervention. *Psychol Med* 2014;44:741–52.
- 25 Tan L, Wang M-J, Modini M, et al. Preventing the development of depression at work: a systematic review and meta-analysis of universal interventions in the workplace. *BMC Med* 2014;12:74. doi:10.1186/1741-7015-12-74
- 26 Imamura K, Kawakami N, Furukawa TA, et al. Does Internet-based cognitive behavioral therapy (iCBT) prevent major depressive episode for workers? A 12-month follow-up of a randomized controlled trial. *Psychol Med* 2015;45:1907–17.
- 27 Imamura K, Kawakami N, Furukawa TA, et al. Effects of an internet-based cognitive behavioral therapy intervention on improving work engagement and other work-related outcomes: an analysis of secondary outcomes of a randomized controlled trial. *J Occup Environ Med* 2015;57:578–84.
- 28 Haller H, Cramer H, Lauche R, et al. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. *BMC Psychiatry* 2014;14:1–13.
- 29 Lokkerbol J, Wijnen B, Ruhe HG, et al. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;21:1031–42.
- 30 Panchal N, Kamal R, Orgera K, et al. The implications of COVID-19 for mental health and substance use. *Kaiser Fam Found* 2020;21.
- 31 Santomauro DF, Herrera AMM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021;398:1700–12.
- 32 Mental Health Productivity Pilots. The Mental Health and Productivity Pilot (MHPP). 2021. <https://mhpp.me/> (accessed 9 Aug 2021).
- 33 Berking M, Whitley B. *Affect Regulation Training: A Practitioners' Manual*. Irvine, California: : Springer 2010
- 34 Lewis, M, Bromley, K, Sutton, CJ, McCray, G, Myers, HL, Lancaster, GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back!. *Pilot and feasibility studies* 2021; 7(1), 1-14.

- 1
2
3 35 Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the
4 GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp*
5 *Psychiatry*. 2016;39:24-31.
6
7 36 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
8 measure. *J Gen Intern Med*. 2001;16(9):606–13. Bastien, C. H., Vallières, A., & Morin,
9 C. M. (2001). Validation of the insomnia severity index as an outcome measure for
10 insomnia research. *Sleep Medicine*, 2, 297–307.
11
12 38 Snow G. blockrand: Randomization for block random clinical trials. R Packag version
13 2013;1.
14
15 39 Michie S, Atkins L, West R. The behaviour change wheel. A Guid to Des Interv 1st ed
16 Gt Britain Silverback Publ 2014.
17
18 40 Vlaev I, Dolan P. Action Change Theory : A Reinforcement Learning Perspective on
19 Behavior Change. *Rev Gen Psychol* 2015;19:69–95. doi:10.1037/gpr0000029
20
21 41 Oehler C, Görge F, Hegerl U, et al. A closer look at negative effects in a guided web-
22 based intervention for mild to moderate depression. *Clin Psychol Sci Pract* 2021;28:131.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Participant flow in REST Trial design

For peer review only



BMJ Open: first published as 10.1136/bmjopen-2021-060545 on 9 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Material

Secondary Measures

The following psychometric will be used to explore their utility as outcome measures for a future fully powered randomised-controlled trial.

The General Anxiety Disorder-7 (GAD-7) is commonly used in primary and secondary mental health settings to measure symptom severity for General Anxiety Disorder (Spitzer, Kroenke, Williams, & Löwe, 2006). The GAD-7 is comprised on seven items each scored on a four-point Likert scale, a score of 10 has been shown to correctly diagnose cases of generalised anxiety disorder with 89% sensitivity and 82% specificity, with high test-retest reliability (ICC = 0.83). The GAD-7 also shows high concurrent validity with high scores being associated with disability and functional impairment (Ruiz et al., 2011; Spitzer et al., 2006).

The Patient Health Questionnaire-9 (PHQ-9) is commonly used, in primary care settings to assess the severity of depression across the nine DSM-IV criteria for major depressive disorder on a four-point Likert scale (Cameron, Crawford, Lawton, & Reid, 2008). The PHQ-9 has been shown to demonstrate high diagnostic accuracy in at risk populations (Haddad et al., 2013; Janneke et al., 2012), and in clinical populations. A criterion score of ≥ 10 has a 88% sensitivity and specificity for major depressive disorder (Kroenke, Spitzer, & Williams, 2001). Empirical research demonstrates high internal consistency ($\alpha = 0.91$; Hansson, Chotai, Nordstöm, & Bodlund, 2009) and a valid latent structure even when administered in nonclinical samples (CFI = 0.914- 0.983; Ito, Takebayashi, Muramatsu, & Horikoshi, 2018).

The Insomnia Severity Index (ISI) is a seven-item psychometric which has been validated with reference to the diagnostic criteria for primary insomnia in the DSM-IV. The ISI uses a five point Likert scale response to each item (score range 0–28). A score of ≥ 15 identifies cases of clinical insomnia with 94% sensitivity and specificity (Bastien, Vallières, & Morin, 2001). A reduction of 8.4 has been shown to be associated with moderate improvement in clinical populations (Morin, Belleville, Bélanger, & Ivers, 2011), with responses being validated in non-clinical samples as demonstrating a high internal reliability ($\alpha = 0.81 - 0.91$ (Morin et al., 2011; Yu, 2010).

Job productivity - measured through the Work Productivity and Activity Impairment: General Health v2.0 (WPAI:GH; (Reilly, Zbrozek, & Dukes, 1993). The WPAI:GH is a six item psychometric which focuses on: 'Absenteeism', 'Presenteeism', 'Work productivity loss' and 'Activity Impairment'. The WPAI:GH has shown strong psychometric properties with good internal consistency ($\alpha = 0.74$), with a high intraclass correlation coefficient ($r = 0.79 - 0.90$) in clinical populations (Zhang et al., 2010). The WPAI has been used in non-clinical samples and has shown good face validity (Duke & Montag, 2017).

Job satisfaction - measured using the Indiana Job Satisfaction Scale (IJSS; Resnick & Bond, 2001). The IJSS is a 32-item psychometric coded on a four-point Likert response of "Strongly disagree" to "Strongly agree", and is comprised of six subscales: 'General Satisfaction', 'Pay', 'Advancement and Security', 'Supervision', 'Coworkers' and 'How I feel about this job'. The IJSS yields strong psychometric properties with high internal consistence ($\alpha = 0.90$) and test-retest reliability ($r = .75$) (Resnick & Bond, 2001).

1
2
3 Well-being – we measure subjective well-being using the Warwick-Edinburgh Mental Health
4 Well-being Scale (WEMWBS, Tennant et al., 2007). The WEMWBS consists of 14-items on
5 a five-point likert scale ranging from “None of the time” to “All of the time”. The scale has
6 been shown to hold good psychometric properties, with strong internal consistency ($\alpha = 0.91$)
7 and was shown to hold high concurrent validity (Tennant et al., 2007). When applied to
8 nonclinical samples the WEMWBS still shows similar psychometric properties with high
9 internal consistency ($\alpha = 0.94$; test-retest = 0.83; Dong et al., 2016).
10
11

12 Quality of life- measured using the EuroQOL EQ-5D-5L questionnaire (Herdman et al.,
13 2011). The EQ-5D-5L consists of six items, five items measured through five-point likert-
14 scale responses to mobility, self-care, usual activities, pain/discomfort and
15 anxiety/depression, with a sixth item of a rating of health on a visual analogue scale ranging
16 from 0-100. The EQ-5D-5L has shown high internal consistency in clinical samples ($\alpha =$
17 0.86; (Bilbao et al., 2018) and in nonclinical populations ($\alpha = 0.84$; Kim & Ko, 2018).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a pilot or feasibility randomised trial in the title	2
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	2
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	3
	2b	Specific objectives or research questions for pilot trial	3
Methods			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	4
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
	4c	How participants were identified and consented	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	6,7
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	N/A
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	N/A

Sample size	7a	Rationale for numbers in the pilot trial	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8,9
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	9
	11b	If relevant, description of the similarity of interventions	9
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	9, 10
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	N/A
	13b	For each group, losses and exclusions after randomisation, together with reasons	N/A
Recruitment	14a	Dates defining the periods of recruitment and follow-up	N/A
	14b	Why the pilot trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	N/A
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	N/A
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	N/A
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A

	19 a	If relevant, other important unintended consequences	N/A
Discussion			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	13
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	13
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	13
	22 a	Implications for progression from pilot to future definitive trial, including any proposed amendments	13
Other information			
Registration	23	Registration number for pilot trial and name of trial registry	14
Protocol	24	Where the pilot trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	14
	26	Ethical approval or approval by research review committee, confirmed with reference number	14

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355.

*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

BMJ Open

A digital Cognitive Behavioural Therapy intervention in the workplace: Study protocol for a feasibility randomised waitlist-controlled trial to improve employee mental wellbeing and help them stay engaged and productive in work.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060545.R2
Article Type:	Protocol
Date Submitted by the Author:	01-Oct-2022
Complete List of Authors:	Patel, Krishane; University of Warwick Moukhtarian, Talar Rita; University of Warwick, WMG Walasek, Lukasz; University of Warwick, Psychology Daly, Guy; Coventry University Russell, Sean; Coventry University Tang, Nicole; University of Warwick, Psychology Toro, Carla; University of Warwick, Warwick Medical School Meyer, Caroline; University of Warwick, Warwick Medical School
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Occupational and environmental medicine
Keywords:	MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Adult psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3 **Title: A digital Cognitive Behavioural Therapy intervention in the workplace: Study**
4 **protocol for a feasibility randomised waitlist-controlled trial to improve employee**
5 **mental wellbeing and help them stay engaged and productive in work**
6
7
8

9 Krishane Patel¹, Talar R Moukhtarian², , Sean Russell³, Guy Daly³, Lukasz Walasek⁴, Nicole
10 Tang⁴, Carla Toro*², and Caroline Meyer²
11
12
13
14

15 **Author affiliation**

16 1 – Warwick Manufacturing Group, University of Warwick, University Road, Coventry, CV4
17 7AL, UK

18 2- Warwick Medical School, University of Warwick, University Road, Coventry, CV4 7AL,
19 UK

20 3- Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1
21 5FB, UK

22 4- Department of Psychology, University of Warwick, University Road, Coventry, CV4 7AL,
23 UK
24
25

26 *Correspondence to Dr Carla Toro, Behaviour and Wellbeing Science, International Digital
27 Laboratory, Warwick Manufacturing Group, University of Warwick, Lord Bhattacharyya
28 Way, Coventry CV4 7AL

29 Email: Carla.toro@warwick.ac.uk
30
31

32 Abstract (283 words)
33
34

35 Introduction: This trial tests the feasibility of implementing a digital cognitive behavioural
36 therapy for Common Mental Disorders in the workplace. The study protocol follows on the
37 CONSORT (Consolidated Standards of Reporting Trials) recommendations.
38

39 Methods and analysis: Feasibility of the implementation using a mixed methods evaluation of
40 a two-arm randomised waitlist control trial consisting of an eight-week digital cognitive
41 behavioural therapy (dCBT) intervention for subthreshold to clinical depression and/or anxiety
42 through self-guided online platform versus waitlist control (i.e. life as usual). This study
43 examines the ease of third-party buy in from organisations from approach to agreement, and
44 the engagement of employees through the trial indicated by the completion of outcome
45 measures. In addition, we also explore how participants use the platform, the appropriateness
46 of the analysis both with reference to the outcome measures and linear modelling. Finally, we
47 examine the acceptability of the intervention based on participants experiences using
48 qualitative interviews through a framework analysis. Assessments take place at baseline (T0),
49 at 8 weeks post-treatment (T1), at short-term follow-up 16-weeks post-randomisation (T2) and
50 long-term follow-ups (6 and 12 months post-randomisation). We will recruit from the 1st July
51 to 31st December 2021 for employees and self-employed workers with depression and anxiety
52 symptoms (sub-clinical and clinical levels) who are not seeking or engaged in treatment at the
53 time of the trial.
54
55
56

57 Ethics and dissemination: Full approval was given by the University of Warwick Biomedical
58 and Research Ethics Committee (BSREC 45/20-21). The current protocol version is 2.8 (Aug-
59 2021). Publication of results in peer- reviewed journals will inform the scientific, clinical and
60

1
2
3 business communities. We will disseminate results through webinars, conferences, newsletter
4 as well as a lay summary of results on the study website (mhpp.me).
5

6
7 Trial registration: ISRCTN, ID: ISRCTN31161020. Registered on 08/06/2021.

8
9 Keywords: Depression, Anxiety, Feasibility, Workplace, dCBT, Online, Mental Health,
10 Productivity
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 Strengths and limitations of this study
4

- 5 •
- 6 • Novel fully self-guided early intervention dCBT for employees in the workplace.
- 7 • Pilot RCT design within feasibility framework will inform full scale RCT in the
8 future.
- 9 • Embedded qualitative study will inform challenges in delivering fully self-guided
10 dCBT within the workplace.
- 11 • Intervention is light touch, accessible and low cost.
- 12 • Study will be underpowered to examine efficacy of intervention.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

In the United Kingdom (UK), poor mental health costs the economy an estimated £70 billion/year, equivalent to 4.5% of the UK's GDP [1]. Common Mental Disorders (CMD) comprising of depressive and anxiety related disorders are a major contributor to these costs. Within the workplace, one in six workers experience some form of mental health problems [2] which may or may not be as a result of their workplace environment. Furthermore, workers who experience CMDs are significantly less likely to remain in employment than their healthy counterparts [3,4]. The prevalence of mental illness in the workplace is problematic because of a) absenteeism where the loss in workforce as a result of sickness, with an estimated 11.6% of sickness absence caused by CMD [5], totalling almost 16 million days across the UK labour market; b) mental health can diminish productivity in the workplace, a concept called presenteeism [6] which can have significant impact on employee productivity across the labour market.

Psychological therapy (e.g. cognitive behavioural therapy) has been shown to be effective in treating depression and anxiety [7]. One common form of psychological treatment is cognitive behavioural therapy (CBT) which uses cognitive and behavioural principles to treat underlying cognitions and behaviour of psychiatric conditions. CBT has been shown to significantly reduce symptoms of anxiety [8], and depression [9]. Despite evidence showing that psychological therapies such as CBT are effective for depression and anxiety disorders [10], provision in primary care is low and in secondary care has been characterised by long waiting lists. In fact, 70-75% of people with diagnosable mental illness receive no treatment at all [11,12]. These could be due to several reasons; for example due to stigma associated with seeking support through traditional NHS routes or services not being accessible particularly to some groups such as those who are socially disadvantaged, or those with lower education level [13]. It has been shown that these groups prefer to manage their mental health themselves [13], which could be using self-guided dCBT for example. To tackle this issue, Improving Access to Psychological Therapies (IAPT) was introduced to make psychological therapies for depression and anxiety available in a stepped approach within a collaborative model [14,15].

The World Health Organisation predicted around 10 years ago that by 2030 depression will be second to HIV/AIDS in international burden of disease with calls to focus on early intervention and prevention of the condition [16]. Effective early interventions can prevent, delay or reduce the onset or progress of a mental health condition [17], and are more cost-effective than treatments through specialist services or primary care providers [18]. However, to be eligible for therapies through IAPT, individuals must have symptoms above the clinical cut-off (10 and above on the PHQ-9 for depression, or 8 and above on the GAD-7 for anxiety) [19]. Currently, there are no evidence-based early intervention provisions for individuals with subthreshold symptoms.

Digital interventions provide low cost, easily scalable delivery methods to provide access at the population-level, and to individuals that usual care services may not reach. This form of digital-based CBT (dCBT) provides access to resources for self-learning or supervised treatment [20]. dCBT is effective in the prevention [20,21] and treatment of the most common CMDs – depression and anxiety [8,22-24], which indicates potential opportunities to tackle large-scale mental health issues through innovative and cost-effective means.

Implementation of CBT and dCBT intervention in workplace settings have been shown to improve mental health and reduce incidence of the clinical levels of CMDs [25,26]. Meta-

1
2
3 analyses of workplace interventions for CMDs show a significant standardized mean
4 difference of 0.12, demonstrating small significant effects [27]. A large randomised
5 controlled trial demonstrated that dCBT showed strong effects in treating employees with
6 major depressive episodes [28], furthermore dCBT interventions have also been shown to
7 promote work engagement amongst sub-clinical and healthy workers [29].
8
9

10 The majority of studies to date have focused on clinical levels of depression and less so on
11 individuals with sub-clinical symptoms. It has been suggested that populations with sub-
12 threshold CMDs are greater in number than their clinical counterparts [30]. In addition,
13 interventions for subclinical populations are deemed highly cost-effective [31]. Cases of
14 CMDs have been further intensified over the COVID-19 pandemic with rates of generalised-
15 anxiety disorder increasing from one in ten to one in four adults in the US populations
16 [32,33]. Interventions to reduce mental health severity in the workplace can therefore have
17 subsequent effects in workplace absenteeism and productivity, as well as increased job
18 satisfaction [29]. Given the relatively few studies that examine intervention on subclinical
19 and clinical levels of CMDs in the workplace, and given that these studies have only assessed
20 the short-term impact of interventions [34], this trial is the first to explore a fully online
21 intervention for a UK sample in the workplace with long-term follow-ups, which could
22 trigger help-seeking for some who haven't pursued the traditional route of getting mental
23 health support (e.g. approaching GP as first contact).
24
25
26

27 This study - will examine the feasibility of a dCBT for mild to severe depression and anxiety
28 for employees in the workplace. The study is one of three trials under the Mental Health
29 Productivity Pilots (MHPP), funded by the Midlands Engine [35] with a focus to improve
30 workforce mental health and productivity.
31
32

33 **Study aims**

34 The primary aim of this trial is to investigate the feasibility of a multi-centre waitlist RCT in
35 the Midlands region of England that examines whether a dCBT treatment for employees
36 reporting mild to clinical levels of depression or anxiety reduces symptom severity for
37 employees in the workplace. The trial will partner with participating employers to recruit
38 participants from workplace settings through employers and through social media
39 advertisement.
40
41

42 Nested within this primary aim is an exploration of the feasibility of the methodological
43 approach, focusing particularly upon:
44

- 45 • Willingness of organisations to participate in a trial (Objective 1);
- 46 • Willingness of employees to participate in a trial (Objective 2);
- 47 • Adherence of participants to the treatment as measured through platform user data
48 (Objective 3);
- 49 • Appropriateness of the analytical approach (Objective 4).
- 50 • Acceptability of the intervention based on participants subjective experiences
51 (Objective 5)
52
53

54 The results of this feasibility trial will be used to inform a future RCT to understand whether
55 a dCBT can help to reduce symptom severity and improve mental health and productivity for
56 employees in the workplace. In addition, secondary aims are to assess the barriers and
57 enablers of the intervention programme to identify key mechanisms of actions through a
58 process evaluation. Tertiary aims explore the impact of the intervention by examining the
59 reduction in symptom severity for depressive and general anxiety related symptoms as
60

measured through the Patient Health Questionnaire-9 (PHQ-9) and the General Anxiety Disorder-7 (GAD-7) psychometrics as well as work productivity.

Methods and analysis

Study design

We implement a multi-centre, waitlist randomised controlled trial (wRCT) in which we explore the feasibility of delivering a CBT intervention against a waitlist-control group (WLC) with no active treatment. We target recruitment for participants with mild to severe depression or general anxiety symptoms who have not received a formal diagnosis or are not currently receiving professional care for a mental health condition. The dCBT will be delivered via a self-guided digital online platform over an eight-week period.

Participants will be screened for the presence of depressive and anxious symptoms. Upon verification that inclusion criteria are met, participants will provide informed consent, complete outcome measure assessments, and complete the intervention through web-based platforms. Online assessment of the primary and secondary dependent variables will take place at week 0 baseline (pre-intervention), week 8 (post-treatment) and week 16 (follow-up). In addition, participants will be followed up in the long-term, at 6 and 12 months post-randomisation. All participants in the WLC group will be offered the dCBT intervention at week 8 (see Fig. 1 for trial flowchart).

Ethical approval has been granted from the University of Warwick Biomedical and Research Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN (ISRCTN13596153).

Participants

The REST (Reducing Stress in the workplace) trial shares a common screening process with two additional trials and therefore a shared Participant Information Leaflet (PIL) is used, under the umbrella of the INWORK program. However, no access is provided between trials and all studies use mutually exclusive inclusion/exclusion criteria to ensure no overlapping participant sample populations or competition in recruitment.

We will recruit full-time and part-time employees and self-employed workers from organisations across the Midlands region of England who fulfil the inclusion/exclusion criteria (Table 1). This is defined by the Midlands Engine as a population of approximately 11 million, with 4.5 million jobs [36].

Table 1. Inclusion/Exclusion criteria for REST study

Inclusion criteria	Exclusion criteria
Able to give informed consent	Currently receiving treatment (psychological or pharmacological) from mental health services (e.g. GP, private clinic, Improving Access to Psychological Therapies (IAPT) services, specialist and community mental health services)
English-speaking	Retiring in the next 10 months
In employment (including being on furlough)	Currently taking part in other psychological intervention trials

Insomnia Severity Index score: $x < 8^{**}$	
General Anxiety Disorder-7 score: $x > 4$ or Patient Health Questionnaire-9 score: $x > 4$	
≥ 18 years of age	

*We do not specify on working hours, or place of work

** We use the Insomnia Severity Index to differentiate REST from other trials being conducted at the same time with the INWORK programme. This criterion is used to ensure that REST can be differentiated and that there is no population overlap between the INWORK trials.

Components of the REST intervention

The REST intervention is an online self-guided programme structured into eight-weekly sessions with varying number of topics each week, lasting approximately 60 minutes each. The content incorporates techniques from Cognitive Behavioural Therapy (CBT) and Emotion Regulation [37] using workplace relevant examples. The goals of the intervention are to reduce symptoms of stress, depression and anxiety and provide participants with practical skills and techniques to help cope with stressful situations. The core components of the REST intervention can be shown below on Table 2.

Table 2. REST content across the intervention

Week 1	<ul style="list-style-type: none"> • What is stress? • Stress cycle • REST diary • Setting SMART goals
Week 2	<ul style="list-style-type: none"> • Non-judgmental awareness • Behavioural activation • Emotion focused skills
Week 3	<ul style="list-style-type: none"> • Work-related stress • Rumination and worrying • Problem solving skills
Week 4	<ul style="list-style-type: none"> • Cognitions • Managing unhelpful thinking styles • Cognitive restructuring
Week 5	<ul style="list-style-type: none"> • Work-life balance • Time management Skills
Week 6	<ul style="list-style-type: none"> • Physiology of stress • Relaxation techniques
Week 7	<ul style="list-style-type: none"> • Behavioural change • Healthy lifestyle choices (e.g. sleep, physical activity)
Week 8	<ul style="list-style-type: none"> • Programme summary • Relapse management • Self-compassion • Resilience

Waitlist control

Participants initially allocated to the waitlist control group, will be asked to provide a baseline response to primary and secondary measures but will not receive any active treatment for the first eight weeks. After the eight-week period, waitlist control participants will be asked to provide a post-control group measure for primary and secondary outcomes at which point they will be automatically enrolled into the intervention group for further eight weeks. The waitlist control group serves two purposes. First, it provides an untreated comparison for the active dCBT group to determine if the treatment had an effect. Secondly and for ethical reasons, it will provide an opportunity for all participants in the trial to receive the active intervention. It will allow us to assess the effect of the intervention against not receiving treatment during that same time period (since the groups are comparable), and any differences between the two groups should reflect (due to randomization) the impacts of exposure to the dCBT.

Measures

Participants will be prompted by email to complete all outcome measures on a secure online survey platform (Qualtrics). The order of the assessments will be consistent across all participants and all time-points. If participants do not complete measures within 5 days they will receive three further email reminders every five days of non-response.

Primary outcomes

To examine the feasibility of our intervention under a multi-centre waitlist randomised controlled trial design, we explore five primary objectives. We examine Objective 1 by monitoring organisational traffic (defined as conversion rates and absolute counts) into the trial across four identified stages:

Stage 1: Contacted

Stage 2: Teleconference

Stage 3: Further engagement

Stage 4: Verbal agreement and branch selection

For each partnership with an organisation we document the number of centres as well as the number of employees.

We examine Objective 2 by exploring participant traffic across the trial flow (through social media and employer pathways). We define the trial flow for participants traffic as follows:

1. Expression of interest
2. Screener completion
3. Invitation to trial
4. Consent to study and randomisation
5. Post-study (which is defined as end of control and beginning of intervention for those initially placed in the waitlist control group)
6. Follow-up measures or outcome measures from Qualtrics

We will explore the conversion rates and absolute counts of employees from each stage of the trial flow, evaluating over recruitment pathways (please see section Recruitment procedures for more information on page 10).

1
2
3 We explore Objective 3 through the user data of platform access for the dCBT intervention.
4 We will explore how much content was consumed by individuals on average, and the time to
5 complete each block on average.
6

7
8 We explore Objective 4 through analysis of secondary measures listed below. We firstly
9 explore the acceptability of the assessment measures themselves; this is conducted by
10 exploring the completion rate of questionnaires, we will further explore the descriptive
11 statistics (e.g. distribution of the outcome measures, skew, kurtosis, ICC, means and
12 variances).
13

14
15 We will evaluate the fit of our statistical model comparing a fixed-effects regression model
16 against a mixed-effects linear model (accounting for clusters in organisation level).
17 Furthermore, we also evaluate the statistical cleaning procedures using a sensitivity analysis
18 in which we compare multiple imputation methods against complete case analysis.
19

20
21 We also examine the feasibility of the trial implementation through semi-structured
22 qualitative interviews as part of Objective 5, which will explore the feasibility and barriers of
23 the intervention. We will use thematic analysis to identify the common themes mapped to a
24 framework to provide a theoretical perspective on how to improve the intervention.
25

26 **Secondary outcomes**

27 Our secondary outcomes explore the impact of the intervention on prevalent mental health
28 questionnaires to assess symptom severity in anxiety and depression. In addition, we also
29 explore the impact of the intervention on job satisfaction, well-being, quality of life, work
30 productivity and insomnia severity. The different measures are listed in the Supplementary
31 section and will be collected at baseline (T0) post-study (T1), short-term (T2) and long-term
32 (6 and 12 months) follow-ups. In addition, the GAD-7, PHQ-9 and the Insomnia Severity
33 Index will be used as part of the screening questionnaire set to identify eligible participants
34 for the study. We also ask participants to self-report use of self-help resources and if since
35 completing the screening questionnaire whether they started receiving treatment from mental
36 health services (psychological and pharmacological). These questions will be used as
37 confounding variables in the analysis models. . See the supplementary file for a detailed list
38 of the outcome measures being used, along with a summary of their psychometric properties.
39
40
41

42 **Sample size**

43 Given little a-priori information, we will explore the feasibility of recruiting participants into
44 the trial. We will recruit for eight months from June to December 2021. We will explore the
45 recruitment rate over time across the employer and direct social media advertisement. We will
46 estimate the effect size obtained from the analysis of the trial detailed under Objective 4 in the
47 Analyses section on page 11, for sample size estimation for a future full scale randomised
48 controlled trial.
49

50 We anticipate a nominal sample size of 60 participants based on Lewis et al recommendations
51 for feasibility trials [38].
52
53

54 **Recruitment procedures**

55 The REST study will recruit through multiple channels. The first pathway denotes employers
56 registering interest as partners via the MHPP website (mhpp.me), who will act as gatekeepers
57 to their employees. They will not recruit participants themselves but only signpost the
58 information, Employers will advertise the intervention within their organisations through
59 newsletters and emails.
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The second pathway is through direct recruitment by the research team via online social media (e.g., Twitter, LinkedIn and Facebook) and print (e.g., leaflets and flyers in public and retail settings) advertisements. Individuals who express interest through this pathway will be from the wider working community in the Midlands.

Initial interest will be taken through a survey form hosted by the Qualtrics servers. This will only take brief employment information (organisation name, location and email address) in order to determine whether this individual is listed under a partner or through direct recruitment strategies.

The research team will then contact interested employees by sending them the INWORK PIL. This trial uses a two-stage consent process, where after initial interest, participants will be asked to take part in an eligibility screening questionnaire set, after which those eligible will be invited to take part in the trial. The screening questionnaire set consists of the GAD-7, PHQ-9 and the ISI. We will also ask participants to confirm they are older than 18, whether they have a diagnosis of a mental health condition, are under the management of a mental health service.

If the scores on any of the three scales yield above the clinical threshold (this is denoted with a score of at-15 on the GAD-7 [39] or the PHQ-9 [40] or 15 of above on the ISI [41]), we will recommend these individuals to contact their GP and signpost to contact Improving Access to Psychological Therapies services. Symptom severity will not exclude them from taking part in the study. Participants will need to acknowledge reading the advice to continue with the screening questionnaire set. Individuals who pass the eligibility criteria as listed in Table 1 above will be invited into the REST trial.

Patient and Public Involvement

We have formed a group of four individuals with lived experience of mental health problems who are currently in employment, and they will contribute during the trial by reviewing participant information sheets, consent form, intervention materials and questionnaire measures. They will advise on recruitment procedures and methods to engage prospective participants/retain enrolled participants.

Randomisation

Participants are assigned to the dCBT or WLC arms through a simple randomisation with blocking using a 1:1 allocation ratio. We use random length block between two and eight, to minimise the risk of uneven groups. The randomisation is conducted using '*blockrand*' package [42]. We stratify the randomisation process across centres based on employee size within the partnered employer pathway.

Due to unknown organisation size considerations, individuals through direct recruitment will not be stratified over centres. Randomisation will be conducted by a researcher independent of allocating participants and will be blinded to the subsequent allocations. Members of the research team will be unable to influence randomisation and will be concealed from future assignments.

Allocation concealment mechanism

The trial statistician (KP) will provide a prescriptive randomisation allocation sequence file stored in a *.csv file. The file is provided to the trial coordination team, who enrolls

1
2
3 participants into the trial, doing so automatically allocates a condition to each participant. The
4 allocation list is locked to prevent any tampering.
5

6 7 **Implementation**

8 The trial statistician (KP) generates the random allocation sequence, and the code to match
9 each participant to their respective allocation sequence (through row wise matching of row
10 numbers). The allocation is conducted as part of the trial coordination team enrolling
11 participants into the trial Masterfile as part of parsing in logistical data. Participants are
12 assigned to their respective allocation through an email sent by the trial coordination team.
13

14 15 **Blinding**

16 As this is a single-blind waitlist RCT, participants after consent will be informed of the two
17 allocation groups, will not be blinded to their randomisation outcome and will be explicitly
18 informed of their allocation once randomised. The trial coordination team who handle the
19 administrative and logistical requirements of the trial will be unblinded to the allocation of
20 participants, however the researchers will be blinded to the trial allocation. Statistical
21 analyses will be conducted by members of the research team who will only have access to all
22 non-identifiable data.
23

24 Any instances of unblinding would be documented and retained in trial documentation. It is
25 likely that the majority of instances of unblinding would usually be involve a participant
26 withdrawing for treatment or undergoing treatment cessation due to unforeseen
27 circumstances and would therefore require no further action from the researcher. However, in
28 cases of mistakes where participants have contacted the researcher, then any further contact
29 with that participant will be handled by a separate researcher.
30

31 32 **Data analyses**

33 We will record and report all participant flow through the trial in accordance with the
34 Consolidated Standards of Reporting Trials (CONSORT) guidelines. We will report
35 descriptive statistics for recruitment, dropout, and completeness of interventions, in addition
36 we will report a sample breakdown.
37

38
39 We assess the feasibility of the REST trial in accordance with the five research objectives:

- 40 • Willingness of organisations to participate in a trial (Objective 1);
- 41 • Willingness of employees to participate in a trial (Objective 2);
- 42 • Adherence of participants to the treatment as measured through platform user data
43 (Objective 3);
- 44 • Appropriateness of the analytical approach (Objective 4).
- 45 • Acceptability of the intervention based on participants subjective experiences
46 (Objective 5)

47
48
49
50 Objective 1 explores organisational traffic in partnering with third-party organisations to
51 recruit employees in workplace settings. To analyse organisational traffic into the study we
52 use descriptive statistics calculating frequency counts and percentage. Table 3 below
53 demonstrates the template in which we will document and present the information across
54 (Stage 1- Engagement; Stage 2-Teleconference; Stage 3-Further engagement; Stage 4-Verbal
55 agreement and centre selection).
56
57
58
59
60

Table 3. Organisational traffic into the REST study

Employer ID	Number of Employees	Number of potential centres	Stage 1	Stage 2	Stage 3	Stage 4
1	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
2	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
...	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
n	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
Total	N	N	N	N	N	N
Attrition	%	%	%	%	%	%

Objective 2 investigates the feasibility of recruiting and maintaining participants in the REST trial. We explore Objective 2 by examining participant traffic across the trial flow (see Figure 1), through social media and employer recruitment pathways. To analyse organisational traffic into the study, we use descriptive statistics calculating frequency counts and percentage across the trial stages (see Table 4).

Table 4. Organisational traffic into the REST study

Recruitment Pathway	Employer ID	Express interest	Screeners	Invite to Trial	Consent, randomise and baseline measure completion (T0)	Post-study outcome measure completion at 8 weeks (T1)	Follow-up measure completion at 16 weeks post randomisation (T2)
Employer pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%
Direct Social media advertisement pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%

We will also conduct a chi-squared test to compare overall attrition rates across the two recruitment pathways to determine if there is any practical utility in one form of recruitment over another.

Objective 3 investigates the adherence of participants to the treatment as measured through platform user data. Here we explore the user data from the platform through exploring the average amount of content consumed by individuals on average for the dCBT intervention.

1
2
3 We will also explore the time taken to consume each block on average. The user data
4 provided will include at the aggregate level information on which links were accessed and
5 frequency count data of link usage. We will obtain aggregate data at the individual level such
6 as the amount of content (at the weekly level) consumed by each participant, but not how
7 long was spent on each page.
8
9

10 Objective 4 explores the appropriateness of the analysis, which consists of exploratory
11 analyses of the secondary measures (which will be used to measure the trial in future case), as
12 well as understanding the most appropriate model to fit to the data. To examine the
13 appropriateness of the assessment measures themselves. We will explore the distribution of
14 the different outcome measures by assessing the skew, kurtosis, means and variances, we will
15 also report the intra-cluster correlation coefficient.
16
17

18 To explore the most appropriate model, we will compare three linear regression models; a
19 simplified fixed effect model, a full fixed-effects model (which includes covariates beyond
20 the control vectors (please see Supplementary for list of such measures) and a mixed-effects
21 regression (includes a random effect to account for clusters in organisation level) and finally
22 a complete case analysis using mixed-effects model (to conduct a sensitivity analysis of
23 multiple imputation).
24
25

26 We will try to fit a model as complex as the fits the following decision rule: 20 participants
27 per variable. We adopt a decision rule to ensure that the models can converge and that the
28 results are interpretable. We will only fit models that conform to the above decision rule
29 using the GAD-7 and PHQ-9 as dependent variables. We account for family-wise error using
30 a Bonferroni correction and divide our alpha-level across our two dependent variables.
31
32

33 We aim to fit three models, each growing in further complexity. The first model uses a
34 simple mixed-effects specification which includes dummy variable for treatment effects with
35 an additional factor for cohort, and an interaction term for both treatment and cohort, we also
36 include a random effect for each participant.
37
38

39 The second model includes the terms specified in the above nested model, in addition, we
40 also include a vector of control variables to account for demographic factors, as well as
41 employer, in addition to potential covariates from the secondary measures (IJSS, WPAI:GH
42 and the WEMWBS) and potential additional treatment. In this model, we also include as a
43 covariate, the baseline values of the ISI, GAD7 and PHQ-9 in this full fixed-effects model.
44
45

46 If the sample size is appropriate we also implement a third more complex model which is the
47 same as the previous model, but we include an additional random-effects term of employer in
48 the mixed-effects model to account for clustering effects.
49
50

51 We will use an intention-to-treat analysis to ensure robustness of the results. We will
52 compare the simplified, full and mixed model fits to identify the most appropriate analysis for
53 a randomised-controlled trial.
54

55 Missing data will be reported (alongside reasons for missingness where available), and the
56 missing data pattern will be explored. To explore the impact of missing data, we will run a
57 sensitivity analysis comparing the complete case analysis against multiple imputation to see
58 any observed differences in effects.
59
60

Objective 5 will be examined through semi-structured qualitative interviews to explore the feasibility of the intervention, facilitators and barriers that impact engagement with the intervention and subsequent behavioural changes. In these interviews, we aim to understand the mechanisms of behaviour change, as facilitated by the intervention, and explore implementation processes to identify the contextual factors that act as barriers and facilitators to engagement. To do this, we ask about user perceptions and experiences of the intervention. We will explore the perceived benefits from the participants perspective, as well as any negative effects and fidelity constraints. We will randomly select 25 participants who have completed the intervention (from both treatment and control arms) and have consented to be contacted about follow-up interviews. These individuals will be invited to take part in an online videoconferencing interview over Microsoft Teams with researchers from the University of Warwick who are independent from the treatment delivery team of the individual. Interviews will be audio-recorded using OBS studio and then subsequently transcribed by a third-party University approved vendor. Qualitative interviews will be conducted using a semi-structured interview schedule, consisting of open-ended questions and suggested prompts. Interview recordings will be analysed using thematic and framework analysis to identify the barriers and facilitators to change (i.e., what helped or prevented participants from implementing aspects of the programme). We map the qualitative codes to the COM-B model [43], using a framework consisting of the three core behavioural determinants within this model : capability, opportunity and motivation. Capability refers to physical and psychological capability (such as disability and memory or knowledge respectfully). Opportunity refers to the physical and social connections and affords the behaviours (such as geography and word of mouth referrals). Motivation denotes the activation of approach and avoidance drives [44]. Themes will be generated using the to the COM-B framework as a guide, where barriers and facilitators relating to each behavioural determinant will be identified, and a thematic map will present a conceptualisation of which barriers and facilitators were particularly important in impacting change. Any other insights relevant to intervention feasibility, that cannot be mapped to the COM-B framework, will also be considered when generating themes.

[Figure 1 here]

Assessment of safety

We anticipate a low risk of serious adverse events (such as death or hospitalisation.) occurring during this trial, given the low base rate of negative events in the literature for dCBT interventions [45]. We will record occurrences of serious adverse events (SAEs) in this trial as resulting; in death, hospitalisation, life threatening, in persistent or significant disability or incapacity, of a congenital abnormality or birth defect or is otherwise considered medically significant by investigator. Adverse events are also a low risk during this trial, however expected adverse events: concentration difficulties and low mood.

To report a AE or SAE, forms will be sent to the trial management team (CB, CK), who will log them in a central database for trial monitoring. All forms will be logged in a central database and reviewed by the trial management team on a monthly basis, with a cumulative review of all safety information by an independent Trial Monitoring Committee (TMC). In addition, the trial management team will monitor and send the total numbers of SAEs per month to the TMC Chair – in order to expedite a safety review if more SAEs are being seen than would be expected.

1
2
3
4 Given the online nature of the intervention and little contact with participants, it is unlikely
5 that the research team will be aware of SAE or AE unless reported by participants through
6 contact channels such as emails.
7

8 9 **Ethics and dissemination**

10 In accordance with Good Clinical Practice, all participants are provided with an information
11 sheet and are required to provide informed consent for the screener and the trial, in order to
12 participate. This included consent for their anonymised data to be published. Ethical approval
13 for the study was granted by the University of Warwick's Biomedical Science and Research
14 Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN
15 (ISRCTN31161020). Protocol modifications will be submitted for approval to the BSREC
16 committees prior to implementation, with the protocol amendments being disseminated
17 across the research team and updated to the trial registry.

18 We will publish the results of this study in peer-reviewed journals. Findings will also be
19 presented at both national and international scientific meetings. The anonymised data will be
20 made accessible online wherever possible, if permitted by journal policies.
21
22
23
24

25 **Trial status**

26 Recruitment commenced on 18 June 2021 and was completed on 31st December 2021.
27

28 **Authors' contributions**

29 KP, TM, CT, CM, LW, and NT were involved in design and interpretation of the work. CT
30 and TM led the treatment development. KP drafted the first version of the manuscript. KP,
31 TM, CT, LW, SR, NT, GD and CM all were involved in revising for critical intellectual
32 content, and shared agreement for accountability in all aspects of the work.
33
34

35 **Competing interests**

36 The authors disclose no competing interests.
37
38
39

40 **Funding**

41 This research is supported by Midlands Engine (R.ESWM.3932). The study funders had no
42 role in the study design, collection, management, analysis, and interpretation of data; writing
43 of the report; and the decision to submit the report for publication
44
45

46 **Acknowledgments**

47 We thank all our participants without whom this research will not be possible. We thank the
48 patient and public advisory committee of the study for their invaluable feedback in the different
49 stages of the study. We also thank the research assistants, therapists and project administrator
50 team facilitating the smooth delivery of the trial.
51
52
53
54
55
56
57
58
59
60


References

- 1 OECD. Mental Health and Work – United Kingdom. 2014. www.oecd.org/els/%0Amental-health-and-work-united-kingdom-9789264204997-en.htm
- 2 Deloitte. Mental health and employers; Refreshing the case for investment. 2020. <https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-monitor-deloitte-oct-2017.pdf%0Ahttps://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-mon>
- 3 Butterworth P, Leach LS, Pirkis J, et al. Poor mental health influences risk and duration of unemployment: a prospective study. *Soc Psychiatry Psychiatr Epidemiol* 2012;47:1013–21.
- 4 Social Exclusion Unit. Mental Health and Social Exclusion. London: 2004.
- 5 ONS. Sickiness absence in the UK labour market. 2020.
- 6 Bubonya M, Cobb-Clark DA, Wooden M. Mental Health and Productivity at Work: Does What You Do Matter? IZA Discuss Pap No 9879, Inst Study Labor Published Online First: 2016.<http://hdl.handle.net/10419/141638>www.econstor.eu (accessed 6 Dec 2021).
- 7 Cuijpers P, Karyotaki E, de Wit L, et al. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. *Psychother Res* 2020;30:279–93.
- 8 Romijn G, Batelaan N, Kok R, et al. Internet-delivered cognitive behavioral therapy for anxiety disorders in open community versus clinical service recruitment: meta-analysis. *J Med Internet Res* 2019;21:e11706.
- 9 Gartlehner G, Gaynes BN, Amick HR, et al. Nonpharmacological versus pharmacological treatments for adult patients with major depressive disorder. 2015.
- 10 Department of Health. Treatment Choice in Psychological Therapies and Counselling: Evidence Based Clinical Practice Guideline. Department of Health, 2001.
- 11 Alonso, J., et al., Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. *Depress Anxiety*, 2018. **35**(3): p. 195-208.
- 12 Evans-Lacko, S., et al., Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. *Psychol Med*, 2018. **48**(9): p. 1560-1571.
- 13 Steele, L., C. Dewa, and K. Lee, *Socioeconomic Status and Self-Reported Barriers to Mental Health Service Use*. *The Canadian Journal of Psychiatry*, 2007. **52**(3): p. 201-206.
- 14 National Collaborating Centre for Mental Health. Depression: Management of Depression in Primary and Secondary Care. National Institute of Health and Clinical Excellence, 2004.
- 15 National Collaborating Centre for Mental Health. Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. National Institute of Health and Clinical Excellence, 2004.
- 16 Mathers, C.D., & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030, *PLoS Med* 2006; **3**(11): e44.
- 17 Muñoz RF, Cuijpers P, Smit F, Barrera AZ, Leykin Y. Prevention of major depression. *Annual Review of Clinical Psychology*. 2010;**6**:181-212.
- 18 Lokkerbol J, Wijnen B, Ruhe HG, et al. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;**21**:1031–42.

- 19 IAPT. The IAPT Data Handbook. NHS. 2021. Accessed <https://webarchive.nationalarchives.gov.uk/ukgwa/20160302154833/http://www.iapt.nhs.uk/silo/files/iapt-data-handbook-v2.pdf>
- 20 Ebert DD, Cuijpers P, Muñoz RF, et al. Prevention of mental health disorders using internet-and mobile-based interventions: a narrative review and recommendations for future research. *Front psychiatry* 2017;**8**:116.
- 21 Sander L, Rausch L, Baumeister H. Effectiveness of internet-based interventions for the prevention of mental disorders: a systematic review and meta-analysis. *JMIR Ment Heal* 2016;**3**:e6061.
- 22 Josephine K, Josefine L, Philipp D, et al. Internet-and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. *J Affect Disord* 2017;**223**:28–40.
- 23 Andersson G, Carlbring P, Titov N, et al. Internet interventions for adults with anxiety and mood disorders: a narrative umbrella review of recent meta-analyses. *Can J Psychiatry* 2019;**64**:465–70.
- 24 Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. *J Anxiety Disord* 2018;**55**:70–8.
- 25 Kojima R, Fujisawa D, Tajima M, et al. Efficacy of cognitive behavioral therapy training using brief e-mail sessions in the workplace: a controlled clinical trial. *Ind Health* 2010;**48**:495–502.
- 26 Phillips R, Schneider J, Molosankwe I, et al. Randomized controlled trial of computerized cognitive behavioural therapy for depressive symptoms: effectiveness and costs of a workplace intervention. *Psychol Med* 2014;**44**:741–52.
- 27 Tan L, Wang M-J, Modini M, et al. Preventing the development of depression at work: a systematic review and meta-analysis of universal interventions in the workplace. *BMC Med* 2014;**12**:74. doi:10.1186/1741-7015-12-74
- 28 Imamura K, Kawakami N, Furukawa TA, et al. Does Internet-based cognitive behavioral therapy (iCBT) prevent major depressive episode for workers? A 12-month follow-up of a randomized controlled trial. *Psychol Med* 2015;**45**:1907–17.
- 29 Imamura K, Kawakami N, Furukawa TA, et al. Effects of an internet-based cognitive behavioral therapy intervention on improving work engagement and other work-related outcomes: an analysis of secondary outcomes of a randomized controlled trial. *J Occup Environ Med* 2015;**57**:578–84.
- 30 Haller H, Cramer H, Lauche R, et al. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. *BMC Psychiatry* 2014;**14**:1–13.
- 31 Lokkerbol J, Wijnen B, Ruhe HG, et al. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;**21**:1031–42.
- 32 Panchal N, Kamal R, Orgera K, et al. The implications of COVID-19 for mental health and substance use. *Kaiser Fam Found* 2020;**21**.
- 33 Santomauro DF, Herrera AMM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021;**398**:1700–12.
- 34 Zhou, T., et al., *Internet-based cognitive behavioural therapy for subthreshold depression: a systematic review and meta-analysis*. *BMC Psychiatry*, 2016. **16**(1): p. 356.
- 35 Mental Health Productivity Pilots. The Mental Health and Productivity Pilot (MHPP). 2021.<https://mhpp.me/> (accessed 9 Aug 2021).

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 36 Midlands Engine. Midlands Engine Partnership: Key facts, strengths & barriers to growth. 2022. <https://www.midlandengine.org/wp-content/uploads/2022/06/Midlands-Engine-Partnership-Factsheet-March-2022.pdf> (accessed 27 July 2022).
- 37 Berking M, Whitley B. Affect Regulation Training: A Practitioners' Manual. Irvine, California: : Springer 2010
- 38 Lewis, M, Bromley, K, Sutton, CJ, McCray, G, Myers, HL, Lancaster, GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back!. *Pilot and feasibility studies* 2021; 7(1), 1-14.
- 39 Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp Psychiatry*. 2016;39:24-31.
- 40 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–13.
- 41 Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the insomnia severity index as an outcome measure for insomnia research. *Sleep Medicine*, 2, 297–307.
- 42 Snow G. blockrand: Randomization for block random clinical trials. R Packag version 2013;1.
- 43 Michie S, Atkins L, West R. The behaviour change wheel. A Guid to Des Interv 1st ed Gt Britain Silverback Publ 2014.
- 44 Vlaev I, Dolan P. Action Change Theory : A Reinforcement Learning Perspective on Behavior Change. *Rev Gen Psychol* 2015;19:69–95. doi:10.1037/gpr0000029
- 45 Oehler C, Görge F, Hegerl U, et al. A closer look at negative effects in a guided web-based intervention for mild to moderate depression. *Clin Psychol Sci Pract* 2021;28:131.

Figure 1. Flow chart diagram showing summary of the trial design for the REST study



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Material

Appendix A- Screening questionnaires

Q1.2 I confirm that I have read and understand the information sheet for the above study (INWORK PIL v1.7_IV- 24.08.21). If you have not already done so, please see the information sheet sent via the link in the screening invitation email. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

Yes (1)

No (2)

Q1.3 I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my employment being affected.

Yes (1)

No (2)

Q1.4 I understand that data collected during the study, may be looked at by individuals from the Universities of Warwick and Birmingham. I give permission for these individuals to have access to my data.

Yes (1)

No (2)

Q1.5 I understand that the screening phase of the above study is designed to assess my eligibility for the interventions being offered.

Yes (1)

No (2)

Q1.6 I understand that if I'm eligible for an intervention, I will be contacted again by the research team with further information on the specific intervention I may be eligible for and instructions on how to proceed.

Yes (1)

No (2)

1
2
3 Q1.7 Whether eligible or not for the INWORK study, would you like to be contacted by the research
4 team with invitations for future studies?
5

6 Yes (1)
7

8 No (2)
9

10
11 *Display This Question:*

12 *If Whether eligible or not for the INWORK study, would you like to be contacted by the research*
13 *team... = Yes*
14

15
16 Q1.8 I understand that my name and email address will be stored on the University of Warwick
17 servers for 5 years.

18 Yes (1)
19

20 No (2)
21
22

23 **End of Block: Consent**
24

25 **Start of Block: Description**
26

27 Q2.1 Over the next series of questions we will assess your mood and sleep. Please answer the
28 questions as accurately as possible and remember there are no correct answers.
29

30
31 You are free to withdraw at any time, should you wish to do so. If you have any issues completing the
32 questionnaires, please contact the research team at
33

34 **End of Block: Description**
35

36 **Start of Block: GAD-7**
37

38 Q3.1 Over the last 2 weeks, how often have you been bothered by any of the following problems?
39
40

41
42
43 Q3.2 Feeling nervous, anxious or on edge?
44

45 Not at all (1)
46

47 Several days (2)
48

49 More than half the days (3)
50

51 Nearly everyday (4)
52
53
54
55
56
57
58
59
60

1
2
3 Q3.3 Not being able to stop or control worrying?
4

- 5
-
- Not at all (1)
-
- 6
-
- 7
-
- Several days (2)
-
- 8
-
- 9
-
- More than half the days (3)
-
- 10
-
- 11
-
- Nearly everyday (4)
-
- 12

13
14
15 Q3.4 Worrying too much about different things?
16

- 17
-
- Not at all (1)
-
- 18
-
- 19
-
- Several days (2)
-
- 20
-
- 21
-
- More than half the days (3)
-
- 22
-
- 23
-
- Nearly everyday (4)
-
- 24

25
26
27 Q3.5 Trouble relaxing?
28

- 29
-
- Not at all (1)
-
- 30
-
- 31
-
- Several days (2)
-
- 32
-
- 33
-
- More than half the days (3)
-
- 34
-
- 35
-
- Nearly everyday (4)
-
- 36
-
- 37

38
39
40 Q3.6 Being so restless that it is hard to sit still?
41

- 42
-
- Not at all (1)
-
- 43
-
- 44
-
- Several days (2)
-
- 45
-
- 46
-
- More than half the days (3)
-
- 47
-
- 48
-
- Nearly everyday (4)
-
- 49

50 Q3.7 Becoming easily annoyed or irritable?
51

- 52
-
- Not at all (1)
-
- 53
-
- 54
-
- Several days (2)
-
- 55
-
- 56
-
- More than half the days (3)
-
- 57
-
- 58
-
- Nearly everyday (4)
-
- 59
-
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q3.8 Feeling afraid as if something awful might happen?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

End of Block: GAD-7

Start of Block: PHQ-9

Q4.1 Over the last two weeks, how often have you been bothered by any of the following problems?

Q4.2 Little interest or pleasure in doing things?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

Q4.3 Feeling down, depressed, or hopeless?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

Q4.4 Trouble falling or staying asleep, or sleeping too much?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

1
2
3 Q4.5 Feeling tired or having little energy?
4

- 5
-
- Not at all (1)
-
- 6
-
- 7
-
- Several days (2)
-
- 8
-
- 9
-
- More than half the days (3)
-
- 10
-
- 11
-
- Nearly everyday (4)
-
- 12
-
- 13

14
15 Q4.6 Poor appetite or overeating?
16

- 17
-
- Not at all (1)
-
- 18
-
- 19
-
- Several days (2)
-
- 20
-
- 21
-
- More than half the days (3)
-
- 22
-
- 23
-
- Nearly everyday (4)
-
- 24
-
- 25

26
27 Q4.7 Feeling bad about yourself - or that you are a failure or have let yourself or your family down?
28

- 29
-
- Not at all (1)
-
- 30
-
- 31
-
- Several days (2)
-
- 32
-
- 33
-
- More than half the days (3)
-
- 34
-
- 35
-
- Nearly everyday (4)
-
- 36
-
- 37

38
39 Q4.8 Trouble concentrating on things, such as reading the newspaper or watching television?
40

- 41
-
- Not at all (1)
-
- 42
-
- 43
-
- Several days (2)
-
- 44
-
- 45
-
- More than half the days (3)
-
- 46
-
- 47
-
- Nearly everyday (4)
-
- 48
-
- 49
-
- 50
-
- 51
-
- 52
-
- 53
-
- 54
-
- 55
-
- 56
-
- 57
-
- 58
-
- 59
-
- 60

1
2
3 Q4.9 Moving or speaking so slowly that other people could have noticed? Or the opposite — being so
4 fidgety or restless that you have been moving around a lot more than usual?
5

- 6 Not at all (1)
7
8 Several days (2)
9
10 More than half the days (3)
11
12 Nearly everyday (4)
13
-

14
15
16 Q4.10 Thoughts that you would be better off dead, or of hurting yourself in some way?
17

- 18 Not at all (1)
19
20 Several days (2)
21
22 More than half the days (3)
23
24 Nearly everyday (4)
25
-

26
27
28 *Display This Question:*

29 *If Thoughts that you would be better off dead, or of hurting yourself in some way? != Not at all*
30

31 **Q4.11 Your safety:** We appreciate that you are willing to share your experiences and feelings with
32 the research team. However, we cannot monitor in real time the information provided by you about
33 your physical and mental health during this research. If you would like emotional support, or
34 completing the survey has caused distress, we encourage you to reach out to someone you trust, or
35 contact the research team on wmg-mhpp@warwick.ac.uk. Alternatively, if it is an emergency, and
36 you need immediate help for yourself, call 999 straight away. For non-emergency physical and mental
37 health support call 111 by or go to 111.nhs.uk.
38

39 **End of Block: PHQ-9**

40
41 **Start of Block: ISI**
42

43 Q5.1 For each question, please select the option that best describes your answer. Please rate the
44 current (i.e. last 2 weeks) severity of your sleep problem(s).
45

46
47
48 Q5.2 Difficulty falling asleep
49

- 50 None (1)
51
52 Mild (2)
53
54 Moderate (3)
55
56 Severe (4)
57
58 Very Severe (5)
59
60

1
2
3
4
5 Q5.3 Difficulty staying asleep
6

- 7 None (1)
8
9 Mild (2)
10
11 Moderate (3)
12
13 Severe (4)
14
15 Very Severe (5)
16
-

17
18
19 Q5.4 Problems waking up too early
20

- 21 None (1)
22
23 Mild (2)
24
25 Moderate (3)
26
27 Severe (4)
28
29 Very Severe (5)
30
31
-

32
33
34 Q5.5 How SATISFIED/DISSATISFIED are you with your CURRENT sleep pattern?
35

- 36 Very Satisfied (1)
37
38 Satisfied (2)
39
40 Moderately Satisfied (3)
41
42 Dissatisfied (4)
43
44 Very Dissatisfied (5)
45

46
47 Q5.6 How NOTICEABLE to others do you think your sleep problem is in terms of impairing the
48 quality of your life?
49

- 50 Not at all Noticeable (1)
51
52 A little (2)
53
54 Somewhat (3)
55
56 Much (4)
57
58 Very Much (5)
59
60

1
2
3
4
5 Q5.7 How WORRIED/DISTRESSED are you about your current sleep problem?
6
7

- 8 Not at all Worried (1)
9 A little (2)
10 Somewhat (3)
11 Much (4)
12 Very Much Worried (5)
13
14
15
16
17

18
19
20 Q5.8 To what extent do you consider your sleep problem to INTERFERE with your daily functioning
21 (e.g. daytime fatigue, mood, ability to function at work/daily chores, concentration, memory, mood,
22 etc.) CURRENTLY?
23

- 24 Not at all Interfering (1)
25 A little (2)
26 Somewhat (3)
27 Much (4)
28 Very Much Interfering (5)
29
30
31
32
33
34

35
36 Q58

37 Copyright notice (C) *Morin, C.M. (1993 and 1996)*
38

39 End of Block: ISI
40

41 Start of Block: IAPT_GP
42



45 Q6.1

46 The responses you provided indicate that you might be having difficulties with your mental health.
47

48 This year has been really tough for many of us, especially when we are unable to do the usual things
49 that bring us joy like seeing friends and family. Whilst you may still be eligible for the study, we
50 strongly advise you to contact your GP or self-refer yourself to an NHS psychological therapies
51 service (IAPT). To get in touch with IAPT please follow this link: [https://www.nhs.uk/service-
52 search/find-a-psychological-therapies-service/](https://www.nhs.uk/service-search/find-a-psychological-therapies-service/).
53

54 The intervention programme you may be offered in the study should not be used as an alternative for
55 seeking diagnosis and treatment from a professional. You will subsequently be asked to consent to
56 have read and take this advice into consideration. While you wait for an appointment, you can access
57 expert advice and practical tips on the [Every Mind Matters](#) website. We have in addition put together
58 resources below which you may find useful to look after your mental health. The Mind charity has
59
60

produced [information on how to take care of your wellbeing](#) during the pandemic including advice for coping in the winter which you might find helpful.

Mind Infoline: Call: 0300 123 3393

Email: info@mind.org.uk

Website: <https://www.mind.org.uk/workplace/> Lines are open 9am to 6pm, Monday to Friday (except for bank holidays).

Samaritans

Call: 116 123

Email: jo@samaritans.org Website: <https://www.samaritans.org/>

For a listening ear or just someone to talk to the Samaritans are open 24 hours a day. If you need mental health information and the above helplines are closed then please visit Mind's Mental health A-Z resource or contact NHS 111.

NHS The NHS also has their own set of resources, this includes a website which provides access to other sources of information: <https://www.england.nhs.uk/mental-health/resources/> If you have any questions or would like more information, please contact the research team at wmg-mhpp@warwick.ac.uk

Please confirm that you understand these requests. This does not impact your ability to take part in these studies in any way.

I understand the request to contact my GP (4)

I understand the request to contact IAPT (5)

End of Block: IAPT_GP

Start of Block: Block 7

Q60 Please confirm your employer and usual place of work.

If your employer is not shown, please select "My employer is not listed".

If your usual place is not shown, please select "My place of work is not listed".

Organisation (1)

Site (2)

End of Block: Block 7

Start of Block: Additional_requirements

Q7.1 Thank you for responding to the questionnaires about your mental wellbeing. We have only a few last questions to ask to help identify which study you may be eligible for out of REST, SLEEP or MENTOR

1
2
3 Q7.2 Are you over the age of 18?
4

5 Yes (1)

6
7 No (2)
8

9
10
11 Q7.3

12 Do you currently manage anyone?
13

14 Yes (21)

15
16 No (22)
17
18

19
20 *Display This Question:*

21 *If Do you currently manage anyone? = Yes*
22

23 Q7.4

24 Would you be happy to participate in the MENTOR trial if someone of your team was selected for
25 MENTOR?
26

27 Yes (21)

28
29 No (22)
30
31

32
33 Q7.5 Do you have a current diagnosis of a mental health condition?
34

35 Yes (1)

36
37 No (2)
38
39

40 *Display This Question:*

41 *If Do you have a current diagnosis of a mental health condition? = Yes*
42
43

44 Q7.6 What is your mental health diagnosis?
45 _____
46
47

48
49 Q7.7 Are you currently under the care of a mental health care practitioner?
50

51
52 To clarify: are you currently receiving care through psychological treatment or through some form of
53 medication?
54
55
56
57
58
59
60

This can include your GP as well as a consultant from NHS services.

Yes (1)

No (2)

Q7.8 Are you currently involved in any psychological intervention trials?

Yes (1)

No (2)

Display This Question:

If Do you have a current diagnosis of a mental health condition? = Yes

Q7.9 Are you currently receiving support from an [Individual Placement and Support Worker](#)?

Yes (1)

No (2)

Display This Question:

If Do you have a current diagnosis of a mental health condition? = Yes

Q7.10 Are you on extended sick leave (i.e. for more than 4 weeks) ?

Yes (1)

No (2)

Display This Question:

If Are you over the age of 18? = Yes

And Do you have a current diagnosis of a mental health condition? = Yes

And Are you currently under the care of a mental health care practitioner? To clarify: are you curren... = Yes

*

Q7.11 What is your line manager's email address?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Display This Question:

If Are you over the age of 18? = Yes

And Do you have a current diagnosis of a mental health condition? = Yes

And Are you currently under the care of a mental health care practitioner? To clarify: are you curren... = Yes



Q7.12 Please confirm your line manager's email address

REST_Questionnaire at each timepoint

Start of Block: Consent

Q1.2 I confirm that I have read and understand the information sheet (REST v1.7 7/07/21) for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

Yes (1)

No (2)

Q1.3 I confirm that I meet ALL the eligibility criteria of this study: English speaking; 18 years or above; Not retiring in the next 10 months; Currently not receiving treatment (psychological or medication) from mental health services; Currently not taking parting in other psychological intervention trials.

Yes (1)

No (2)

Q1.4 I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my employment being affected.

Yes (1)

No (2)

Q1.5 I understand that data collected during the study, may be looked at by individuals from University of Warwick. I give permission for these individuals to have access to my data.

Yes (1)

No (2)

1
2
3 Q1.6 Would you like to be contacted to participate in a qualitative interview to understand how we
4 can improve the intervention further
5

6 Yes (1)

7
8 No (2)
9

10 -----
11
12 Q1.7 I am happy for my anonymised data to be used in future research.
13

14 Yes (1)

15
16 No (2)
17

18 -----
19
20 Q1.8 I agree to take part in the above study.
21

22 Yes (1)

23
24 No (2)
25

26
27 **End of Block: Consent**
28

29 **Start of Block: Demographics**
30

31 Q2.1 Thank you for consenting to take part in the REST trial. This study will last for 8 weeks during
32 this time you will have access to an online e-learning platform. You will receive further information
33 on how to access these in due course. For us to evaluate how well this intervention improves your
34 sleep and wellbeing, we ask you next to complete a set of questionnaires. This will take
35 approximately 45 minutes. Please read each question carefully before responding and feel free to take
36 breaks where you need. If you do feel you need to take a break, please do not close the survey.
37 If you have any questions, please contact us at wmg-rest@warwick.ac.uk
38

39
40
41 Q2.2 How old are you?

42 0 10 20 30 40 50 60 70 80 90 100

43
44 Age in years ()



45
46
47
48 -----
49 JS
50
51
52
53
54
55
56
57
58
59
60

Q2.3 What gender do you identify as?

- Female (1)
- Male (2)
- Non-binary (3)
- Other (please specify) (4) _____
- Prefer not to specify (5)



Q2.4 What is your ethnicity? (1 of 2)

- White... (1)
- Mixed / Multiple ethnic groups... (2)
- Asian or Asian British... (3)
- Black or Black British... (4)
- Mixed (5)
- Hispanic/Latino (6)
- Other (please specify) (7)

Display This Question:

If What is your ethnicity? (1 of 2) = White...

Q2.5 What is your ethnicity? (2 of 2)

- English / Welsh / Scottish / Northern Irish / British (1)
- Irish (2)
- Gypsy or Irish Traveller (3)
- Any other White background (please describe if you wish) (4)

Display This Question:

If What is your ethnicity? (1 of 2) = Mixed

1
2
3 Q2.6 What is your ethnicity? (2 of 2)
4

- 5 White and Black Caribbean (1)
6
7 White and Black African (2)
8
9 White and Asian (3)
10
11 Any other Mixed / Multiple ethnic background (please describe if you wish) (4)
12 _____
13

14
15 *Display This Question:*

16 *If What is your ethnicity? (1 of 2) = Asian or Asian British...*
17

18
19 Q2.7 What is your ethnicity? (2 of 2)
20

- 21 Indian (1)
22
23 Pakistani (5)
24
25 Bangladeshi (6)
26
27 Chinese (7)
28
29 Any other Asian background (please describe if you wish) (8)
30 _____
31

32
33 *Display This Question:*

34 *If What is your ethnicity? (1 of 2) = Black or Black British...*
35

36 Q2.8 What is your ethnicity? (2 of 2)
37

- 38 African (1)
39
40 Caribbean (4)
41
42 Any other Black / African / Caribbean background (please describe if you wish) (5)
43 _____
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Q2.9 How many hours do you work per week?
5

6 0 5 10 15 20 25 30 35 40 45 50

7
8 Number of hours ()
9
10
11



12
13
14 Q2.10 Information about income is very important to understand. Would you please give your best
15 guess? Please indicate the answer that includes your entire household income in (previous year) before
16 taxes.
17

- 18 £10,000 to £29,999 (1)
19 £30,000 to £49,999 (2)
20 £50,000 to £69,999 (3)
21 £70,000 to £89,999 (4)
22 £90,000 to £109,999 (5)
23 £110,000 to £149,999 (6)
24 £150,000 or more (7)
25
26
27
28
29
30
31

32
33 JS
34
35

36 Q2.11 How would you describe your current relationship status?
37

- 38 Single (1)
39 Cohabiting (2)
40 Married (3)
41 Separated (4)
42 Divorced (5)
43 Widowed (6)
44 Other (please specify) (7) _____
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Q2.12 Who do you live with?
4

- 5 I live by myself (1)
6
7 I live with flatmates (2)
8
9 I live with my partner (3)
10
11 I live with my parents/carers (4)
12
13 I live with other family members (6)
14
-

15
16 JS
17

18
19 Q2.13 What is your highest educational qualification?
20

- 21 No formal qualification (1)
22
23 Primary (2)
24
25 Secondary (e.g., GCSE, O-levels, GNVQ) (3)
26
27 Diploma (or professional qualification) (4)
28
29 Bachelor's degree (5)
30
31 Master's degree (6)
32
33 Doctorate degree (7)
34
35 Other (please specify) (8) _____
36
-

37
38 JS
39

40
41 Q2.14 In the last 8 weeks, to the best of your recollection, how much sick leave have you taken?
42

- 43 I have taken (1) _____
44
45 I have not taken any sick leave (2)
46
47 I would prefer not to answer this question (3)
48
-

49
50
51 Q2.15 Are you currently using any self-help resources?
52

53
54 This includes but is not limited to self help books, apps and websites
55

- 56 Yes (1)
57
58 No (2)
59
60

1
2
3
4
5 Q2.16 Since completing the screening questionnaire of this study, did you start receiving treatment
6 from mental health services?
7

8 Yes (1)

9
10 No (2)
11

12 **End of Block: Demographics**

13
14

Start of Block: Contact

15 Page Break
16

17
18
19 Q3.1 As part of this study we need to request some further personal information for us to contact you
20 during this study.
21



26 Q3.2 What is your phone number?
27
28 _____

29 **End of Block: Contact**

30
31

Start of Block: COVID_19

32
33 Q5.1 As part of our research, we are interested in your experiences with COVID-19 and how this has
34 impacted your life. Please read each question carefully and select the most appropriate response for
35 you.
36
37

38
39
40 Q5.2 How worried are you about contracting COVID-19?

41 Not worried at all (1)

42 Slightly worried (2)

43 Moderately worried (3)

44 Very worried (4)

45 Extremely worried (5)
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Q5.3 In which category are you considered to be in regard to COVID-19 according to the NHS and
4 UK Government guidelines of England?
5

- 6 Clinically extremely vulnerable (1)
7
8 Clinically vulnerable (2)
9
10 Low risk (3)
11
-

12
13
14 Q5.4 Since the start of the pandemic, have you tested positive for COVID-19?
15

- 16 Yes (1)
17
18 No (2)
19
20
-

21
22 *Display This Question:*

23 *If Since the start of the pandemic, have you tested positive for COVID-19? = Yes*
24

25 Q5.5 Have you required hospitalised treatment for COVID-19?
26

- 27 Yes (1)
28
29 No (2)
30
-

31
32 *Display This Question:*

33 *If Since the start of the pandemic, have you tested positive for COVID-19? = No*
34

35 Q5.6 Do you suspect that you may have had COVID-19 due to presenting with symptoms?
36 (temperature/fever, new persistent cough, loss of smell & taste)
37

- 38 Definitely (1)
39
40 Probably (2)
41
42 Unsure (3)
43
44 No (4)
45
-

46
47
48 *Display This Question:*

49 *If Since the start of the pandemic, have you tested positive for COVID-19? = Yes*
50

51 Q5.7 For some people, coronavirus can cause symptoms that last weeks or months after the infection
52 has gone. This is sometimes called post-COVID-19 syndrome or "long COVID". Have you
53
54
55
56
57
58
59
60

1
2
3 experienced any of the following long COVID symptoms 12 weeks after initial infection? (Check all
4 that apply)
5

- 6 No (I feel fully recovered) (1)
7
8 Extreme tiredness (fatigue) (2)
9
10 Shortness of breath (3)
11
12 Chest pain or tightness (4)
13
14 Problems with memory and concentration ("brain fog") (5)
15
16 Difficulty sleeping (insomnia) (6)
17
18 Heart palpitations (7)
19
20 Dizziness (8)
21
22 Pins and needles (9)
23
24 Joint pain (10)
25
26 Depression and anxiety (11)
27
28 Tinnitus, earaches (12)
29
30 Feeling sick, diarrhoea, stomach aches, loss of appetite (13)
31
32 A high temperature, cough, headaches, sore throat, changes to sense of smell or taste
33
34 (14)
35
36 Rashes (15)
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-

1
2
3 Q5.8 Since the start of the pandemic, have any people you know tested positive for COVID-19?
4 (Choose all that apply)
5

- 6 Immediate family members (1)
7
8 Extended family members (2)
9
10 Neighbours (3)
11
12 Friends (4)
13
14 Colleagues (5)
15
16 No one I know has tested positive (6)
17
18
19
20
-

21
22
23 Q5.9 Since the start of the pandemic, have you been asked to stop working temporarily under the
24 government “furlough” scheme?
25

- 26 No (1)
27
28 Yes, I am currently on furlough (2)
29
30 Yes, I will soon be on furlough (3)
31
32 Yes, but have since returned to work (full time or part time) (4)
33
34
-

35
36 Q5.10 As a result of colleagues being placed on furlough, do you think your workload will/has:
37

- 38 Increase (d) (1)
39
40 Decrease (d) (2)
41
42 Stay (ed) the same (3)
43
44 Can't say yet (4)
45
46 N/A, as no one I work with has been furloughed (5)
47
48 N/A, as I am currently been furloughed (6)
49
50
-

51 Page Break
52
53
54
55
56
57
58
59
60

1
2
3
4 Q5.11 In light of the COVID-19 pandemic, what changes had been made within your organisation
5 that have impacted you? (Tick all that apply)
6

- 7 Hours of work (1)
8
9 Pay cut (2)
10
11 Working remotely (3)
12
13 Not applicable (4)
14
15
16

17
18 *Display This Question:*

19 *If In light of the COVID-19 pandemic, what changes had been made within your organisation*
20 *that have... = Working remotely*
21

22
23 Q5.12 Have you experienced any ongoing challenges in working remotely? (Tick all that apply)

- 24 Technical difficulties (e.g. with internet, computers, access to workplace data storage)
25 (1)
26
27 Practical difficulties (no separate/private area from which to work) (2)
28
29 Balancing work with caregiving/parenting responsibilities (3)
30
31 Motivational difficulties (4)
32
33 Other (please specify) (5)
34
35 No challenges experienced (6)
36
37
38
39

40
41 *Display This Question:*

42 *If In light of the COVID-19 pandemic, what changes had been made within your organisation*
43 *that have... = Working remotely*
44

45 Q5.13 How comfortable do you feel returning back to work and having the appropriate support from
46 your organisation? (e.g. Covid-19 risk assessment)?
47

- 48 Not comfortable at all (1)
49
50 Slightly comfortable (2)
51
52 Moderately comfortable (3)
53
54 Very comfortable (4)
55
56 Extremely comfortable (5)
57
58
59
60

Display This Question:

If In light of the COVID-19 pandemic, what changes had been made within your organisation that have... = Working remotely

Q5.14 How have these issues affected your ability to work?

- (Negative impact) -3 (1)
- 2 (2)
- 1 (3)
- 0 (4)
- 1 (5)
- 2 (6)
- (Positive Impact) 3 (7)

Q5.15 Have you experienced any of the following due to COVID-19? (Tick all that apply)

We understand this question may trigger distress and undesirable memories or thoughts. If so, please speak to a friend or family member or seek professional support (e.g. GP).

- Lost your job/unable to earn money (1)
- Another bill payer in your household lost their job or is/was unable to earn money (2)
- Unable to pay bills (3)
- Had difficulties accessing sufficient food (4)
- Evicted / lost accommodation (5)
- Had difficulties accessing required medication (6)
- Somebody close to you in hospital (7)
- Somebody close to you died (we are very sorry for your loss. We realise answering this question might make you uncomfortable or trigger unsettling feelings. If you feel you need to speak to someone or require support, please refer to this NHS resource) (8)
- Difficulties with family or social relationships (9)
- If you're a parent/carer, concerns about your child's/children's well-being and/or education (10)
- Having to change or delay major life plans or events (11)
- Not applicable (12)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q5.16 How comfortable do you feel raising COVID-19 related issues with your organisation (e.g. line manager, human resources)?

- Not comfortable at all (1)
- Slightly comfortable (2)
- Moderately comfortable (3)
- Very comfortable (4)
- Extremely comfortable (5)
-

Q5.17 Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a research trial)

- Yes (1)
- No (2)
-

Display This Question:

If Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a resea... = Yes

Q5.19 Have you experienced any of the following symptoms as a result of having the vaccine? (Tick all that apply)

- Headaches (1)
- Feeling tired (2)
- Feeling achy (3)
- Soreness, redness and swelling at the site of the vaccination (4)
- Mild or high fever (5)
- Feeling or being sick (6)
- Allergic reaction (7)
- I did not have any symptoms (8)
-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Display This Question:

If Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a resea... = Yes

*

Q5.22 When did you receive your first dose? (please enter date as DD/MM/YYYY)

Display This Question:

If Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a resea... = Yes

Q5.23 Have you received a second dose of a COVID-19 vaccine?

Yes (1)

No (2)

Display This Question:

If Have you received a second dose of a COVID-19 vaccine? = Yes

Q5.24 When did you receive your second dose? (please enter date as DD/MM/YYYY)

Q5.25 What would you say is your one biggest concern or problem encountered, since the start of the pandemic?

Page Break

Q5.26 Did you receive any help overcoming the concern/problem outlined above and if yes, what has been helpful or unhelpful? If no, what kind of help do you think you need right now?

End of Block: COVID_19

Start of Block: WPAI_GH

1
2
3 Q6.1 The following questions ask about the effect of your health problems on your ability to work and
4 perform regular activities. By health problems we mean any physical or emotional problem or
5 symptom. Please fill in the blanks or indicate your response.
6
7

8
9
10 Q6.2 Are you currently employed (working for pay)?

11 Yes (1)

12 No (2)
13
14

15 **Skip To: Q6.7 If Are you currently employed (working for pay)? = No**
16
17

18
19 Q6.3 The next questions are about the **past seven days**, not including today.
20
21

22 *

23
24
25 Q6.4 During the past seven days, how many hours did you miss from work because of your health
26 problems? Include hours you missed on sick days, times you went in late, left early, etc., because of
27 your health problems. *Do not include time you missed to participate in this study.*
28
29

30
31 *

32
33 Q6.5 During the past seven days, how many hours did you miss from work because of any other
34 reason, such as vacation, holidays, time off to participate in this study?
35
36

37
38
39 *

40
41 Q6.6 During the past seven days, how many hours did you actually work?
42
43

44
45
46
47 Q6.7 During the past seven days, how much did your health problems affect your productivity while
48 you were working? *Think about days you were limited in the amount or kind of work you could do,*
49 *days you accomplished less than you would like, or days you could not do your work as carefully as*
50 *usual. If health problems affected your work only a little, choose a low number. Choose a high*
51 *number if health problems affected your work a great deal. Consider only how much health*
52 *problems affected productivity while you were working.*

53 No effect on my work

54 Completely prevented me
55 from working

56
57 0 1 2 3 4 5 6 7 8 9 10
58
59
60

1 ()



Q6.8 During the past seven days, how much did your health problems affect your ability to do your regular daily activities, other than work at a job?

By regular activities, we mean the usual activities you do, such as work around the house, shopping, childcare, exercising, studying, etc. Think about times you were limited in the amount or kind of activities you could do and times you accomplished less than you would like. If health problems affected your activities only a little, choose a low number. Choose a high number if health problems affected your activities a great deal.

Consider only how much health problems affected your ability to do your regular daily activities, other than work at a job.

No effect on my daily activities Completely prevented me from doing my daily activities

0 1 2 3 4 5 6 7 8 9 10

1 ()



End of Block: WPAI_GH

Start of Block: IJSS

Q7.1 As part of our research, we are interested in the amount of job satisfaction with respect to your current role. This questionnaire is a valid and reliable measure of job satisfaction. Please read each statement carefully and tell us how much you agree with each statement.

There are no incorrect answers and none of the information you provide will be shared with your employer.

Q7.2 I feel good about this job

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

1
2
3 Q7.3 This job is worthwhile
4

- 5 Strongly agree (1)
6
7 Somewhat agree (2)
8
9 Somewhat disagree (3)
10
11 Strongly disagree (4)
12
-

13
14
15 Q7.4 The working conditions are good
16

- 17 Strongly agree (1)
18
19 Somewhat agree (2)
20
21 Somewhat disagree (3)
22
23 Strongly disagree (4)
24
-

25
26
27 Q7.5 I want to quit this job
28

- 29 Strongly agree (1)
30
31 Somewhat agree (2)
32
33 Somewhat disagree (3)
34
35 Strongly disagree (4)
36
37
-

38
39
40 Q7.6 This job is boring
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.7 I am happy with the amount this job pays
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q7.8 The vacation time and other benefits on this job are okay

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
-

Q7.9 I need more money than this job pays

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
-

Q7.10 This job does not provide the medical coverage I need

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
 - Not Applicable (5)
-

Q7.11 I have a fairly good chance for promotion in this job

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

1
2
3 Q7.12 This is a dead-end job
4

- 5 Strongly agree (1)
6
7 Somewhat agree (2)
8
9 Somewhat disagree (3)
10
11 Strongly disagree (4)
12
-

13
14
15 Q7.13 I feel that there is a good chance of my losing this job in the future
16

- 17 Strongly agree (1)
18
19 Somewhat agree (2)
20
21 Somewhat disagree (3)
22
23 Strongly disagree (4)
24
-

25
26
27 Q7.14 My supervisor is fair
28

- 29 Strongly agree (1)
30
31 Somewhat agree (2)
32
33 Somewhat disagree (3)
34
35 Strongly disagree (4)
36
37
-

38
39
40 Q7.15 My supervisor is hard to please
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.16 My supervisor praises me when I do my job well
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5 Q7.17 My supervisor is difficult to get along with
6

- 7 Strongly agree (1)
8
9 Somewhat agree (2)
10
11 Somewhat disagree (3)
12
13 Strongly disagree (4)
14
-

15
16
17 Q7.18 My supervisor recognizes my efforts
18

- 19 Strongly agree (1)
20
21 Somewhat agree (2)
22
23 Somewhat disagree (3)
24
25 Strongly disagree (4)
26
27
-

28
29
30 Q7.19 My coworkers are easy to get along with
31

- 32 Strongly agree (1)
33
34 Somewhat agree (2)
35
36 Somewhat disagree (3)
37
38 Strongly disagree (4)
39

40 Q7.20 My coworkers are lazy
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.21 My coworkers are unpleasant
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q7.22 My coworkers don't like me

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
-

Q7.23 My coworkers help me to like this job more

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
-

Q7.24 I have a coworker I can rely on

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

Q7.25 I have a coworker I consider a friend

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

Q7.26 I look forward to coming to work

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

1
2
3
4
5 Q7.27 I often feel tense on the job
6

- 7 Strongly agree (1)
8
9 Somewhat agree (2)
10
11 Somewhat disagree (3)
12
13 Strongly disagree (4)
14
-

15
16
17 Q7.28 I don't know what's expected of me on this job
18

- 19 Strongly agree (1)
20
21 Somewhat agree (2)
22
23 Somewhat disagree (3)
24
25 Strongly disagree (4)
26
27
-

28
29
30 Q7.29 I feel physically worn out at the end of the day
31

- 32 Strongly agree (1)
33
34 Somewhat agree (2)
35
36 Somewhat disagree (3)
37
38 Strongly disagree (4)
39

40 Q7.30 Working makes me feel like I'm needed
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.31 My job keeps me busy
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5 Q7.32 I get to do a lot of different things on my job
6
7

- 8 Strongly agree (1)
9 Somewhat agree (2)
10 Somewhat disagree (3)
11 Strongly disagree (4)
12
13
14
15

16
17
18 Q7.33 I am satisfied with my schedule
19

- 20 Strongly agree (1)
21 Somewhat agree (2)
22 Somewhat disagree (3)
23 Strongly disagree (4)
24
25
26
27

28 **End of Block: IJSS**

29
30 **Start of Block: WEMWBS**

31 Page Break
32

33 Q8.1 Below are some statements about feelings and thoughts.
34

35 Please select the option that best describes your experience of each over the last 2 weeks
36

37 Q8.2 I've been feeling optimistic about the future
38

- 39 None of the time (1)
40 Rarely (2)
41 Some of the time (3)
42 Often (4)
43 All of the time (5)
44
45
46
47

48 Q8.3 I've been feeling useful
49

- 50 None of the time (1)
51 Rarely (2)
52 Some of the time (3)
53 Often (4)
54 All of the time (5)
55
56
57
58
59
60

1
2
3
4
5 Q8.4 I've been feeling relaxed
6

- 7 None of the time (1)
8
9 Rarely (2)
10
11 Some of the time (3)
12
13 Often (4)
14
15 All of the time (5)
16

17
18
19 Q8.5 I've been feeling interested in other people
20

- 21 None of the time (1)
22
23 Rarely (2)
24
25 Some of the time (3)
26
27 Often (4)
28
29 All of the time (5)
30
31

32
33
34 Q8.6 I've had energy to spare
35

- 36 None of the time (1)
37
38 Rarely (2)
39
40 Some of the time (3)
41
42 Often (4)
43
44 All of the time (5)
45

46
47
48 Q8.7 I've been dealing with problems well
49

- 50 None of the time (1)
51
52 Rarely (2)
53
54 Some of the time (3)
55
56 Often (4)
57
58 All of the time (5)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q8.8 I've been thinking clearly

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.9 I've been feeling good about myself

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.10 I've been feeling close to other people

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.11 I've been feeling confident

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q8.12 I've been able to make up my own mind about things

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)
-

Q8.13 I've been feeling loved

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)
-

Q8.14 I've been interested in new things

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)
-

Q8.15 I've been feeling cheerful

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)

End of Block: WEMWBS

Start of Block: Medication_checklist

Q9.1 We would like to know what medication (prescriptions and/or over the counter) you use, what dose and for what condition. Medications are tablets or capsules, but could also be (eye) drops, sprays, creams, drinks, inhaler puffs, suppositories etc. Prescription medications are ones that a doctor prescribes. Over the counter medication are ones that you can purchase yourself without a prescription such as ibuprofen, vitamins, herbal remedies etc.

	Name of medication (1)	Dosage (mg/g/ml) (2)	How often do you take this medication (per day / week/ as needed) (3)	How much do you take per time (e.g. 2 tablets) (4)	What is this medication for? (5)	How long have you been using it for? (6)	Additional comments (7)
1. (1)							
2. (2)							
3 (6)							
4 (7)							
5 (8)							
6 (9)							
7 (10)							

1
2
3
4 **End of Block: Medication_checklist**
5

6 **Start of Block: ISI**
7

8 Page Break
9

10
11 **Q12.1** For each question, please select the option that best describes your answer. Please rate the
12 current (i.e. last 2 weeks) severity of your sleep problem(s).
13

14
15
16 **Q12.2** Difficulty falling asleep

- 17
18 None (1)
19
20 Mild (2)
21
22 Moderate (3)
23
24 Severe (4)
25
26 Very Severe (5)
27

28
29
30 **Q12.3** Difficulty staying asleep

- 31
32 None (1)
33
34 Mild (2)
35
36 Moderate (3)
37
38 Severe (4)
39
40 Very Severe (5)
41

42
43
44 **Q12.4** Problems waking up too early

- 45
46 None (1)
47
48 Mild (2)
49
50 Moderate (3)
51
52 Severe (4)
53
54 Very Severe (5)
55
56

57
58
59
60

1
2
3 Q12.5 How SATISFIED/DISSATISFIED are you with your CURRENT sleep pattern?
4

- 5 Very Satisfied (1)
6
7 Satisfied (2)
8
9 Moderately Satisfied (3)
10
11 Dissatisfied (4)
12
13 Very Dissatisfied (5)
14
-

15
16
17 Q12.6 How NOTICEABLE to others do you think your sleep problem is in terms of impairing the
18 quality of your life?
19

- 20 Not at all Noticeable (1)
21
22 A little (2)
23
24 Somewhat (3)
25
26 Much (4)
27
28 Very Much (5)
29
-

30
31
32 Q12.7 How WORRIED/DISTRESSED are you about your current sleep problem?
33

- 34 Not at all Worried (1)
35
36 A little (2)
37
38 Somewhat (3)
39
40 Much (4)
41
42 Very Much Worried (5)
43
44
45

46 Q12.8 To what extent do you consider your sleep problem to INTERFERE with your daily
47 functioning (e.g. daytime fatigue, mood, ability to function at work/daily chores, concentration,
48 memory, mood, etc.) CURRENTLY?
49

- 50 Not at all Interfering (1)
51
52 A little (2)
53
54 Somewhat (3)
55
56 Much (4)
57
58 Very Much Interfering (5)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q12.9

Copyright notice (C) Morin, C.M. (1993, 1996, 2000, 2006)

For any information on the use of the Insomnia Severity Index, please contact Mapi Research Trust, Lyon, France. Internet: <https://eprovide.mapi-trust.org>

End of Block: ISI

Start of Block: GAD7

Page Break

Q10.1 Over the next series of questions we will assess your mood and sleep. Please answer the questions as accurately as possible and remember there are no correct answers.

Q10.2 Over the last 2 weeks, how often have you been bothered by any of the following problems?

Q10.3 Feeling nervous, anxious or on edge?

- Not at all (1)
 - Several days (2)
 - More than half the days (3)
 - Nearly everyday (4)
-

Q10.4 Not being able to stop or control worrying?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

Q10.5 Worrying too much about different things?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q10.6 Trouble relaxing?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.7 Being so restless that it is hard to sit still?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.8 Becoming easily annoyed or irritable?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.9 Feeling afraid as if something awful might happen?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

End of Block: GAD7

Start of Block: PHQ9

Page Break

Q11.1 Over the last two weeks, how often have you been bothered by any of the following problems?

1
2
3
4 Q11.2 Little interest or pleasure in doing things?
5

- 6 Not at all (1)
7
8 Several days (2)
9
10 More than half the days (3)
11
12 Nearly everyday (4)
13
-

14
15
16 Q11.3 Feeling down, depressed, or hopeless?
17

- 18 Not at all (1)
19
20 Several days (2)
21
22 More than half the days (3)
23
24 Nearly everyday (4)
25
-

26
27
28
29 Q11.4 Trouble falling or staying asleep, or sleeping too much?
30

- 31 Not at all (1)
32
33 Several days (2)
34
35 More than half the days (3)
36
37 Nearly everyday (4)
38

39
40 Q11.5 Feeling tired or having little energy?
41

- 42 Not at all (1)
43
44 Several days (2)
45
46 More than half the days (3)
47
48 Nearly everyday (4)
49

50 Q11.6 Poor appetite or overeating?
51

- 52 Not at all (1)
53
54 Several days (2)
55
56 More than half the days (3)
57
58 Nearly everyday (4)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q11.7 Feeling bad about yourself - or that you are a failure or have let yourself or your family down?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q11.8 Trouble concentrating on things, such as reading the newspaper or watching television?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q11.9 Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q11.10 Thoughts that you would be better off dead, or of hurting yourself in some way?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

End of Block: PHQ9

Start of Block: disclaimer



1
2
3 Q13.1 The responses you provided indicate that you might be having difficulties with your mental
4 health. This year has been really tough for many of us, especially when we are unable to do the usual
5 things that bring us joy like seeing friends and family. We strongly advise you to contact your GP or
6 self-refer yourself to an NHS psychological therapies service (IAPT). To get in touch with IAPT
7 please follow this link: <https://www.nhs.uk/service-search/find-a-psychological-therapies-service/>.
8 The intervention programme should not be used as an alternative for seeking diagnosis and treatment
9 from a professional. While you wait for an appointment, you can access expert advice and practical
10 tips on the Every Mind Matters website. We have in addition put together resources below which you
11 may find useful to look after your mental health. The Mind charity has produced information on how
12 to take care of your wellbeing during the pandemic including advice for coping in the winter which
13 you might find helpful. Mind Infoline: Call: 0300 123 3393

14 Email: info@mind.org.uk

15 Website: <https://www.mind.org.uk/workplace/> Lines are open 9am to 6pm, Monday to Friday
16 (except for bank holidays). Samaritans

17 Call: 116 123

18 Email: jo@samaritans.org Website: <https://www.samaritans.org/>

19 For a listening ear or just someone to talk to the Samaritans are open 24 hours a day. If you need
20 mental health information and the above helplines are closed then please visit Mind's Mental health
21 A-Z resource or contact NHS 111. NHS The NHS also has their own set of resources, this includes
22 a website which provides access to other sources of information: [https://www.england.nhs.uk/mental-](https://www.england.nhs.uk/mental-health/resources/)
23 [health/resources/](https://www.england.nhs.uk/mental-health/resources/) If you have any questions or would like more information, please contact the
24 research team at wmg-rest@warwick.ac.uk

25
26
27 Please confirm that you understand these requests. This does not impact your ability to take part in
28 these studies in any way.

29
30

31 I understand the request to contact my GP (4)

32
33

34 I understand the request to contact IAPT (5)

35
36 End of Block: disclaimer

37 38 39 Appendix B- Outcome measures

40 The following psychometric will be used to explore their utility as outcome measures for a future
41 fully powered randomised-controlled trial.

42
43 The General Anxiety Disorder-7 (GAD-7) is commonly used in primary and secondary mental health
44 settings to measure symptom severity for General Anxiety Disorder (Spitzer, Kroenke, Williams, &
45 Löwe, 2006). The GAD-7 is comprised on seven items each scored on a four-point Likert scale, a
46 score of 10 has been shown to correctly diagnose cases of generalised anxiety disorder with 89%
47 sensitivity and 82% specificity, with high test-retest reliability (ICC = 0.83). The GAD-7 also shows
48 high concurrent validity with high scores being associated with disability and functional impairment
49 (Ruiz et al., 2011; Spitzer et al., 2006).

50
51 The Patient Health Questionnaire-9 (PHQ-9) is commonly used, in primary care settings to assess the
52 severity of depression across the nine DSM-IV criteria for major depressive disorder on a four-point
53 Likert scale (Cameron, Crawford, Lawton, & Reid, 2008). The PHQ-9 has been shown to demonstrate
54 high diagnostic accuracy in at risk populations (Haddad et al., 2013; Janneke et al., 2012), and in
55 clinical populations. A criterion score of ≥ 10 has a 88% sensitivity and specificity for major
56 depressive disorder (Kroenke, Spitzer, & Williams, 2001). Empirical research demonstrates high
57 internal consistency ($\alpha = 0.91$; Hansson, Chotai, Nordstöm, & Bodlund, 2009) and a valid latent
58
59
60

1
2
3 structure even when administered in nonclinical samples (CFI = 0.914- 0.983; Ito, Takebayashi,
4 Muramatsu, & Horikoshi, 2018).
5

6 The Insomnia Severity Index (ISI) is a seven-item psychometric which has been validated with
7 reference to the diagnostic criteria for primary insomnia in the DSM-IV. The ISI uses a five-point
8 Likert scale response to each item (score range 0–28). A score of ≥ 15 identifies cases of clinical
9 insomnia with 94% sensitivity and specificity (Bastien, Vallières, & Morin, 2001). A reduction of 8.4
10 has been shown to be associated with moderate improvement in clinical populations (Morin,
11 Belleville, Bélanger, & Ivers, 2011), with responses being validated in non-clinical samples as
12 demonstrating a high internal reliability ($\alpha = 0.81 - 0.91$ (Morin et al., 2011; Yu, 2010)).
13
14

15 Job productivity - measured through the Work Productivity and Activity Impairment: General Health
16 v2.0 (WPAI:GH; (Reilly, Zbrozek, & Dukes, 1993). The WPAI:GH is a six item psychometric which
17 focuses on: 'Absenteeism', 'Presenteeism', 'Work productivity loss' and 'Activity Impairment'. The
18 WPAI:GH has shown strong psychometric properties with good internal consistency ($\alpha = 0.74$), with
19 a high intraclass correlation coefficient ($r = 0.79 - 0.90$) in clinical populations (Zhang et al., 2010).
20 The WPAI has been used in non-clinical samples and has shown good face validity (Duke & Montag,
21 2017).
22

23 Job satisfaction - measured using the Indiana Job Satisfaction Scale (IJSS; Resnick & Bond, 2001).
24 The IJSS is a 32-item psychometric coded on a four-point Likert response of "Strongly disagree" to
25 "Strongly agree", and is comprised of six subscales: 'General Satisfaction', 'Pay', 'Advancement and
26 Security', 'Supervision', 'Coworkers' and 'How I feel about this job'. The IJSS yields strong
27 psychometric properties with high internal consistence ($\alpha = 0.90$) and test-retest reliability ($r = .75$)
28 (Resnick & Bond, 2001).
29

30 Well-being – we measure subjective well-being using the Warwick-Edinburgh Mental Health Well-
31 being Scale (WEMWBS, Tennant et al., 2007). The WEMWBS consists of 14-items on a five-point
32 likert scale ranging from "None of the time" to "All of the time". The scale has been shown to hold
33 good psychometric properties, with strong internal consistency ($\alpha = 0.91$) and was shown to hold high
34 concurrent validity (Tennant et al., 2007). When applied to nonclinical samples the WEMWBS still
35 shows similar psychometric properties with high internal consistency ($\alpha = 0.94$; test-retest = 0.83;
36 Dong et al., 2016).
37
38

39 Quality of life- measured using the EuroQOL EQ-5D-5L questionnaire (Herdman et al., 2011). The
40 EQ-5D-5L consists of six items, five items measured through five-point likert-scale responses to
41 mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with a sixth item of a
42 rating of health on a visual analogue scale ranging from 0-100. The EQ-5D-5L has shown high
43 internal consistency in clinical samples ($\alpha = 0.86$; (Bilbao et al., 2018) and in nonclinical populations
44 ($\alpha = 0.84$; Kim & Ko, 2018).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

A digital Cognitive Behavioural Therapy intervention in the workplace: Study protocol for a feasibility randomised waitlist-controlled trial to improve employee mental wellbeing, engagement and productivity.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060545.R3
Article Type:	Protocol
Date Submitted by the Author:	02-Nov-2022
Complete List of Authors:	Patel, Krishane; University of Warwick Moukhtarian, Talar Rita; University of Warwick, Warwick Medical School, Division of Health Sciences Russell, Sean; Coventry University, Faculty of Health and Life Sciences Daly, Guy; Coventry University, Faculty of Health and Life Sciences Walasek, Lukasz; University of Warwick, Psychology Tang, Nicole; University of Warwick, Psychology Toro, Carla; University of Warwick, Warwick Medical School, Division of Health Sciences Meyer, Caroline; University of Warwick, Warwick Medical School, Division of Health Sciences
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Occupational and environmental medicine
Keywords:	MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Adult psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3 **Title: A digital Cognitive Behavioural Therapy intervention in the workplace: Study**
4 **protocol for a feasibility randomised waitlist-controlled trial to improve employee**
5 **mental wellbeing, engagement and productivity.**
6
7
8

9 Krishane Patel¹, Talar R Moukhtarian², Sean Russell³, Guy Daly³, Lukasz Walasek⁴, Nicole
10 Tang⁴, Carla Toro*², and Caroline Meyer²
11
12
13

14 **Author affiliation**

15 1 – Warwick Manufacturing Group, University of Warwick, University Road, Coventry, CV4
16 7AL, UK

17 2- Warwick Medical School, Division of Health Sciences, University of Warwick, University
18 Road, Coventry, CV4 7HL, UK

19 3- Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1
20 5FB, UK

21 4- Department of Psychology, University of Warwick, University Road, Coventry, CV4 7AL,
22 UK
23
24

25 *Correspondence to Dr Carla Toro, Warwick Medical School, Division of Health Sciences,
26 Mental Health and Wellbeing group, University of Warwick, University Road, Coventry, CV4
27 7HL, UK
28

29 Email: Carla.toro@warwick.ac.uk
30

31 Abstract (283 words)
32

33 Introduction: One in six workers experience some form of mental health problems at work
34 costing the UK economy an estimated £70 billion/year. Digital interventions provide low cost
35 and easily scalable delivery methods to implement psychological interventions in the
36 workplace. This trial tests the feasibility of implementing a self-guided eight-week digital
37 cognitive behavioural therapy (dCBT) intervention for subthreshold to clinical depression
38 and/or anxiety versus waitlist control (i.e. life as usual) in the workplace.
39
40

41 Methods and analysis: Feasibility of implementation will be tested using a mixed methods
42 evaluation of the two-arm randomised waitlist control trial. Evaluation will include
43 examination of organisational buy-in, and the engagement of employees through the trial
44 indicated by the completion of outcome measures. In addition, we also explore how
45 participants use the platform, the appropriateness of the analysis both with reference to the
46 outcome measures and linear modelling. Finally, we examine the acceptability of the
47 intervention based on participants experiences using qualitative interviews. Assessments take
48 place at baseline (T0), at 8 weeks post-treatment (T1), at short-term follow-up 4-weeks post-
49 treatment (T2) and long-term follow-ups (6 and 12 months after-end of treatment). We will
50 recruit from the 1st July to 31st December 2021 for employees and self-employed workers with
51 depression and anxiety symptoms (sub-clinical and clinical levels) who are not seeking or
52 engaged in treatment at the time of the trial.
53
54
55

56 Ethics and dissemination: Full approval was given by the University of Warwick Biomedical
57 and Research Ethics Committee (BSREC 45/20-21). The current protocol version is 2.8 (Aug-
58 2021). Publication of results in peer-reviewed journals will inform the scientific, clinical and
59
60

1
2
3 business communities. We will disseminate results through webinars, conferences, newsletter
4 as well as a lay summary of results on the study website (mhpp.me).
5

6
7 Trial registration: ISRCTN, ID: ISRCTN31161020. Registered on 08/06/2021.

8
9 Keywords: Depression, Anxiety, Feasibility, Workplace, dCBT, Online, Mental Health,
10 Productivity
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 Strengths and limitations of this study
4
5

- 6 • REST is a novel self-guided, light touch, accessible and low cost intervention of
7 dCBT for employees in the workplace.
- 8 • .
- 9 • randomization A detailed mixed-methods evaluation will provide multiple insights to
10 feasibility and acceptability of the intervention.
- 11 • To enhance rigour, the design of this feasibility study incorporates single-blinding and
12 randomization.
- 13 • The study will be underpowered to examine efficacy of the intervention, but may still
14 inform a future full-scale RCT.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

In the United Kingdom (UK), poor mental health costs the economy an estimated £70 billion/year, equivalent to 4.5% of the UK's GDP [1]. Common Mental Disorders (CMD) comprising of depressive and anxiety related disorders are a major contributor to these costs. Within the workplace, one in six workers experience some form of mental health problems [2] which may or may not be as a result of their workplace environment. Furthermore, workers who experience CMDs are significantly less likely to remain in employment than their healthy counterparts [3,4]. The prevalence of mental illness in the workplace is problematic because of a) absenteeism where the loss in workforce as a result of sickness, with an estimated 11.6% of sickness absence caused by CMD [5], totalling almost 16 million days across the UK labour market; b) mental health can diminish productivity in the workplace, a concept called presenteeism [6] which can have significant impact on employee productivity across the labour market.

Psychological therapies are effective in treating depression and anxiety [7]. One common form of psychological treatment is cognitive behavioural therapy (CBT) which uses cognitive and behavioural principles to treat underlying cognitions and behaviour of psychiatric conditions. CBT has been shown to significantly reduce symptoms of anxiety [8], and depression [9]. In the UK, CBT is available for depression and anxiety disorders via primary care 'Improving Access to Psychological Therapies' (IAPT), however, issues around eligibility, access to care and low adherence means that not all those who could benefit manage to improve [10]. Furthermore, a high proportion (reported as 70 to 75%) of people with diagnosable mental illness receive no treatment at all [11,12]. These could be due to several reasons; for example, due to stigma associated with seeking support through traditional NHS routes or services not being accessible particularly to some groups such as those who are socially disadvantaged, or those with lower education level [13]. It has been shown that many individuals prefer to manage their mental health themselves and could benefit from, self-guided dCBT, for example [13,14].

The World Health Organisation predicted around 10 years ago that by 2030 depression will be second to HIV/AIDS in international burden of disease with calls to focus on early intervention and prevention of the condition [15]. Effective early interventions can prevent, delay or reduce the onset or progress of a mental health condition [16], and are more cost-effective than treatments through specialist services or primary care providers [17]. However, to be eligible for therapies through IAPT, individuals must have symptoms above the clinical cut-off (10 and above on the PHQ-9 for depression, or 8 and above on the GAD-7 for anxiety) [18]. Currently, there are no evidence-based early intervention provisions for individuals with subthreshold symptoms.

Digital interventions provide low cost, easily scalable delivery methods to provide access at the population-level, and to individuals that usual care services may not reach. This form of digital-based CBT (dCBT) provides access to resources for self-learning or supervised treatment [19]. dCBT is effective in the prevention [17,18] and treatment of the most common CMDs – depression and anxiety [8,14,20-22], which indicates potential opportunities to tackle large-scale mental health issues through innovative and cost-effective means.

Implementation of CBT and dCBT intervention in workplace settings have been shown to improve mental health and reduce incidence of the clinical levels of CMDs [23,24]. Meta-analyses of workplace interventions for CMDs show a significant standardized mean

1
2
3 difference of 0.12, demonstrating small significant effects [25]. A large randomised
4 controlled trial demonstrated that dCBT showed strong effects in treating employees with
5 major depressive episodes [26], furthermore dCBT interventions have also been shown to
6 promote work engagement amongst sub-clinical and healthy workers [27].
7
8

9 The majority of studies to date have focused on clinical levels of depression and less so on
10 individuals with sub-clinical symptoms. It has been suggested that populations with sub-
11 threshold CMDs are greater in number than their clinical counterparts [28]. In addition,
12 interventions for subclinical populations are deemed highly cost-effective [29]. Cases of
13 CMDs have been further intensified over the COVID-19 pandemic with rates of generalised-
14 anxiety disorder increasing from one in ten to one in four adults in the US populations
15 [30,31]. Interventions to reduce mental health severity in the workplace can therefore have
16 subsequent effects in workplace absenteeism and productivity, as well as increased job
17 satisfaction [27]. Given the relatively few studies that examine intervention on subclinical
18 and clinical levels of CMDs in the workplace, and given that these studies have only assessed
19 the short-term impact of interventions [32], this trial is the first to explore a fully online
20 intervention for a UK sample in the workplace with long-term follow-ups, which could
21 trigger help-seeking for some who haven't pursued the traditional route of getting mental
22 health support (e.g. approaching GP as first contact).
23
24
25

26 This study will examine the feasibility of a dCBT for mild to severe depression and anxiety
27 for employees in the workplace. The study is one of three trials under the Mental Health
28 Productivity Pilots (MHPP), funded by the Midlands Engine [33] with a focus to improve
29 workforce mental health and productivity.
30
31

32 **Study aims**

33 The primary aim of this trial is to investigate the feasibility of a multi-centre waitlist RCT in
34 the Midlands region of England that examines whether a dCBT treatment for employees
35 reporting mild to clinical levels of depression or anxiety reduces symptom severity for
36 employees in the workplace. The trial will partner with participating employers to recruit
37 participants from workplace settings through employers and through social media
38 advertisement.
39
40

41 Nested within this primary aim is an exploration of the feasibility of the methodological
42 approach, focusing particularly upon:

- 43 • Willingness of organisations to participate in a trial (Objective 1);
- 44 • Willingness of employees to participate in a trial (Objective 2);
- 45 • Adherence of participants to the treatment as measured through platform user data
46 (Objective 3);
- 47 • Appropriateness of the analytical approach (Objective 4).
- 48 • Acceptability of the intervention based on participants subjective experiences
49 (Objective 5)
- 50
51
52

53 The results of this feasibility trial will be used to inform a future RCT to understand whether
54 a dCBT can help to reduce symptom severity and improve mental health and productivity for
55 employees in the workplace. In addition, secondary aims are to assess the barriers and
56 enablers of the intervention programme to identify key mechanisms of actions through a
57 process evaluation. Tertiary aims explore the impact of the intervention by examining the
58 reduction in symptom severity for depressive and general anxiety related symptoms as
59
60

measured through the Patient Health Questionnaire-9 (PHQ-9) and the General Anxiety Disorder-7 (GAD-7) psychometrics as well as work productivity.

Methods and analysis

Study design

We implement a multi-centre, waitlist randomised controlled trial (wRCT) in which we explore the feasibility of delivering a CBT intervention against a waitlist-control group (WLC) with no active treatment. We target recruitment for participants with mild to severe depression or general anxiety symptoms who have not received a formal diagnosis or are not currently receiving professional care for a mental health condition. The dCBT will be delivered via a self-guided digital online platform over an eight-week period.

Participants will be screened for the presence of depressive and anxious symptoms. Upon verification that inclusion criteria are met, participants will provide informed consent, complete outcome measure assessments, and complete the intervention through web-based platforms. Online assessment of the primary and secondary dependent variables will take place at week 0 baseline (pre-intervention), week 8 (post-treatment) and week 16 (follow-up). In addition, participants will be followed up in the long-term, at 6 and 12 months post-randomisation. All participants in the WLC group will be offered the dCBT intervention at week 8 (see Fig. 1 for trial flowchart).

Ethical approval has been granted from the University of Warwick Biomedical and Research Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN (ISRCTN13596153).

Participants

The REST (Reducing Stress in the workplace) trial shares a common screening process with two additional trials and therefore a shared Participant Information Leaflet (PIL) is used, under the umbrella of the INWORK program. However, no access is provided between trials and all studies use mutually exclusive inclusion/exclusion criteria to ensure no overlapping participant sample populations or competition in recruitment.

We will recruit full-time and part-time employees and self-employed workers from organisations across the Midlands region of England who fulfil the inclusion/exclusion criteria (Table 1). This is defined by the Midlands Engine as a population of approximately 11 million, with 4.5 million jobs [34].

Table 1. Inclusion/Exclusion criteria for REST study

Inclusion criteria	Exclusion criteria
Able to give informed consent	Currently receiving treatment (psychological or pharmacological) from mental health services (e.g. GP, private clinic, Improving Access to Psychological Therapies (IAPT) services, specialist and community mental health services)
English-speaking	Retiring in the next 10 months
In employment (including being on furlough)	Currently taking part in other psychological intervention trials

Insomnia Severity Index score: $x < 8^{**}$	
General Anxiety Disorder-7 score: $x > 4$ or Patient Health Questionnaire-9 score: $x > 4$	
≥ 18 years of age	

*We do not specify on working hours, or place of work

** We use the Insomnia Severity Index to differentiate REST from other trials being conducted at the same time with the INWORK programme. This criterion is used to ensure that REST can be differentiated and that there is no population overlap between the INWORK trials.

Components of the REST intervention

The REST intervention is an online self-guided programme structured into eight-weekly sessions with varying number of topics each week, lasting approximately 60 minutes each. The content incorporates techniques from Cognitive Behavioural Therapy (CBT) and Emotion Regulation [35] using workplace relevant examples. The goals of the intervention are to reduce symptoms of stress, depression and anxiety and provide participants with practical skills and techniques to help cope with stressful situations. The core components of the REST intervention can be shown below on Table 2.

Table 2. REST content across the intervention

Week 1	<ul style="list-style-type: none"> • What is stress? • Stress cycle • REST diary • Setting SMART goals
Week 2	<ul style="list-style-type: none"> • Non-judgmental awareness • Behavioural activation • Emotion focused skills
Week 3	<ul style="list-style-type: none"> • Work-related stress • Rumination and worrying • Problem solving skills
Week 4	<ul style="list-style-type: none"> • Cognitions • Managing unhelpful thinking styles • Cognitive restructuring
Week 5	<ul style="list-style-type: none"> • Work-life balance • Time management Skills
Week 6	<ul style="list-style-type: none"> • Physiology of stress • Relaxation techniques
Week 7	<ul style="list-style-type: none"> • Behavioural change • Healthy lifestyle choices (e.g. sleep, physical activity)
Week 8	<ul style="list-style-type: none"> • Programme summary • Relapse management • Self-compassion • Resilience

Waitlist control

Participants initially allocated to the waitlist control group, will be asked to provide a baseline response to primary and secondary measures but will not receive any active treatment for the first eight weeks. After the eight-week period, waitlist control participants will be asked to provide a post-control group measure for primary and secondary outcomes at which point they will be automatically enrolled into the intervention group for further eight weeks. The waitlist control group serves two purposes. First, it provides an untreated comparison for the active dCBT group to determine if the treatment had an effect. Secondly and for ethical reasons, it will provide an opportunity for all participants in the trial to receive the active intervention. It will allow us to assess the effect of the intervention against not receiving treatment during that same time period (since the groups are comparable), and any differences between the two groups should reflect (due to randomization) the impacts of exposure to the dCBT.

Measures

Participants will be prompted by email to complete all outcome measures on a secure online survey platform (Qualtrics). The order of the assessments will be consistent across all participants and all time-points. If participants do not complete measures within 5 days they will receive three further email reminders every five days of non-response.

Primary outcomes

To examine the feasibility of our intervention under a multi-centre waitlist randomised controlled trial design, we explore five primary objectives. We examine Objective 1 by monitoring organisational traffic (defined as conversion rates and absolute counts) into the trial across four identified stages:

Stage 1: Contacted

Stage 2: Teleconference

Stage 3: Further engagement

Stage 4: Verbal agreement and branch selection

For each partnership with an organisation we document the number of centres as well as the number of employees.

We examine Objective 2 by exploring participant traffic across the trial flow (through social media and employer pathways). We define the trial flow for participants traffic as follows:

1. Expression of interest
2. Screener completion
3. Invitation to trial
4. Consent to study and randomisation
5. Post-study (which is defined as end of control and beginning of intervention for those initially placed in the waitlist control group)
6. Follow-up measures or outcome measures from Qualtrics

We will explore the conversion rates and absolute counts of employees from each stage of the trial flow, evaluating over recruitment pathways (please see section Recruitment procedures for more information on page 10).

1
2
3 We explore Objective 3 through the user data of platform access for the dCBT intervention.
4 We will explore how much content was consumed by individuals on average, and the time to
5 complete each block on average.
6

7
8 We explore Objective 4 through analysis of secondary measures listed below. We firstly
9 explore the acceptability of the assessment measures themselves; this is conducted by
10 exploring the completion rate of questionnaires, we will further explore the descriptive
11 statistics (e.g. distribution of the outcome measures, skew, kurtosis, ICC, means and
12 variances).
13

14
15 We will evaluate the fit of our statistical model comparing a fixed-effects regression model
16 against a mixed-effects linear model (accounting for clusters in organisation level).
17 Furthermore, we also evaluate the statistical cleaning procedures using a sensitivity analysis
18 in which we compare multiple imputation methods against complete case analysis.
19

20
21 We also examine the feasibility of the trial implementation through semi-structured
22 qualitative interviews as part of Objective 5, which will explore the feasibility and barriers of
23 the intervention. We will use thematic analysis to identify the common themes mapped to a
24 framework to provide a theoretical perspective on how to improve the intervention.
25

26 **Secondary outcomes**

27 Our secondary outcomes explore the impact of the intervention on prevalent mental health
28 questionnaires to assess symptom severity in anxiety and depression. In addition, we also
29 explore the impact of the intervention on job satisfaction, well-being, quality of life, work
30 productivity and insomnia severity. The different measures are listed in the Supplementary
31 section and will be collected at baseline (T0) post-study (T1), short-term (T2) and long-term
32 (6 and 12 months) follow-ups. In addition, the GAD-7, PHQ-9 and the Insomnia Severity
33 Index will be used as part of the screening questionnaire set to identify eligible participants
34 for the study. We also ask participants to self-report use of self-help resources and if since
35 completing the screening questionnaire whether they started receiving treatment from mental
36 health services (psychological and pharmacological). These questions will be used as
37 confounding variables in the analysis models. See the supplementary file for a detailed list of
38 the outcome measures being used, along with a summary of their psychometric properties.
39
40
41

42 **Sample size**

43 Given little a-priori information, we will explore the feasibility of recruiting participants into
44 the trial. We will recruit for eight months from June to December 2021. We will explore the
45 recruitment rate over time across the employer and direct social media advertisement. We will
46 estimate the effect size obtained from the analysis of the trial detailed under Objective 4 in the
47 Analyses section on page 11, for sample size estimation for a future full scale randomised
48 controlled trial.
49

50 We anticipate a nominal sample size of 60 participants based on Lewis et al recommendations
51 for feasibility trials [36].
52
53

54 **Recruitment procedures**

55 The REST study will recruit through multiple channels. The first pathway denotes employers
56 registering interest as partners via the MHPP website (mhpp.me), who will act as gatekeepers
57 to their employees. They will not recruit participants themselves but only signpost the
58 information, Employers will advertise the intervention within their organisations through
59 newsletters and emails.
60

1
2
3
4 The second pathway is through direct recruitment by the research team via online social
5 media (e.g., Twitter, LinkedIn and Facebook) and print (e.g., leaflets and flyers in public and
6 retail settings) advertisements. Individuals who express interest through this pathway will be
7 from the wider working community in the Midlands.
8
9

10 Initial interest will be taken through a survey form hosted by the Qualtrics servers. This will
11 only take brief employment information (organisation name, location and email address) in
12 order to determine whether this individual is listed under a partner or through direct
13 recruitment strategies.
14
15

16 The research team will then contact interested employees by sending them the INWORK
17 PIL. This trial uses a two-stage consent process, where after initial interest, participants will
18 be asked to take part in an eligibility screening questionnaire set, after which those eligible
19 will be invited to take part in the trial. The screening questionnaire set consists of the GAD-7,
20 PHQ-9 and the ISI. We will also ask participants to confirm they are older than 18, whether
21 they have a diagnosis of a mental health condition, are under the management of a mental
22 health service.
23
24

25 If the scores on any of the three scales yield above the clinical threshold (this is denoted with
26 a score of at-15 on the GAD-7 [37] or the PHQ-9 [38] or 15 of above on the ISI [39], we will
27 recommend these individuals to contact their GP and signpost to contact Improving Access to
28 Psychological Therapies services. Symptom severity will not exclude them from taking part
29 in the study. Participants will need to acknowledge reading the advice to continue with the
30 screening questionnaire set. Individuals who pass the eligibility criteria as listed in Table 1
31 above will be invited into the REST trial.
32
33

34 **Patient and Public Involvement**

35 We have formed a group of four individuals with lived experience of mental health problems
36 who are currently in employment, and they will contribute during the trial by reviewing
37 participant information sheets, consent form, intervention materials and questionnaire
38 measures. They will advise on recruitment procedures and methods to engage prospective
39 participants/retain enrolled participants.
40
41

42 **Randomisation**

43 Participants are assigned to the dCBT or WLC arms through a simple randomisation with
44 blocking using a 1:1 allocation ratio. We use random length block between two and eight, to
45 minimise the risk of uneven groups. The randomisation is conducted using '*blockrand*'
46 package [40]. We stratify the randomisation process across centres based on employee size
47 within the partnered employer pathway.
48
49

50 Due to unknown organisation size considerations, individuals through direct recruitment will
51 not be stratified over centres. Randomisation will be conducted by a researcher independent
52 of allocating participants and will be blinded to the subsequent allocations. Members of the
53 research team will be unable to influence randomisation and will be concealed from future
54 assignments.
55
56

57 **Allocation concealment mechanism**

58 The trial statistician (KP) will provide a prescriptive randomisation allocation sequence file
59 stored in a *.csv file. The file is provided to the trial coordination team, who enrolls
60

1
2
3 participants into the trial, doing so automatically allocates a condition to each participant. The
4 allocation list is locked to prevent any tampering.
5

6 7 **Implementation**

8 The trial statistician (KP) generates the random allocation sequence, and the code to match
9 each participant to their respective allocation sequence (through row wise matching of row
10 numbers). The allocation is conducted as part of the trial coordination team enrolling
11 participants into the trial Masterfile as part of parsing in logistical data. Participants are
12 assigned to their respective allocation through an email sent by the trial coordination team.
13

14 15 **Blinding**

16 As this is a single-blind waitlist RCT, participants after consent will be informed of the two
17 allocation groups, will not be blinded to their randomisation outcome and will be explicitly
18 informed of their allocation once randomised. The trial coordination team who handles the
19 administrative and logistical requirements of the trial will be unblinded to the allocation of
20 participants, however the researchers will be blinded to the trial allocation. Statistical
21 analyses will be conducted by members of the research team who will only have access to all
22 non-identifiable data.
23

24 Any instances of unblinding would be documented and retained in trial documentation. It is
25 likely that the majority of instances of unblinding would usually be involve a participant
26 withdrawing for treatment or undergoing treatment cessation due to unforeseen
27 circumstances and would therefore require no further action from the researcher. However, in
28 cases of mistakes where participants have contacted the researcher, then any further contact
29 with that participant will be handled by a separate researcher.
30

31 32 **Data analyses**

33 We will record and report all participant flow through the trial in accordance with the
34 Consolidated Standards of Reporting Trials (CONSORT) guidelines. We will report
35 descriptive statistics for recruitment, dropout, and completeness of interventions, in addition
36 we will report a sample breakdown.
37

38
39 We assess the feasibility of the REST trial in accordance with the five research objectives:

- 40 • Willingness of organisations to participate in a trial (Objective 1);
- 41 • Willingness of employees to participate in a trial (Objective 2);
- 42 • Adherence of participants to the treatment as measured through platform user data
43 (Objective 3);
- 44 • Appropriateness of the analytical approach (Objective 4).
- 45 • Acceptability of the intervention based on participants subjective experiences
46 (Objective 5)

47
48
49
50 Objective 1 explores organisational traffic in partnering with third-party organisations to
51 recruit employees in workplace settings. To analyse organisational traffic into the study we
52 use descriptive statistics calculating frequency counts and percentage. Table 3 below
53 demonstrates the template in which we will document and present the information across
54 (Stage 1- Engagement; Stage 2-Teleconference; Stage 3-Further engagement; Stage 4-Verbal
55 agreement and centre selection).
56
57
58
59
60

Table 3. Organisational traffic into the REST study

Employer ID	Number of Employees	Number of potential centres	Stage 1	Stage 2	Stage 3	Stage 4
1	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
2	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
...	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
n	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No	Yes or No
Total	N	N	N	N	N	N
Attrition	%	%	%	%	%	%

Objective 2 investigates the feasibility of recruiting and maintaining participants in the REST trial. We explore Objective 2 by examining participant traffic across the trial flow (see Figure 1), through social media and employer recruitment pathways. To analyse organisational traffic into the study, we use descriptive statistics calculating frequency counts and percentage across the trial stages (see Table 4).

Table 4. Organisational traffic into the REST study

Recruitment Pathway	Employer ID	Express interest	Screeners	Invite to Trial	Consent, randomise and baseline measure completion (T0)	Post-study outcome measure completion at 8 weeks (T1)	Follow-up measure completion at 16 weeks post randomisation (T2)
Employer pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%
Direct Social media advertisement pathway	1						
	2						
	...						
	n						
	Total	N	N	N	N	N	N
	Attrition	%	%	%	%	%	%

We will also conduct a chi-squared test to compare overall attrition rates across the two recruitment pathways to determine if there is any practical utility in one form of recruitment over another.

Objective 3 investigates the adherence of participants to the treatment as measured through platform user data. Here we explore the user data from the platform through exploring the average amount of content consumed by individuals on average for the dCBT intervention.

1
2
3 We will also explore the time taken to consume each block on average. The user data
4 provided will include at the aggregate level information on which links were accessed and
5 frequency count data of link usage. We will obtain aggregate data at the individual level such
6 as the amount of content (at the weekly level) consumed by each participant, but not how
7 long was spent on each page.
8
9

10 Objective 4 explores the appropriateness of the analysis, which consists of exploratory
11 analyses of the secondary measures (which will be used to measure the trial in future case), as
12 well as understanding the most appropriate model to fit to the data. To examine the
13 appropriateness of the assessment measures themselves. We will explore the distribution of
14 the different outcome measures by assessing the skew, kurtosis, means and variances, we will
15 also report the intra-cluster correlation coefficient.
16
17

18 To explore the most appropriate model, we will compare three linear regression models; a
19 simplified fixed effect model, a full fixed-effects model (which includes covariates beyond
20 the control vectors (please see Supplementary for list of such measures) and a mixed-effects
21 regression (includes a random effect to account for clusters in organisation level) and finally
22 a complete case analysis using mixed-effects model (to conduct a sensitivity analysis of
23 multiple imputation).
24
25

26 We will try to fit a model as complex as the fits the following decision rule: 20 participants
27 per variable. We adopt a decision rule to ensure that the models can converge and that the
28 results are interpretable. We will only fit models that conform to the above decision rule
29 using the GAD-7 and PHQ-9 as dependent variables. We account for family-wise error using
30 a Bonferroni correction and divide our alpha-level across our two dependent variables.
31
32

33 We aim to fit three models, each growing in further complexity. The first model uses a
34 simple mixed-effects specification which includes dummy variable for treatment effects with
35 an additional factor for cohort, and an interaction term for both treatment and cohort, we also
36 include a random effect for each participant.
37
38

39 The second model includes the terms specified in the above nested model, in addition, we
40 also include a vector of control variables to account for demographic factors, as well as
41 employer, in addition to potential covariates from the secondary measures (IJSS, WPAI:GH
42 and the WEMWBS) and potential additional treatment. In this model, we also include as a
43 covariate, the baseline values of the ISI, GAD7 and PHQ-9 in this full fixed-effects model.
44
45

46 If the sample size is appropriate, we also implement a third more complex model which is the
47 same as the previous model, but we include an additional random-effects term of employer in
48 the mixed-effects model to account for clustering effects.
49
50

51 We will use an intention-to-treat analysis to ensure robustness of the results. We will
52 compare the simplified, full and mixed model fits to identify the most appropriate analysis for
53 a randomised-controlled trial.
54

55 Missing data will be reported (alongside reasons for missingness where available), and the
56 missing data pattern will be explored. To explore the impact of missing data, we will run a
57 sensitivity analysis comparing the complete case analysis against multiple imputation to see
58 any observed differences in effects.
59
60

Objective 5 will be examined through semi-structured qualitative interviews to explore the feasibility of the intervention, facilitators and barriers that impact engagement with the intervention and subsequent behavioural changes. In these interviews, we aim to understand the mechanisms of behaviour change, as facilitated by the intervention, and explore implementation processes to identify the contextual factors that act as barriers and facilitators to engagement. To do this, we ask about user perceptions and experiences of the intervention. We will explore the perceived benefits from the participants perspective, as well as any negative effects and fidelity constraints. We will randomly select 25 participants who have completed the intervention (from both treatment and control arms) and have consented to be contacted about follow-up interviews. These individuals will be invited to take part in an online videoconferencing interview over Microsoft Teams with researchers from the University of Warwick who are independent from the treatment delivery team of the individual. Interviews will be audio-recorded using OBS studio and then subsequently transcribed by a third-party University approved vendor. Qualitative interviews will be conducted using a semi-structured interview schedule, consisting of open-ended questions and suggested prompts. Interview recordings will be analysed using thematic and framework analysis to identify the barriers and facilitators to change (i.e., what helped or prevented participants from implementing aspects of the programme). We map the qualitative codes to the COM-B model [41], using a framework consisting of the three core behavioural determinants within this model : capability, opportunity and motivation. Capability refers to physical and psychological capability (such as disability and memory or knowledge respectfully). Opportunity refers to the physical and social connections and affords the behaviours (such as geography and word of mouth referrals). Motivation denotes the activation of approach and avoidance drives [42]. Themes will be generated using the to the COM-B framework as a guide, where barriers and facilitators relating to each behavioural determinant will be identified, and a thematic map will present a conceptualisation of which barriers and facilitators were particularly important in impacting change. Any other insights relevant to intervention feasibility, that cannot be mapped to the COM-B framework, will also be considered when generating themes.

[Figure 1 here]

Assessment of safety

We anticipate a low risk of serious adverse events (such as death or hospitalisation.) occurring during this trial, given the low base rate of negative events in the literature for dCBT interventions [43]. We will record occurrences of serious adverse events (SAEs) in this trial as resulting; in death, hospitalisation, life threatening, in persistent or significant disability or incapacity, of a congenital abnormality or birth defect or is otherwise considered medically significant by investigator. Adverse events are also a low risk during this trial, however expected adverse events: concentration difficulties and low mood.

To report a AE or SAE, forms will be sent to the trial management team (CB, CK), who will log them in a central database for trial monitoring. All forms will be logged in a central database and reviewed by the trial management team on a monthly basis, with a cumulative review of all safety information by an independent Trial Monitoring Committee (TMC). In addition, the trial management team will monitor and send the total numbers of SAEs per month to the TMC Chair – in order to expedite a safety review if more SAEs are being seen than would be expected.

1
2
3
4 Given the online nature of the intervention and little contact with participants, it is unlikely
5 that the research team will be aware of SAE or AE unless reported by participants through
6 contact channels such as emails.
7

8 9 **Ethics and dissemination**

10 In accordance with Good Clinical Practice, all participants are provided with an information
11 sheet and are required to provide informed consent for the screener and the trial, in order to
12 participate. This included consent for their anonymised data to be published. Ethical approval
13 for the study was granted by the University of Warwick's Biomedical Science and Research
14 Ethics Committee (BSREC 45/20-21 AM01) and the trial is registered at ISRCTN
15 (ISRCTN31161020). Protocol modifications will be submitted for approval to the BSREC
16 committees prior to implementation, with the protocol amendments being disseminated
17 across the research team and updated to the trial registry.
18

19 We will publish the results of this study in peer-reviewed journals. Findings will also be
20 presented at both national and international scientific meetings. The anonymised data will be
21 made accessible online wherever possible, if permitted by journal policies.
22
23
24

25 **Trial status**

26 Recruitment commenced on 18 June 2021 and was completed on 31st December 2021.
27

28 **Authors' contributions**

29 KP, TM, CT, CM, LW, and NT were involved in design and interpretation of the work. CT
30 and TM led the treatment development. KP drafted the first version of the manuscript. KP,
31 TM, CT, LW, SR, NT, GD and CM all were involved in revising for critical intellectual
32 content, and shared agreement for accountability in all aspects of the work.
33
34

35 **Competing interests**

36 The authors disclose no competing interests.
37
38
39

40 **Funding**

41 This research is supported by Midlands Engine (R.ESWM.3932). The study funders had no
42 role in the study design, collection, management, analysis, and interpretation of data; writing
43 of the report; and the decision to submit the report for publication
44
45

46 **Acknowledgments**

47 We thank all our participants without whom this research will not be possible. We thank the
48 patient and public advisory committee of the study for their invaluable feedback in the different
49 stages of the study. We also thank the research assistants, therapists and project administrator
50 team facilitating the smooth delivery of the trial.
51
52
53
54
55
56
57
58
59
60

References

- 1 OECD. Mental Health and Work – United Kingdom. 2014. www.oecd.org/els/%0Amental-health-and-work-united-kingdom-9789264204997-en.htm
- 2 Deloitte. Mental health and employers; Refreshing the case for investment. 2020. <https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-monitor-deloitte-oct-2017.pdf%0Ahttps://www2.deloitte.com/content/dam/Deloitte/uk/Documents/public-sector/deloitte-uk-mental-health-employers-mon>
- 3 Butterworth P, Leach LS, Pirkis J, et al. Poor mental health influences risk and duration of unemployment: a prospective study. *Soc Psychiatry Psychiatr Epidemiol* 2012;47:1013–21.
- 4 Social Exclusion Unit. Mental Health and Social Exclusion. London: 2004.
- 5 ONS. Sickness absence in the UK labour market. 2020.
- 6 Bubonya M, Cobb-Clark DA, Wooden M. Mental Health and Productivity at Work: Does What You Do Matter? IZA Discuss Pap No 9879, Inst Study Labor Published Online First: 2016.<http://hdl.handle.net/10419/141638>www.econstor.eu (accessed 6 Dec 2021).
- 7 Cuijpers P, Karyotaki E, de Wit L, et al. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. *Psychother Res* 2020;30:279–93.
- 8 Romijn G, Batelaan N, Kok R, et al. Internet-delivered cognitive behavioral therapy for anxiety disorders in open community versus clinical service recruitment: meta-analysis. *J Med Internet Res* 2019;21:e11706.
- 9 Gartlehner G, Gaynes BN, Amick HR, et al. Nonpharmacological versus pharmacological treatments for adult patients with major depressive disorder. 2015.
- 10 Martin C, Iqbal Z, Airey ND et al. Improving Access to Psychological Therapies (IAPT) has potential but is not sufficient: How can it better meet the range of primary care mental health needs? *B J Clin Psychol* 2022; **61**: 157–174.
- 11 Alonso, J., et al., Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. *Depress Anxiety*, 2018. **35**(3): p. 195-208.
- 12 Evans-Lacko, S., et al., Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. *Psychol Med*, 2018. **48**(9): p. 1560-1571.
- 13 Steele, L., C. Dewa, and K. Lee, *Socioeconomic Status and Self-Reported Barriers to Mental Health Service Use*. *The Canadian Journal of Psychiatry*, 2007. **52**(3): p. 201-206.
- 14 Josephine K, Josefine L, Philipp D, et al. Internet-and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. *J Affect Disord* 2017;**223**:28–40.
- 15 Mathers, C.D., & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030, *PLoS Med* 2006; **3**(11): e44.
- 16 Muñoz RF, Cuijpers P, Smit F, Barrera AZ, Leykin Y. Prevention of major depression. *Annual Review of Clinical Psychology*. 2010;**6**:181-212.
- 17 Lokkerbol J, Wijnen B, Ruhe HG, et al. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;**21**:1031–42.
- 18 IAPT. The IAPT Data Handbook. NHS. 2021. Accessed <https://webarchive.nationalarchives.gov.uk/ukgwa/20160302154833/http://www.iapt.nhs.uk/silo/files/iapt-data-handbook-v2.pdf>


- 19 Ebert DD, Cuijpers P, Muñoz RF, et al. Prevention of mental health disorders using internet-and mobile-based interventions: a narrative review and recommendations for future research. *Front psychiatry* 2017;**8**:116.
- 20 Sander L, Rausch L, Baumeister H. Effectiveness of internet-based interventions for the prevention of mental disorders: a systematic review and meta-analysis. *JMIR Ment Heal* 2016;**3**:e6061.
- 21 Andersson G, Carlbring P, Titov N, et al. Internet interventions for adults with anxiety and mood disorders: a narrative umbrella review of recent meta-analyses. *Can J Psychiatry* 2019;**64**:465–70.
- 22 Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. *J Anxiety Disord* 2018;**55**:70–8.
- 23 Kojima R, Fujisawa D, Tajima M, et al. Efficacy of cognitive behavioral therapy training using brief e-mail sessions in the workplace: a controlled clinical trial. *Ind Health* 2010;**48**:495–502.
- 24 Phillips R, Schneider J, Molosankwe I, et al. Randomized controlled trial of computerized cognitive behavioural therapy for depressive symptoms: effectiveness and costs of a workplace intervention. *Psychol Med* 2014;**44**:741–52.
- 25 Tan L, Wang M-J, Modini M, et al. Preventing the development of depression at work: a systematic review and meta-analysis of universal interventions in the workplace. *BMC Med* 2014;**12**:74. doi:10.1186/1741-7015-12-74
- 26 Imamura K, Kawakami N, Furukawa TA, et al. Does Internet-based cognitive behavioral therapy (iCBT) prevent major depressive episode for workers? A 12-month follow-up of a randomized controlled trial. *Psychol Med* 2015;**45**:1907–17.
- 27 Imamura K, Kawakami N, Furukawa TA, et al. Effects of an internet-based cognitive behavioral therapy intervention on improving work engagement and other work-related outcomes: an analysis of secondary outcomes of a randomized controlled trial. *J Occup Environ Med* 2015;**57**:578–84.
- 28 Haller H, Cramer H, Lauche R, et al. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. *BMC Psychiatry* 2014;**14**:1–13.
- 29 Lokkerbol J, Wijnen B, Ruhe HG, et al. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. *Expert Rev Pharmacoecon Outcomes Res* 2021;**21**:1031–42.
- 30 Panchal N, Kamal R, Orgera K, et al. The implications of COVID-19 for mental health and substance use. *Kaiser Fam Found* 2020;**21**.
- 31 Santomauro DF, Herrera AMM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021;**398**:1700–12.
- 32 Zhou, T., et al., *Internet-based cognitive behavioural therapy for subthreshold depression: a systematic review and meta-analysis*. *BMC Psychiatry*, 2016. **16**(1): p. 356.
- 33 Mental Health Productivity Pilots. The Mental Health and Productivity Pilot (MHPP). 2021. <https://mhpp.me/> (accessed 9 Aug 2021).
- 34 Midlands Engine. Midlands Engine Partnership: Key facts, strengths & barriers to growth. 2022. <https://www.midlandengine.org/wp-content/uploads/2022/06/Midlands-Engine-Partnership-Factsheet-March-2022.pdf> (accessed 27 July 2022).
- 35 Berking M, Whitley B. *Affect Regulation Training: A Practitioners' Manual*. Irvine, California: Springer 2010.

- 1
2
3 36 Lewis, M, Bromley, K, Sutton, CJ, McCray, G, Myers, HL, Lancaster, GA. Determining
4 sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes
5 back!. *Pilot and feasibility studies* 2021; 7(1), 1-14.
6
7 37 Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the
8 GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp*
9 *Psychiatry*. 2016;39:24-31.
10 38 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
11 measure. *J Gen Intern Med*. 2001;16(9):606–13. Bastien, C. H., Vallières, A., & Morin,
12 C. M. (2001). Validation of the insomnia severity index as an outcome measure for
13 insomnia research. *Sleep Medicine*, 2, 297–307.
14 40 Snow G. blockrand: Randomization for block random clinical trials. R Packag version
15 2013;1.
16 41 Michie S, Atkins L, West R. The behaviour change wheel. A Guid to Des Interv 1st ed
17 Gt Britain Silverback Publ 2014.
18 42 Vlaev I, Dolan P. Action Change Theory : A Reinforcement Learning Perspective on
19 Behavior Change. *Rev Gen Psychol* 2015;19:69–95. doi:10.1037/gpr0000029
20 43 Oehler C, Görges F, Hegerl U, et al. A closer look at negative effects in a guided web-
21 based intervention for mild to moderate depression. *Clin Psychol Sci Pract* 2021;28:131.
22
23
24
25

26 Figure Legends

27
28 **Figure 1:** Flow chart diagram showing a summary of the trial design for the REST study
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Flow chart diagram showing summary of the trial design for the REST study



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplementary Material

Appendix A- Screening questionnaires

Q1.2 I confirm that I have read and understand the information sheet for the above study (INWORK PIL v1.7_IV- 24.08.21). If you have not already done so, please see the information sheet sent via the link in the screening invitation email. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

Yes (1)

No (2)

Q1.3 I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my employment being affected.

Yes (1)

No (2)

Q1.4 I understand that data collected during the study, may be looked at by individuals from the Universities of Warwick and Birmingham. I give permission for these individuals to have access to my data.

Yes (1)

No (2)

Q1.5 I understand that the screening phase of the above study is designed to assess my eligibility for the interventions being offered.

Yes (1)

No (2)

Q1.6 I understand that if I'm eligible for an intervention, I will be contacted again by the research team with further information on the specific intervention I may be eligible for and instructions on how to proceed.

Yes (1)

No (2)

1
2
3 Q1.7 Whether eligible or not for the INWORK study, would you like to be contacted by the research
4 team with invitations for future studies?
5

6 Yes (1)

7
8 No (2)
9

10
11 *Display This Question:*

12 *If Whether eligible or not for the INWORK study, would you like to be contacted by the research*
13 *team... = Yes*
14

15
16 Q1.8 I understand that my name and email address will be stored on the University of Warwick
17 servers for 5 years.

18 Yes (1)

19
20 No (2)
21
22

23 **End of Block: Consent**
24

25 **Start of Block: Description**
26

27 Q2.1 Over the next series of questions we will assess your mood and sleep. Please answer the
28 questions as accurately as possible and remember there are no correct answers.
29

30
31 You are free to withdraw at any time, should you wish to do so. If you have any issues completing the
32 questionnaires, please contact the research team at
33

34 **End of Block: Description**
35

36 **Start of Block: GAD-7**
37

38 Q3.1 Over the last 2 weeks, how often have you been bothered by any of the following problems?
39
40

41
42
43 Q3.2 Feeling nervous, anxious or on edge?
44

45 Not at all (1)

46 Several days (2)

47 More than half the days (3)

48 Nearly everyday (4)
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Q3.3 Not being able to stop or control worrying?
4

- 5
-
- Not at all (1)
-
- 6
-
- 7
-
- Several days (2)
-
- 8
-
- 9
-
- More than half the days (3)
-
- 10
-
- 11
-
- Nearly everyday (4)
-
- 12

13
14
15 Q3.4 Worrying too much about different things?
16

- 17
-
- Not at all (1)
-
- 18
-
- 19
-
- Several days (2)
-
- 20
-
- 21
-
- More than half the days (3)
-
- 22
-
- 23
-
- Nearly everyday (4)
-
- 24

25
26
27 Q3.5 Trouble relaxing?
28

- 29
-
- Not at all (1)
-
- 30
-
- 31
-
- Several days (2)
-
- 32
-
- 33
-
- More than half the days (3)
-
- 34
-
- 35
-
- Nearly everyday (4)
-
- 36
-
- 37

38
39
40 Q3.6 Being so restless that it is hard to sit still?
41

- 42
-
- Not at all (1)
-
- 43
-
- 44
-
- Several days (2)
-
- 45
-
- 46
-
- More than half the days (3)
-
- 47
-
- 48
-
- Nearly everyday (4)
-
- 49

50 Q3.7 Becoming easily annoyed or irritable?
51

- 52
-
- Not at all (1)
-
- 53
-
- 54
-
- Several days (2)
-
- 55
-
- 56
-
- More than half the days (3)
-
- 57
-
- 58
-
- Nearly everyday (4)
-
- 59
-
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q3.8 Feeling afraid as if something awful might happen?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

End of Block: GAD-7

Start of Block: PHQ-9

Q4.1 Over the last two weeks, how often have you been bothered by any of the following problems?

Q4.2 Little interest or pleasure in doing things?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

Q4.3 Feeling down, depressed, or hopeless?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

Q4.4 Trouble falling or staying asleep, or sleeping too much?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

1
2
3 Q4.5 Feeling tired or having little energy?
4

- 5
-
- Not at all (1)
-
- 6
-
- 7
-
- Several days (2)
-
- 8
-
- 9
-
- More than half the days (3)
-
- 10
-
- 11
-
- Nearly everyday (4)
-
- 12
-
- 13

14
15 Q4.6 Poor appetite or overeating?
16

- 17
-
- Not at all (1)
-
- 18
-
- 19
-
- Several days (2)
-
- 20
-
- 21
-
- More than half the days (3)
-
- 22
-
- 23
-
- Nearly everyday (4)
-
- 24
-
- 25

26
27 Q4.7 Feeling bad about yourself - or that you are a failure or have let yourself or your family down?
28

- 29
-
- Not at all (1)
-
- 30
-
- 31
-
- Several days (2)
-
- 32
-
- 33
-
- More than half the days (3)
-
- 34
-
- 35
-
- Nearly everyday (4)
-
- 36
-
- 37

38
39 Q4.8 Trouble concentrating on things, such as reading the newspaper or watching television?
40

- 41
-
- Not at all (1)
-
- 42
-
- 43
-
- Several days (2)
-
- 44
-
- 45
-
- More than half the days (3)
-
- 46
-
- 47
-
- Nearly everyday (4)
-
- 48
-
- 49
-
- 50
-
- 51
-
- 52
-
- 53
-
- 54
-
- 55
-
- 56
-
- 57
-
- 58
-
- 59
-
- 60

1
2
3 Q4.9 Moving or speaking so slowly that other people could have noticed? Or the opposite — being so
4 fidgety or restless that you have been moving around a lot more than usual?
5

- 6 Not at all (1)
7
8 Several days (2)
9
10 More than half the days (3)
11
12 Nearly everyday (4)
13
-

14
15
16 Q4.10 Thoughts that you would be better off dead, or of hurting yourself in some way?
17

- 18 Not at all (1)
19
20 Several days (2)
21
22 More than half the days (3)
23
24 Nearly everyday (4)
25
-

26
27
28 *Display This Question:*

29 *If Thoughts that you would be better off dead, or of hurting yourself in some way? != Not at all*
30

31 **Q4.11 Your safety:** We appreciate that you are willing to share your experiences and feelings with
32 the research team. However, we cannot monitor in real time the information provided by you about
33 your physical and mental health during this research. If you would like emotional support, or
34 completing the survey has caused distress, we encourage you to reach out to someone you trust, or
35 contact the research team on wmg-mhpp@warwick.ac.uk. Alternatively, if it is an emergency, and
36 you need immediate help for yourself, call 999 straight away. For non-emergency physical and mental
37 health support call 111 by or go to 111.nhs.uk.
38

39 **End of Block: PHQ-9**

40
41 **Start of Block: ISI**
42

43 Q5.1 For each question, please select the option that best describes your answer. Please rate the
44 current (i.e. last 2 weeks) severity of your sleep problem(s).
45

46
47
48 Q5.2 Difficulty falling asleep
49

- 50 None (1)
51
52 Mild (2)
53
54 Moderate (3)
55
56 Severe (4)
57
58 Very Severe (5)
59
60

1
2
3
4
5 Q5.3 Difficulty staying asleep
6

- 7 None (1)
8
9 Mild (2)
10
11 Moderate (3)
12
13 Severe (4)
14
15 Very Severe (5)
16
-

17
18
19 Q5.4 Problems waking up too early
20

- 21 None (1)
22
23 Mild (2)
24
25 Moderate (3)
26
27 Severe (4)
28
29 Very Severe (5)
30
31
-

32
33
34 Q5.5 How SATISFIED/DISSATISFIED are you with your CURRENT sleep pattern?
35

- 36 Very Satisfied (1)
37
38 Satisfied (2)
39
40 Moderately Satisfied (3)
41
42 Dissatisfied (4)
43
44 Very Dissatisfied (5)
45

46
47 Q5.6 How NOTICEABLE to others do you think your sleep problem is in terms of impairing the
48 quality of your life?
49

- 50 Not at all Noticeable (1)
51
52 A little (2)
53
54 Somewhat (3)
55
56 Much (4)
57
58 Very Much (5)
59
60

1
2
3
4
5 Q5.7 How WORRIED/DISTRESSED are you about your current sleep problem?
6
7

- 8 Not at all Worried (1)
9 A little (2)
10 Somewhat (3)
11 Much (4)
12 Very Much Worried (5)
13
14
15
16
17

18
19
20 Q5.8 To what extent do you consider your sleep problem to INTERFERE with your daily functioning
21 (e.g. daytime fatigue, mood, ability to function at work/daily chores, concentration, memory, mood,
22 etc.) CURRENTLY?
23

- 24 Not at all Interfering (1)
25 A little (2)
26 Somewhat (3)
27 Much (4)
28 Very Much Interfering (5)
29
30
31
32
33
34

35
36 Q58

37 Copyright notice (C) *Morin, C.M. (1993 and 1996)*
38

39 End of Block: ISI
40

41 Start of Block: IAPT_GP
42



44
45 Q6.1

46 The responses you provided indicate that you might be having difficulties with your mental health.
47

48 This year has been really tough for many of us, especially when we are unable to do the usual things
49 that bring us joy like seeing friends and family. Whilst you may still be eligible for the study, we
50 strongly advise you to contact your GP or self-refer yourself to an NHS psychological therapies
51 service (IAPT). To get in touch with IAPT please follow this link: [https://www.nhs.uk/service-
52 search/find-a-psychological-therapies-service/](https://www.nhs.uk/service-search/find-a-psychological-therapies-service/).
53

54 The intervention programme you may be offered in the study should not be used as an alternative for
55 seeking diagnosis and treatment from a professional. You will subsequently be asked to consent to
56 have read and take this advice into consideration. While you wait for an appointment, you can access
57 expert advice and practical tips on the [Every Mind Matters](#) website. We have in addition put together
58 resources below which you may find useful to look after your mental health. The Mind charity has
59
60

produced [information on how to take care of your wellbeing](#) during the pandemic including advice for coping in the winter which you might find helpful.

Mind Infoline: Call: 0300 123 3393

Email: info@mind.org.uk

Website: <https://www.mind.org.uk/workplace/> Lines are open 9am to 6pm, Monday to Friday (except for bank holidays).

Samaritans

Call: 116 123

Email: jo@samaritans.org Website: <https://www.samaritans.org/>

For a listening ear or just someone to talk to the Samaritans are open 24 hours a day. If you need mental health information and the above helplines are closed then please visit Mind's Mental health A-Z resource or contact NHS 111.

NHS The NHS also has their own set of resources, this includes a website which provides access to other sources of information: <https://www.england.nhs.uk/mental-health/resources/> If you have any questions or would like more information, please contact the research team at wmg-mhpp@warwick.ac.uk

Please confirm that you understand these requests. This does not impact your ability to take part in these studies in any way.

I understand the request to contact my GP (4)

I understand the request to contact IAPT (5)

End of Block: IAPT_GP

Start of Block: Block 7

Q60 Please confirm your employer and usual place of work.

If your employer is not shown, please select "My employer is not listed".

If your usual place is not shown, please select "My place of work is not listed".

Organisation (1)

Site (2)

End of Block: Block 7

Start of Block: Additional_requirements

Q7.1 Thank you for responding to the questionnaires about your mental wellbeing. We have only a few last questions to ask to help identify which study you may be eligible for out of REST, SLEEP or MENTOR

1
2
3 Q7.2 Are you over the age of 18?
4

5 Yes (1)

6
7 No (2)
8

9
10
11 Q7.3

12 Do you currently manage anyone?
13

14 Yes (21)

15
16 No (22)
17
18

19
20 *Display This Question:*

21 *If Do you currently manage anyone? = Yes*
22

23 Q7.4

24 Would you be happy to participate in the MENTOR trial if someone of your team was selected for
25 MENTOR?
26

27 Yes (21)

28
29 No (22)
30
31

32
33 Q7.5 Do you have a current diagnosis of a mental health condition?
34

35 Yes (1)

36
37 No (2)
38
39

40 *Display This Question:*

41 *If Do you have a current diagnosis of a mental health condition? = Yes*
42
43

44 Q7.6 What is your mental health diagnosis?
45 _____
46
47

48
49 Q7.7 Are you currently under the care of a mental health care practitioner?
50

51
52 To clarify: are you currently receiving care through psychological treatment or through some form of
53 medication?
54
55
56
57
58
59
60

1
2
3
4 This can include your GP as well as a consultant from NHS services.
5

6 Yes (1)
7

8 No (2)
9

10 -----
11
12 Q7.8 Are you currently involved in any psychological intervention trials?
13

14 Yes (1)
15

16 No (2)
17
18 -----
19

20 *Display This Question:*

21 *If Do you have a current diagnosis of a mental health condition? = Yes*
22

23 Q7.9 Are you currently receiving support from an [Individual Placement and Support Worker](#)?
24

25 Yes (1)
26

27 No (2)
28
29 -----
30

31 *Display This Question:*

32 *If Do you have a current diagnosis of a mental health condition? = Yes*
33

34 Q7.10 Are you on extended sick leave (i.e. for more than 4 weeks) ?
35

36 Yes (1)
37

38 No (2)
39
40 -----
41

42 *Display This Question:*

43 *If Are you over the age of 18? = Yes*

44 *And Do you have a current diagnosis of a mental health condition? = Yes*

45 *And Are you currently under the care of a mental health care practitioner? To clarify: are you curren... = Yes*
46

47 *

48 Q7.11 What is your line manager's email address?
49
50 _____
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Display This Question:

If Are you over the age of 18? = Yes

And Do you have a current diagnosis of a mental health condition? = Yes

And Are you currently under the care of a mental health care practitioner? To clarify: are you curren... = Yes



Q7.12 Please confirm your line manager's email address

REST_Questionnaire at each timepoint

Start of Block: Consent

Q1.2 I confirm that I have read and understand the information sheet (REST v1.7 7/07/21) for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

Yes (1)

No (2)

Q1.3 I confirm that I meet ALL the eligibility criteria of this study: English speaking; 18 years or above; Not retiring in the next 10 months; Currently not receiving treatment (psychological or medication) from mental health services; Currently not taking parting in other psychological intervention trials.

Yes (1)

No (2)

Q1.4 I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my employment being affected.

Yes (1)

No (2)

Q1.5 I understand that data collected during the study, may be looked at by individuals from University of Warwick. I give permission for these individuals to have access to my data.

Yes (1)

No (2)

1
2
3 Q1.6 Would you like to be contacted to participate in a qualitative interview to understand how we
4 can improve the intervention further
5

6 Yes (1)

7
8 No (2)
9

10 -----
11
12 Q1.7 I am happy for my anonymised data to be used in future research.
13

14 Yes (1)

15
16 No (2)
17

18 -----
19
20 Q1.8 I agree to take part in the above study.
21

22 Yes (1)

23
24 No (2)
25

26
27 **End of Block: Consent**
28

29 **Start of Block: Demographics**
30

31 Q2.1 Thank you for consenting to take part in the REST trial. This study will last for 8 weeks during
32 this time you will have access to an online e-learning platform. You will receive further information
33 on how to access these in due course. For us to evaluate how well this intervention improves your
34 sleep and wellbeing, we ask you next to complete a set of questionnaires. This will take
35 approximately 45 minutes. Please read each question carefully before responding and feel free to take
36 breaks where you need. If you do feel you need to take a break, please do not close the survey.
37 If you have any questions, please contact us at wmg-rest@warwick.ac.uk
38

39
40 Q2.2 How old are you?
41

42 0 10 20 30 40 50 60 70 80 90 100

43
44 Age in years ()



45
46
47
48 -----
49 JS
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Q2.3 What gender do you identify as?
4

- 5 Female (1)
6
7 Male (2)
8
9 Non-binary (3)
10
11 Other (please specify) (4) _____
12
13 Prefer not to specify (5)
14



17
18
19 Q2.4 What is your ethnicity? (1 of 2)
20

- 21 White... (1)
22
23 Mixed / Multiple ethnic groups... (2)
24
25 Asian or Asian British... (3)
26
27 Black or Black British... (4)
28
29 Mixed (5)
30
31 Hispanic/Latino (6)
32
33 Other (please specify) (7)
34
35

36 *Display This Question:*

37 *If What is your ethnicity? (1 of 2) = White...*
38

39
40 Q2.5 What is your ethnicity? (2 of 2)

- 41 English / Welsh / Scottish / Northern Irish / British (1)
42
43 Irish (2)
44
45 Gypsy or Irish Traveller (3)
46
47 Any other White background (please describe if you wish) (4)
48 _____
49

50
51 *Display This Question:*

52 *If What is your ethnicity? (1 of 2) = Mixed*
53
54
55
56
57
58
59
60

1
2
3 Q2.6 What is your ethnicity? (2 of 2)
4

- 5 White and Black Caribbean (1)
6
7 White and Black African (2)
8
9 White and Asian (3)
10
11 Any other Mixed / Multiple ethnic background (please describe if you wish) (4)
12 _____
13

14
15 *Display This Question:*

16 *If What is your ethnicity? (1 of 2) = Asian or Asian British...*
17

18
19 Q2.7 What is your ethnicity? (2 of 2)
20

- 21 Indian (1)
22
23 Pakistani (5)
24
25 Bangladeshi (6)
26
27 Chinese (7)
28
29 Any other Asian background (please describe if you wish) (8)
30 _____
31

32
33 *Display This Question:*

34 *If What is your ethnicity? (1 of 2) = Black or Black British...*
35

36 Q2.8 What is your ethnicity? (2 of 2)
37

- 38 African (1)
39
40 Caribbean (4)
41
42 Any other Black / African / Caribbean background (please describe if you wish) (5)
43 _____
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Q2.9 How many hours do you work per week?
5
6

0 5 10 15 20 25 30 35 40 45 50

7
8 Number of hours ()
9
10
11



12
13
14 Q2.10 Information about income is very important to understand. Would you please give your best
15 guess? Please indicate the answer that includes your entire household income in (previous year) before
16 taxes.
17

- 18 £10,000 to £29,999 (1)
19
20 £30,000 to £49,999 (2)
21
22 £50,000 to £69,999 (3)
23
24 £70,000 to £89,999 (4)
25
26 £90,000 to £109,999 (5)
27
28 £110,000 to £149,999 (6)
29
30 £150,000 or more (7)
31

32
33 JS
34
35

36 Q2.11 How would you describe your current relationship status?
37

- 38 Single (1)
39
40 Cohabiting (2)
41
42 Married (3)
43
44 Separated (4)
45
46 Divorced (5)
47
48 Widowed (6)
49
50 Other (please specify) (7) _____
51
52
53
54
55
56
57
58
59
60

1
2
3 Q2.12 Who do you live with?
4

- 5 I live by myself (1)
6
7 I live with flatmates (2)
8
9 I live with my partner (3)
10
11 I live with my parents/carers (4)
12
13 I live with other family members (6)
14
-

15
16 JS
17

18
19 Q2.13 What is your highest educational qualification?
20

- 21 No formal qualification (1)
22
23 Primary (2)
24
25 Secondary (e.g., GCSE, O-levels, GNVQ) (3)
26
27 Diploma (or professional qualification) (4)
28
29 Bachelor's degree (5)
30
31 Master's degree (6)
32
33 Doctorate degree (7)
34
35 Other (please specify) (8) _____
36
-

37
38 JS
39

40
41 Q2.14 In the last 8 weeks, to the best of your recollection, how much sick leave have you taken?
42

- 43 I have taken (1) _____
44
45 I have not taken any sick leave (2)
46
47 I would prefer not to answer this question (3)
48
-

49
50
51 Q2.15 Are you currently using any self-help resources?
52

53
54 This includes but is not limited to self help books, apps and websites
55

- 56 Yes (1)
57
58 No (2)
59
60

1
2
3
4
5 Q2.16 Since completing the screening questionnaire of this study, did you start receiving treatment
6 from mental health services?
7

8 Yes (1)

9
10 No (2)
11

12 **End of Block: Demographics**

13
14

Start of Block: Contact

15 Page Break
16

17
18
19 Q3.1 As part of this study we need to request some further personal information for us to contact you
20 during this study.
21



25
26 Q3.2 What is your phone number?
27

28
29 **End of Block: Contact**

30
31

Start of Block: COVID_19

32
33 Q5.1 As part of our research, we are interested in your experiences with COVID-19 and how this has
34 impacted your life. Please read each question carefully and select the most appropriate response for
35 you.
36

37
38
39
40 Q5.2 How worried are you about contracting COVID-19?

41 Not worried at all (1)

42 Slightly worried (2)

43 Moderately worried (3)

44 Very worried (4)

45 Extremely worried (5)
46
47
48
49
50
51

1
2
3 Q5.3 In which category are you considered to be in regard to COVID-19 according to the NHS and
4 UK Government guidelines of England?
5

- 6 Clinically extremely vulnerable (1)
7
8 Clinically vulnerable (2)
9
10 Low risk (3)
11
-

12
13
14 Q5.4 Since the start of the pandemic, have you tested positive for COVID-19?
15

- 16 Yes (1)
17
18 No (2)
19
-

20
21
22 *Display This Question:*

23 *If Since the start of the pandemic, have you tested positive for COVID-19? = Yes*
24

25 Q5.5 Have you required hospitalised treatment for COVID-19?
26

- 27 Yes (1)
28
29 No (2)
30
-

31
32 *Display This Question:*

33 *If Since the start of the pandemic, have you tested positive for COVID-19? = No*
34

35 Q5.6 Do you suspect that you may have had COVID-19 due to presenting with symptoms?
36 (temperature/fever, new persistent cough, loss of smell & taste)
37

- 38 Definitely (1)
39
40 Probably (2)
41
42 Unsure (3)
43
44 No (4)
45
-

46
47
48 *Display This Question:*

49 *If Since the start of the pandemic, have you tested positive for COVID-19? = Yes*
50

51 Q5.7 For some people, coronavirus can cause symptoms that last weeks or months after the infection
52 has gone. This is sometimes called post-COVID-19 syndrome or "long COVID". Have you
53
54
55
56
57
58
59
60

1
2
3 experienced any of the following long COVID symptoms 12 weeks after initial infection? (Check all
4 that apply)
5

- 6 No (I feel fully recovered) (1)
7
8 Extreme tiredness (fatigue) (2)
9
10 Shortness of breath (3)
11
12 Chest pain or tightness (4)
13
14 Problems with memory and concentration ("brain fog") (5)
15
16 Difficulty sleeping (insomnia) (6)
17
18 Heart palpitations (7)
19
20 Dizziness (8)
21
22 Pins and needles (9)
23
24 Joint pain (10)
25
26 Depression and anxiety (11)
27
28 Tinnitus, earaches (12)
29
30 Feeling sick, diarrhoea, stomach aches, loss of appetite (13)
31
32 A high temperature, cough, headaches, sore throat, changes to sense of smell or taste
33
34 (14)
35
36 Rashes (15)
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-

1
2
3 Q5.8 Since the start of the pandemic, have any people you know tested positive for COVID-19?
4 (Choose all that apply)
5

- 6 Immediate family members (1)
7
8 Extended family members (2)
9
10 Neighbours (3)
11
12 Friends (4)
13
14 Colleagues (5)
15
16 No one I know has tested positive (6)
17
18
19
-

20
21
22
23 Q5.9 Since the start of the pandemic, have you been asked to stop working temporarily under the
24 government “furlough” scheme?
25

- 26 No (1)
27
28 Yes, I am currently on furlough (2)
29
30 Yes, I will soon be on furlough (3)
31
32 Yes, but have since returned to work (full time or part time) (4)
33
-

34
35
36 Q5.10 As a result of colleagues being placed on furlough, do you think your workload will/has:
37

- 38 Increase (d) (1)
39
40 Decrease (d) (2)
41
42 Stay (ed) the same (3)
43
44 Can't say yet (4)
45
46 N/A, as no one I work with has been furloughed (5)
47
48 N/A, as I am currently been furloughed (6)
49
-

50
51 Page Break
52
53
54
55
56
57
58
59
60

1
2
3
4 Q5.11 In light of the COVID-19 pandemic, what changes had been made within your organisation
5 that have impacted you? (Tick all that apply)
6

- 7 Hours of work (1)
8
9 Pay cut (2)
10
11 Working remotely (3)
12
13 Not applicable (4)
14
15
16

17
18 *Display This Question:*

19 *If In light of the COVID-19 pandemic, what changes had been made within your organisation*
20 *that have... = Working remotely*
21

22
23 Q5.12 Have you experienced any ongoing challenges in working remotely? (Tick all that apply)

- 24 Technical difficulties (e.g. with internet, computers, access to workplace data storage)
25 (1)
26
27 Practical difficulties (no separate/private area from which to work) (2)
28
29 Balancing work with caregiving/parenting responsibilities (3)
30
31 Motivational difficulties (4)
32
33 Other (please specify) (5)
34
35 No challenges experienced (6)
36
37
38
39

40
41 *Display This Question:*

42 *If In light of the COVID-19 pandemic, what changes had been made within your organisation*
43 *that have... = Working remotely*
44

45 Q5.13 How comfortable do you feel returning back to work and having the appropriate support from
46 your organisation? (e.g. Covid-19 risk assessment)?
47

- 48 Not comfortable at all (1)
49
50 Slightly comfortable (2)
51
52 Moderately comfortable (3)
53
54 Very comfortable (4)
55
56 Extremely comfortable (5)
57
58
59
60

Display This Question:

If In light of the COVID-19 pandemic, what changes had been made within your organisation that have... = Working remotely

Q5.14 How have these issues affected your ability to work?

- (Negative impact) -3 (1)
- 2 (2)
- 1 (3)
- 0 (4)
- 1 (5)
- 2 (6)
- (Positive Impact) 3 (7)

Q5.15 Have you experienced any of the following due to COVID-19? (Tick all that apply)

We understand this question may trigger distress and undesirable memories or thoughts. If so, please speak to a friend or family member or seek professional support (e.g. GP).

- Lost your job/unable to earn money (1)
- Another bill payer in your household lost their job or is/was unable to earn money (2)
- Unable to pay bills (3)
- Had difficulties accessing sufficient food (4)
- Evicted / lost accommodation (5)
- Had difficulties accessing required medication (6)
- Somebody close to you in hospital (7)
- Somebody close to you died (we are very sorry for your loss. We realise answering this question might make you uncomfortable or trigger unsettling feelings. If you feel you need to speak to someone or require support, please refer to this NHS resource) (8)
- Difficulties with family or social relationships (9)
- If you're a parent/carer, concerns about your child's/children's well-being and/or education (10)
- Having to change or delay major life plans or events (11)
- Not applicable (12)

1
2
3
4
5 Q5.16 How comfortable do you feel raising COVID-19 related issues with your organisation (e.g. line
6 manager, human resources)?
7

- 8 Not comfortable at all (1)
9
10 Slightly comfortable (2)
11
12 Moderately comfortable (3)
13
14 Very comfortable (4)
15
16 Extremely comfortable (5)
17

18
19
20
21 Q5.17 Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a
22 research trial)

- 23 Yes (1)
24
25 No (2)
26
27

28
29 *Display This Question:*

30 *If Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a*
31 *rese... = Yes*
32

33 Q5.19 Have you experienced any of the following symptoms as a result of having the vaccine? (Tick
34 all that apply)
35

- 36 Headaches (1)
37
38 Feeling tired (2)
39
40 Feeling achy (3)
41
42 Soreness, redness and swelling at the site of the vaccination (4)
43
44 Mild or high fever (5)
45
46 Feeling or being sick (6)
47
48 Allergic reaction (7)
49
50 I did not have any symptoms (8)
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Display This Question:

If Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a resea... = Yes

*

Q5.22 When did you receive your first dose? (please enter date as DD/MM/YYYY)

Display This Question:

If Have you had at least one dose of a COVID-19 vaccine (as part of the national roll-out or a resea... = Yes

Q5.23 Have you received a second dose of a COVID-19 vaccine?

Yes (1)

No (2)

Display This Question:

If Have you received a second dose of a COVID-19 vaccine? = Yes

Q5.24 When did you receive your second dose? (please enter date as DD/MM/YYYY)

Q5.25 What would you say is your one biggest concern or problem encountered, since the start of the pandemic?

Page Break

Q5.26 Did you receive any help overcoming the concern/problem outlined above and if yes, what has been helpful or unhelpful? If no, what kind of help do you think you need right now?

End of Block: COVID_19

Start of Block: WPAI_GH

1
2
3 Q6.1 The following questions ask about the effect of your health problems on your ability to work and
4 perform regular activities. By health problems we mean any physical or emotional problem or
5 symptom. Please fill in the blanks or indicate your response.
6
7

8
9
10 Q6.2 Are you currently employed (working for pay)?

11 Yes (1)

12 No (2)

13
14
15
16 *Skip To: Q6.7 If Are you currently employed (working for pay)? = No*

17
18
19 Q6.3 The next questions are about the **past seven days**, not including today.
20
21

22 *

23
24
25 Q6.4 During the past seven days, how many hours did you miss from work because of your health
26 problems? Include hours you missed on sick days, times you went in late, left early, etc., because of
27 your health problems. *Do not include time you missed to participate in this study.*
28
29 _____

30
31 *

32
33 Q6.5 During the past seven days, how many hours did you miss from work because of any other
34 reason, such as vacation, holidays, time off to participate in this study?
35
36 _____

37
38
39 *

40
41 Q6.6 During the past seven days, how many hours did you actually work?
42
43 _____

44
45
46
47 Q6.7 During the past seven days, how much did your health problems affect your productivity while
48 you were working? *Think about days you were limited in the amount or kind of work you could do,*
49 *days you accomplished less than you would like, or days you could not do your work as carefully as*
50 *usual. If health problems affected your work only a little, choose a low number. Choose a high*
51 *number if health problems affected your work a great deal. Consider only how much health*
52 *problems affected productivity while you were working.*

53 No effect on my work

54 Completely prevented me
55 from working

56
57 0 1 2 3 4 5 6 7 8 9 10
58
59
60

1 ()



Q6.8 During the past seven days, how much did your health problems affect your ability to do your regular daily activities, other than work at a job?

By regular activities, we mean the usual activities you do, such as work around the house, shopping, childcare, exercising, studying, etc. Think about times you were limited in the amount or kind of activities you could do and times you accomplished less than you would like. If health problems affected your activities only a little, choose a low number. Choose a high number if health problems affected your activities a great deal.

Consider only how much health problems affected your ability to do your regular daily activities, other than work at a job.

No effect on my daily activities Completely prevented me from doing my daily activities

0 1 2 3 4 5 6 7 8 9 10

1 ()



End of Block: WPAI_GH

Start of Block: IJSS

Q7.1 As part of our research, we are interested in the amount of job satisfaction with respect to your current role. This questionnaire is a valid and reliable measure of job satisfaction. Please read each statement carefully and tell us how much you agree with each statement.

There are no incorrect answers and none of the information you provide will be shared with your employer.

Q7.2 I feel good about this job

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

1
2
3 Q7.3 This job is worthwhile
4

- 5 Strongly agree (1)
6
7 Somewhat agree (2)
8
9 Somewhat disagree (3)
10
11 Strongly disagree (4)
12
-

13
14
15 Q7.4 The working conditions are good
16

- 17 Strongly agree (1)
18
19 Somewhat agree (2)
20
21 Somewhat disagree (3)
22
23 Strongly disagree (4)
24
-

25
26
27 Q7.5 I want to quit this job
28

- 29 Strongly agree (1)
30
31 Somewhat agree (2)
32
33 Somewhat disagree (3)
34
35 Strongly disagree (4)
36
37
-

38
39
40 Q7.6 This job is boring
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.7 I am happy with the amount this job pays
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q7.8 The vacation time and other benefits on this job are okay

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)
-

Q7.9 I need more money than this job pays

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)
-

Q7.10 This job does not provide the medical coverage I need

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)
- Not Applicable (5)
-

Q7.11 I have a fairly good chance for promotion in this job

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

1
2
3 Q7.12 This is a dead-end job
4

- 5 Strongly agree (1)
6
7 Somewhat agree (2)
8
9 Somewhat disagree (3)
10
11 Strongly disagree (4)
12
-

13
14
15 Q7.13 I feel that there is a good chance of my losing this job in the future
16

- 17 Strongly agree (1)
18
19 Somewhat agree (2)
20
21 Somewhat disagree (3)
22
23 Strongly disagree (4)
24
-

25
26
27 Q7.14 My supervisor is fair
28

- 29 Strongly agree (1)
30
31 Somewhat agree (2)
32
33 Somewhat disagree (3)
34
35 Strongly disagree (4)
36
37
-

38
39
40 Q7.15 My supervisor is hard to please
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.16 My supervisor praises me when I do my job well
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5 Q7.17 My supervisor is difficult to get along with
6

- 7 Strongly agree (1)
8
9 Somewhat agree (2)
10
11 Somewhat disagree (3)
12
13 Strongly disagree (4)
14
-

15
16
17 Q7.18 My supervisor recognizes my efforts
18

- 19 Strongly agree (1)
20
21 Somewhat agree (2)
22
23 Somewhat disagree (3)
24
25 Strongly disagree (4)
26
27
-

28
29
30 Q7.19 My coworkers are easy to get along with
31

- 32 Strongly agree (1)
33
34 Somewhat agree (2)
35
36 Somewhat disagree (3)
37
38 Strongly disagree (4)
39

40 Q7.20 My coworkers are lazy
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.21 My coworkers are unpleasant
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q7.22 My coworkers don't like me

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
-

Q7.23 My coworkers help me to like this job more

- Strongly agree (1)
 - Somewhat agree (2)
 - Somewhat disagree (3)
 - Strongly disagree (4)
-

Q7.24 I have a coworker I can rely on

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

Q7.25 I have a coworker I consider a friend

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

Q7.26 I look forward to coming to work

- Strongly agree (1)
- Somewhat agree (2)
- Somewhat disagree (3)
- Strongly disagree (4)

1
2
3
4
5 Q7.27 I often feel tense on the job
6

- 7 Strongly agree (1)
8
9 Somewhat agree (2)
10
11 Somewhat disagree (3)
12
13 Strongly disagree (4)
14
-

15
16
17 Q7.28 I don't know what's expected of me on this job
18

- 19 Strongly agree (1)
20
21 Somewhat agree (2)
22
23 Somewhat disagree (3)
24
25 Strongly disagree (4)
26
27
-

28
29
30 Q7.29 I feel physically worn out at the end of the day
31

- 32 Strongly agree (1)
33
34 Somewhat agree (2)
35
36 Somewhat disagree (3)
37
38 Strongly disagree (4)
39

40 Q7.30 Working makes me feel like I'm needed
41

- 42 Strongly agree (1)
43
44 Somewhat agree (2)
45
46 Somewhat disagree (3)
47
48 Strongly disagree (4)
49

50 Q7.31 My job keeps me busy
51

- 52 Strongly agree (1)
53
54 Somewhat agree (2)
55
56 Somewhat disagree (3)
57
58 Strongly disagree (4)
59
60

1
2
3
4
5 Q7.32 I get to do a lot of different things on my job
6
7

- 8 Strongly agree (1)
9 Somewhat agree (2)
10 Somewhat disagree (3)
11 Strongly disagree (4)
12
13
14
15

16
17
18 Q7.33 I am satisfied with my schedule
19

- 20 Strongly agree (1)
21 Somewhat agree (2)
22 Somewhat disagree (3)
23 Strongly disagree (4)
24
25
26
27

28 **End of Block: IJSS**

29
30 **Start of Block: WEMWBS**

31 Page Break
32

33 Q8.1 Below are some statements about feelings and thoughts.
34

35 Please select the option that best describes your experience of each over the last 2 weeks
36

37 Q8.2 I've been feeling optimistic about the future
38

- 39 None of the time (1)
40 Rarely (2)
41 Some of the time (3)
42 Often (4)
43 All of the time (5)
44
45
46
47

48 Q8.3 I've been feeling useful
49

- 50 None of the time (1)
51 Rarely (2)
52 Some of the time (3)
53 Often (4)
54 All of the time (5)
55
56
57
58
59
60

1
2
3
4
5 Q8.4 I've been feeling relaxed
6

- 7 None of the time (1)
8
9 Rarely (2)
10
11 Some of the time (3)
12
13 Often (4)
14
15 All of the time (5)
16

17
18
19 Q8.5 I've been feeling interested in other people
20

- 21 None of the time (1)
22
23 Rarely (2)
24
25 Some of the time (3)
26
27 Often (4)
28
29 All of the time (5)
30
31

32
33
34 Q8.6 I've had energy to spare
35

- 36 None of the time (1)
37
38 Rarely (2)
39
40 Some of the time (3)
41
42 Often (4)
43
44 All of the time (5)
45

46
47
48 Q8.7 I've been dealing with problems well
49

- 50 None of the time (1)
51
52 Rarely (2)
53
54 Some of the time (3)
55
56 Often (4)
57
58 All of the time (5)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q8.8 I've been thinking clearly

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.9 I've been feeling good about myself

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.10 I've been feeling close to other people

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.11 I've been feeling confident

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q8.12 I've been able to make up my own mind about things

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.13 I've been feeling loved

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.14 I've been interested in new things

- None of the time (1)
 - Rarely (2)
 - Some of the time (3)
 - Often (4)
 - All of the time (5)
-

Q8.15 I've been feeling cheerful

- None of the time (1)
- Rarely (2)
- Some of the time (3)
- Often (4)
- All of the time (5)

End of Block: WEMWBS

Start of Block: Medication_checklist

Q9.1 We would like to know what medication (prescriptions and/or over the counter) you use, what dose and for what condition. Medications are tablets or capsules, but could also be (eye) drops, sprays, creams, drinks, inhaler puffs, suppositories etc. Prescription medications are ones that a doctor prescribes. Over the counter medication are ones that you can purchase yourself without a prescription such as ibuprofen, vitamins, herbal remedies etc.

	Name of medication (1)	Dosage (mg/g/ml) (2)	How often do you take this medication (per day / week/ as needed) (3)	How much do you take per time (e.g. 2 tablets) (4)	What is this medication for? (5)	How long have you been using it for? (6)	Additional comments (7)
1. (1)							
2. (2)							
3 (6)							
4 (7)							
5 (8)							
6 (9)							
7 (10)							

1
2
3
4 **End of Block: Medication_checklist**
5

6 **Start of Block: ISI**
7

8 Page Break
9

10
11 **Q12.1** For each question, please select the option that best describes your answer. Please rate the
12 current (i.e. last 2 weeks) severity of your sleep problem(s).
13

14
15
16 **Q12.2** Difficulty falling asleep

- 17
18 None (1)
19
20 Mild (2)
21
22 Moderate (3)
23
24 Severe (4)
25
26 Very Severe (5)
27

28
29
30 **Q12.3** Difficulty staying asleep

- 31
32 None (1)
33
34 Mild (2)
35
36 Moderate (3)
37
38 Severe (4)
39
40 Very Severe (5)
41

42
43
44 **Q12.4** Problems waking up too early

- 45
46 None (1)
47
48 Mild (2)
49
50 Moderate (3)
51
52 Severe (4)
53
54 Very Severe (5)
55
56

57
58
59
60

1
2
3 Q12.5 How SATISFIED/DISSATISFIED are you with your CURRENT sleep pattern?
4

- 5 Very Satisfied (1)
6
7 Satisfied (2)
8
9 Moderately Satisfied (3)
10
11 Dissatisfied (4)
12
13 Very Dissatisfied (5)
14
-

15
16
17 Q12.6 How NOTICEABLE to others do you think your sleep problem is in terms of impairing the
18 quality of your life?
19

- 20 Not at all Noticeable (1)
21
22 A little (2)
23
24 Somewhat (3)
25
26 Much (4)
27
28 Very Much (5)
29
-

30
31
32 Q12.7 How WORRIED/DISTRESSED are you about your current sleep problem?
33

- 34 Not at all Worried (1)
35
36 A little (2)
37
38 Somewhat (3)
39
40 Much (4)
41
42 Very Much Worried (5)
43
44
45

46 Q12.8 To what extent do you consider your sleep problem to INTERFERE with your daily
47 functioning (e.g. daytime fatigue, mood, ability to function at work/daily chores, concentration,
48 memory, mood, etc.) CURRENTLY?
49

- 50 Not at all Interfering (1)
51
52 A little (2)
53
54 Somewhat (3)
55
56 Much (4)
57
58 Very Much Interfering (5)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q12.9

Copyright notice (C) Morin, C.M. (1993, 1996, 2000, 2006)

For any information on the use of the Insomnia Severity Index, please contact Mapi Research Trust, Lyon, France. Internet: <https://eprovide.mapi-trust.org>

End of Block: ISI

Start of Block: GAD7

Page Break

Q10.1 Over the next series of questions we will assess your mood and sleep. Please answer the questions as accurately as possible and remember there are no correct answers.

Q10.2 Over the last 2 weeks, how often have you been bothered by any of the following problems?

Q10.3 Feeling nervous, anxious or on edge?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.4 Not being able to stop or control worrying?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.5 Worrying too much about different things?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q10.6 Trouble relaxing?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.7 Being so restless that it is hard to sit still?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.8 Becoming easily annoyed or irritable?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q10.9 Feeling afraid as if something awful might happen?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

End of Block: GAD7

Start of Block: PHQ9

Page Break

Q11.1 Over the last two weeks, how often have you been bothered by any of the following problems?

1
2
3
4 Q11.2 Little interest or pleasure in doing things?
5

- 6 Not at all (1)
7
8 Several days (2)
9
10 More than half the days (3)
11
12 Nearly everyday (4)
13
-

14
15
16 Q11.3 Feeling down, depressed, or hopeless?
17

- 18 Not at all (1)
19
20 Several days (2)
21
22 More than half the days (3)
23
24 Nearly everyday (4)
25
-

26
27
28
29 Q11.4 Trouble falling or staying asleep, or sleeping too much?
30

- 31 Not at all (1)
32
33 Several days (2)
34
35 More than half the days (3)
36
37 Nearly everyday (4)
38

39
40 Q11.5 Feeling tired or having little energy?
41

- 42 Not at all (1)
43
44 Several days (2)
45
46 More than half the days (3)
47
48 Nearly everyday (4)
49

50 Q11.6 Poor appetite or overeating?
51

- 52 Not at all (1)
53
54 Several days (2)
55
56 More than half the days (3)
57
58 Nearly everyday (4)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Q11.7 Feeling bad about yourself - or that you are a failure or have let yourself or your family down?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q11.8 Trouble concentrating on things, such as reading the newspaper or watching television?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q11.9 Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)
-

Q11.10 Thoughts that you would be better off dead, or of hurting yourself in some way?

- Not at all (1)
- Several days (2)
- More than half the days (3)
- Nearly everyday (4)

End of Block: PHQ9

Start of Block: disclaimer



1
2
3 Q13.1 The responses you provided indicate that you might be having difficulties with your mental
4 health. This year has been really tough for many of us, especially when we are unable to do the usual
5 things that bring us joy like seeing friends and family. We strongly advise you to contact your GP or
6 self-refer yourself to an NHS psychological therapies service (IAPT). To get in touch with IAPT
7 please follow this link: <https://www.nhs.uk/service-search/find-a-psychological-therapies-service/>.
8 The intervention programme should not be used as an alternative for seeking diagnosis and treatment
9 from a professional. While you wait for an appointment, you can access expert advice and practical
10 tips on the Every Mind Matters website. We have in addition put together resources below which you
11 may find useful to look after your mental health. The Mind charity has produced information on how
12 to take care of your wellbeing during the pandemic including advice for coping in the winter which
13 you might find helpful. Mind Infoline: Call: 0300 123 3393

14 Email: info@mind.org.uk

15 Website: <https://www.mind.org.uk/workplace/> Lines are open 9am to 6pm, Monday to Friday
16 (except for bank holidays). Samaritans

17 Call: 116 123

18 Email: jo@samaritans.org Website: <https://www.samaritans.org/>

19 For a listening ear or just someone to talk to the Samaritans are open 24 hours a day. If you need
20 mental health information and the above helplines are closed then please visit Mind's Mental health
21 A-Z resource or contact NHS 111. NHS The NHS also has their own set of resources, this includes
22 a website which provides access to other sources of information: [https://www.england.nhs.uk/mental-](https://www.england.nhs.uk/mental-health/resources/)
23 [health/resources/](https://www.england.nhs.uk/mental-health/resources/) If you have any questions or would like more information, please contact the
24 research team at wmg-rest@warwick.ac.uk

25
26
27 Please confirm that you understand these requests. This does not impact your ability to take part in
28 these studies in any way.

29
30

31 I understand the request to contact my GP (4)

32
33

34 I understand the request to contact IAPT (5)

35
36 End of Block: disclaimer
37

38 39 Appendix B- Outcome measures

40 The following psychometric will be used to explore their utility as outcome measures for a future
41 fully powered randomised-controlled trial.

42
43 The General Anxiety Disorder-7 (GAD-7) is commonly used in primary and secondary mental health
44 settings to measure symptom severity for General Anxiety Disorder (Spitzer, Kroenke, Williams, &
45 Löwe, 2006). The GAD-7 is comprised on seven items each scored on a four-point Likert scale, a
46 score of 10 has been shown to correctly diagnose cases of generalised anxiety disorder with 89%
47 sensitivity and 82% specificity, with high test-retest reliability (ICC = 0.83). The GAD-7 also shows
48 high concurrent validity with high scores being associated with disability and functional impairment
49 (Ruiz et al., 2011; Spitzer et al., 2006).

50
51 The Patient Health Questionnaire-9 (PHQ-9) is commonly used, in primary care settings to assess the
52 severity of depression across the nine DSM-IV criteria for major depressive disorder on a four-point
53 Likert scale (Cameron, Crawford, Lawton, & Reid, 2008). The PHQ-9 has been shown to demonstrate
54 high diagnostic accuracy in at risk populations (Haddad et al., 2013; Janneke et al., 2012), and in
55 clinical populations. A criterion score of ≥ 10 has a 88% sensitivity and specificity for major
56 depressive disorder (Kroenke, Spitzer, & Williams, 2001). Empirical research demonstrates high
57 internal consistency ($\alpha = 0.91$; Hansson, Chotai, Nordstöm, & Bodlund, 2009) and a valid latent
58
59
60

1
2
3 structure even when administered in nonclinical samples (CFI = 0.914- 0.983; Ito, Takebayashi,
4 Muramatsu, & Horikoshi, 2018).
5

6 The Insomnia Severity Index (ISI) is a seven-item psychometric which has been validated with
7 reference to the diagnostic criteria for primary insomnia in the DSM-IV. The ISI uses a five-point
8 Likert scale response to each item (score range 0–28). A score of ≥ 15 identifies cases of clinical
9 insomnia with 94% sensitivity and specificity (Bastien, Vallières, & Morin, 2001). A reduction of 8.4
10 has been shown to be associated with moderate improvement in clinical populations (Morin,
11 Belleville, Bélanger, & Ivers, 2011), with responses being validated in non-clinical samples as
12 demonstrating a high internal reliability ($\alpha = 0.81 - 0.91$ (Morin et al., 2011; Yu, 2010)).
13
14

15 Job productivity - measured through the Work Productivity and Activity Impairment: General Health
16 v2.0 (WPAI:GH; (Reilly, Zbrozek, & Dukes, 1993). The WPAI:GH is a six item psychometric which
17 focuses on: 'Absenteeism', 'Presenteeism', 'Work productivity loss' and 'Activity Impairment'. The
18 WPAI:GH has shown strong psychometric properties with good internal consistency ($\alpha = 0.74$), with
19 a high intraclass correlation coefficient ($r = 0.79 - 0.90$) in clinical populations (Zhang et al., 2010).
20 The WPAI has been used in non-clinical samples and has shown good face validity (Duke & Montag,
21 2017).
22

23 Job satisfaction - measured using the Indiana Job Satisfaction Scale (IJSS; Resnick & Bond, 2001).
24 The IJSS is a 32-item psychometric coded on a four-point Likert response of "Strongly disagree" to
25 "Strongly agree", and is comprised of six subscales: 'General Satisfaction', 'Pay', 'Advancement and
26 Security', 'Supervision', 'Coworkers' and 'How I feel about this job'. The IJSS yields strong
27 psychometric properties with high internal consistence ($\alpha = 0.90$) and test-retest reliability ($r = .75$)
28 (Resnick & Bond, 2001).
29

30 Well-being – we measure subjective well-being using the Warwick-Edinburgh Mental Health Well-
31 being Scale (WEMWBS, Tennant et al., 2007). The WEMWBS consists of 14-items on a five-point
32 likert scale ranging from "None of the time" to "All of the time". The scale has been shown to hold
33 good psychometric properties, with strong internal consistency ($\alpha = 0.91$) and was shown to hold high
34 concurrent validity (Tennant et al., 2007). When applied to nonclinical samples the WEMWBS still
35 shows similar psychometric properties with high internal consistency ($\alpha = 0.94$; test-retest = 0.83;
36 Dong et al., 2016).
37
38

39 Quality of life- measured using the EuroQOL EQ-5D-5L questionnaire (Herdman et al., 2011). The
40 EQ-5D-5L consists of six items, five items measured through five-point likert-scale responses to
41 mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with a sixth item of a
42 rating of health on a visual analogue scale ranging from 0-100. The EQ-5D-5L has shown high
43 internal consistency in clinical samples ($\alpha = 0.86$; (Bilbao et al., 2018) and in nonclinical populations
44 ($\alpha = 0.84$; Kim & Ko, 2018).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60